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ABSTRACT 
 
The role of cell death in atherosclerosis remains ill-defined, however, a growing body of 
evidence suggests that cell death stimulates atherogenesis through the induction of 
inflammation and enlargement of the necrotic core. Although there is solid evidence to 
suggest that lipid oxidation and toxicity are linked, indications that protein oxidation 
may play an important role in cytotoxicity are numerous. The abundance of dead cells 
in atherosclerotic plaques and their co-localization with HOCl-modified proteins 
provides an opening for the suggestion that the products of protein oxidation may be at 
the heart of oxLDL-induced cell death. Examination of the modification of LDL and 
albumin by HOCl, and the cytotoxicity of these oxidised molecules were the focus of 
this study, along with the elucidation of their cell death mechanisms toward U937 cells. 
 Measurement of lipid peroxidation markers, TBARS and 7-ketocholesterol, showed no 
significant increase in HOCl-oxLDL compared to native levels although all α-
tocopherol had been lost. In contrast there was a large loss of tyrosine, of which a small 
percentage went to dityrosine, indicating that the protein moiety of LDL was the main 
target of HOCl attack. Albumin became fragmented and smeared on SDS-PAGE gels 
with increasing HOCl/BSA molar ratios. In addition there was significant reduction in 
tyrosine levels and a small increase in dityrosine.  
Both HOCl-oxLDL and oxidised albumin (oxALB) caused concentration-dependent 
cell viability loss in U937 cells following a significant drop in intracellular GSH 
concentration, coinciding with a peak in oxidative stress. Removal of chloramines with 
methionine significantly reduced the toxicity of oxALB, but at higher concentrations 
this effect was reduced. This was in contrast to HOCl-oxLDL where the removal of 
chloramines had no effect on its toxicity. Morphological observations of cell swelling, 
cell membrane integrity loss and rupture, along with flow cytometry results indicate that 
U937 cells underwent necrosis, but only after intracellular GSH was lost. Intracellular 
GSH and cell viability loss were prevented by 200 μM extracellular 7,8-
dihydroneopterin (78NP), indicating that 78NP scavenging of ROS generated in 
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response to the oxidised proteins was sufficient to prevent cell death. This study 
demonstrates the cytotoxicity of HOCl-damaged LDL and albumin is likely due to a 
common oxidative product or structural motif which may be active within 
atherosclerotic plaques.   
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1. INTRODUCTION 
 
 
1.1 Overview 
Atherosclerosis is a condition of the major arteries in which progressive occlusion of the 
vessel occurs and is the result of an on-going inflammatory process (Lusis, 2000). The 
involvement of low density lipoproteins (LDL) in the pathogenesis of atherosclerosis is 
widely accepted. According to the oxidative modification hypothesis of atherogenesis, 
LDL within the artery wall undergoes oxidative modification, forming oxidised LDL 
(oxLDL) which is then taken up by macrophage cells in an unregulated manner, 
triggering their transformation into lipid laden foam cells (Libby et al., 2002).  
Oxidised lipids are thought to be involved in the cell death process that characterises 
that progression of the fatty streak to advanced atherosclerotic plaque. Although 
cytotoxicity of lipids to many cells types has been reported (Clare et al., 1995, Larsson 
et al., 2006, Lizard et al., 1998), such studies have failed to acknowledge the role 
oxidised proteins are likely to play in cellular death. Myeloperoxidase, a heme protein 
secreted by activated neutrophils, plays a critical role in the killing of evading micro-
organisms. However,  MPO can also induce damage to surrounding tissue (though the 
over production of potent oxidant hypochlorite), and is thought to contribute to the 
pathogenesis of several diseases including atherosclerosis (Malle et al., 2000; 
Daugherty et al., 1994; Baldus et al., 2002).   Further to this, hypochlorite (HOCl)-
modified proteins that have been identified in human atherosclerotic plaque, and HOCl 
has been shown to transform LDL to a high-uptake form without significant lipid 
oxidation (Hazell et al., 1996). Accumulation of reactive protein oxidation products 
such as advanced oxidation protein products (AOPPs) may also cause further damage to 
other cellular macromolecules in the vicinity.  A clear understanding of the products of 
HOCl-induced oxidation, together with analysis of oxidation products in vivo will allow 
for evaluation of the role in atherosclerosis of myeloperoxidase, and the phagocytic 
cells that produce it.  
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1.2    Atherosclerosis  
Atherosclerosis is a progressive disease, characterised by the accumulation of lipids and 
fibrous elements in the large arteries (Libby, 2002). It primarily presents as 
cardiovascular disease, cardiac infarction and stroke. Overall it is responsible for 
approximately 50% of deaths in the westernized world (Lusis, 2000).  Atherosclerosis 
manifests itself through progressive morphological changes, from the precursor „fatty 
streaks‟ to advanced fibrous lesions. Early lesions of atherosclerosis consist of 
accumulations of cholesterol-laden macrophages termed „foam cells‟. These fatty 
streaks although clinically insignificant, are precursors of more advanced lesions, 
characterised by accumulation of lipid-rich necrotic debris and smooth muscle cells 
(Lusis, 2000). These advanced lesions (or plaques) can become increasingly complex 
with calcium and iron deposits, often with an unstable necrotic core. Although advanced 
lesions may grow sufficiently large enough to slow, or block blood flow, it is more 
likely that the danger of these plaques comes from clinical complications. The plaque 
can rupture or erode, resulting in complete occlusion of the blood vessel, consequently 
leading to myocardial infarction or ischemic stroke. 
 
1.3   Oxidised LDL and atherosclerosis  
Epidemiological, clinical and genetic studies have provided clues for the underlying 
causes of atherosclerosis. It is known that individuals whose levels of low density 
lipoprotein (LDL) are elevated by lifestyle or genetic heritage show an increased risk 
for myocardial infarction (Heinecke, 1998). Although this correlation has been made, 
LDL does not appear to display atherogenic properties in vitro. Macrophages incubated 
with high levels of LDL failed to internalize excess cholesterol (Goldstein et. al., 1979; 
Fogelman et. a.l, 1980), yet cholesterol-laden macrophages are a hallmark of early 
atherosclerotic lesions, and LDL is the major cholesterol transporter in blood. One 
hypothesis to account for this anomaly and a driving factor for many studies is the 
„oxidative modification‟ hypothesis. The implication is that LDL must be somehow 
altered or modified prior to its uptake by macrophages and then taken up, not by the 
native LDL receptor, which is tightly regulated, but rather by some alternative 
macrophage receptor.   
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The oxidative modification hypothesis of atherogenesis is based upon four potentially 
atherogenic effects of oxLDL. These effects are: chemotactic activity that facilitates the 
recruitment of circulating monocytes to the endothelium; the inhibition of macrophage 
migration from within the artery back to the plasma compartment; enhanced uptake of 
LDL by macrophages via scavenger receptors contributing to the formation of foam 
cells; and cytotoxicity resulting in endothelial integrity (Steinberg et al., 1989).     
    
 
 
Figure 1.1   Oxidative modification hypothesis and its causal role in atherogenesis.  Cells 
enter the artery wall as monocytes and collect in the intimal layer, before differentiating into 
larger macrophage cells. Native LDL does not promote foam cell formation because the activity 
of the LDL receptor is tightly regulated, however upon oxidative modification of the LDL 
molecule, scavenger receptors on the macrophage recognize and bind oxLDL internalizing in an 
uncontrolled high uptake manner, resulting in so called foam cells. These cells no longer have 
the same physiological properties as a macrophage and aggregate within the intima. OxLDL is 
thought to attract and recruit cells of various types including monocyte and smooth muscle cells 
to the fatty streak site leading to formation of the atheroma and subsequent plaque.   
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Lesion initiation is thought to occur with the accumulation of LDL and lipoproteins in 
the sub-endothelial matrix. Trapped LDL is then thought to undergo modifications such 
as oxidation, proteolysis and aggregation, which may be caused in part by exposure to 
oxidants released by vascular cells (Lusis, 2000).   
OxLDL and other forms of modified LDL are taken up by macrophages via scavenger 
receptors, such as CD36 and SR-A (Steinberg et al., 1989). Foam cells are loaded with 
droplets rich in cholesteryl esters, derived mainly from arterial wall macrophages, 
originating from circulating monocytes that have penetrated into the sub endothelial 
arterial intima (Steinberg, 2000), formed when macrophages internalize oxLDL in an 
uncontrolled manner. They are the main constituent of the early stage atherosclerotic 
lesion, known as the fatty streak (figure 1.1).  
Fatty streaks evolve into complicated atheromas though the replication and migration of 
smooth muscle cells (SMCs); these accumulate and lay down an abundant extracellular 
matrix in response to cytokines, growth factors and reactive species secreted by 
activated macrophages and T lymphocytes (Lusis, 2000). SMC migration and 
proliferation signifies an important acceleration in the process of atherosclerosis as it 
significantly expands the lesion size (Berliner & Heinecke, 1995). Cell death appears to 
be central to the formation of a necrotic core in advanced atherosclerotic plaques 
(Gieseg et al., 2009). Together with the wealth of experimental evidence that confirms 
the cytotoxicity of oxLDL (Baird et al., 2004, Bjorkerud and Bjorkerud, 1996, Harada-
Shiba et al., 1998, Reid and Mitchinson, 1993) and its presence within atherosclerotic 
plaques (Brown et al., 1997, Fu et al., 1998, Ylaherttuala et al., 1989), it is likely that 
oxLDL is a major driver of cell death in vivo and hence, necrotic core development.  
Advanced atherosclerotic lesions consist of a fibrous cap of smooth muscle cells and 
dense connective tissue covering surrounding areas with necrotic debris, inflammatory 
infiltrates, macrophage foam cells, cholesterol clefts, calcium deposits and secreted 
extracellular matrix proteins (Crisby, 1997; Glass and Witztum, 2001).  Plaque rupture 
with subsequent thrombus formation is considered the most common cause of acute 
ischemic infarction, but the mechanisms responsible remain poorly understood. The 
formation of a lipid core appears to be associated with progressive tissue destruction 
and eroding the surrounding fibrous cap (Newby, 1998). This degeneration is likely to 
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be of key importance for plaque rupture. Macrophages within the intima have been 
shown to secrete cytokines that amplify a local inflammatory response and matrix 
metalloproteinases that can degrade the fibrous cap, weakening the plaque (Halliwell & 
Gutteridge, 2007).  Cells in the ruptured fibrous cap and the overlying thrombus have 
exhibited signs of DNA fragmentation, thus indicating that cell death in the cap had 
occurred close to the time of rupture (Newby, 1998). 
OxLDL is known to stimulate macrophages to induce foam cell formation and 
inflammatory responses. Although the pathological aspects of oxLDL have been well 
studied, the formation, distribution, and overall fate of oxLDL in vivo remain unclear. 
 
1.4   Cell death and oxidative stress  
OxLDL has been implicated as a key indicator in a number of plaque promoting 
processes. OxLDL has been shown to be taken up by macrophages in a rapid and 
uncontrolled manner leading to formation of cholesterol filled foam cells, the major 
component of fatty streaks. However, oxLDL may also modulate atherogenesis by 
inducing death of cells and tissues within the inflammatory site (Ermak et.al, 2008).  
Two types of cell death, termed necrosis and apoptosis have been extensively described. 
Necrosis is characterised by cellular swelling, rupture of plasma membrane, and leakage 
of cellular components during cell lysis. Apoptosis is characterised by DNA 
fragmentation, alterations of nucleus morphology, and cell fragmentation (Salvayre 
et.al., 2002).  
Apoptosis is the mechanism which removes cells that have been produced in excess, or 
that have been damaged, through activation of an internally encoded suicide program. 
The cell becomes fragmented and enclosed in membrane bound apoptotic vesicles, 
which are removed by neighbouring cells though phagocytosis. Distinctions between 
apoptosis and oncosis (primary necrosis), can be drawn by distinct morphological 
changes in the cells which are characteristic to each cell death mechanism. Cells can be 
identified as going through apoptosis by condensation of the nucleus, cytoskeletal 
disruption, cell shrinkage, and membrane blebbing (Crisby et.al, 1997). Necrosis is 
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characterized by a gain in cell volume, swelling of organelles, rupture of the plasma 
membrane and subsequent loss of intracellular contents (Martinet et.al., 2011). 
Cell death induced by oxLDL is well demonstrated in cultured cells in vitro including 
U937, THP-1 cell lines, smooth muscle cells (SMC) and endothelial cells (EC) and 
human monocyte derived macrophages (HMDM). Cell death also occurs in 
atherosclerotic areas, potentially leading to defects in the endothelial cell lining, to 
necrotic core formation, and possibly plaque rupture or erosion (Salvayre, 2000). 
Although both oxLDL and apoptotic/necrotic cells are present in atherosclerotic lesions, 
a direct link between oxLDL and apoptosis remains to be demonstrated in vivo. 
Various stimuli in the plaque including high levels of oxidative stress, depletion of 
cellular ATP, impaired clearance of apoptotic cells and increased intracellular calcium 
may cause necrotic death (Martinet et.al., 2011). Although the role of necrosis in 
atherosclerosis remains ill-defined, a growing body of evidence suggests that necrotic 
death stimulates atherogenesis through induction of inflammation and enlargement of 
the necrotic core. In addition, necrosis contributes to plaque instability by releasing 
tissue factor, matrix degrading proteases and pro-angiogenic compounds (Ermak et.al., 
2008; Halliwell & Gutteridge, 2007; Martinet et.al., 2011; Newby, 1998) 
The type of oxidative modification may play a role in the pro-apoptotic effects of 
oxLDL.  Two separate caspase-dependent apoptotic pathways have been implicated in 
oxLDL induced apoptosis (Ermak et.al., 2008); the extrinsic pathway – mediated by 
death receptors, and downstream activation of caspase-8/caspase-3; and the intrinsic 
mitochondrial apoptotic pathway – involving cytochrome c and caspase-3/caspase-9.   
Studies have shown the involvement of reactive oxygen species (ROS) in apoptosis, 
induced by different agents including oxLDL (Assinger et.al., 2010). Indeed, lipid 
peroxidation, production of ROS and down-regulation of antioxidant defence have been 
observed in several apoptotic situations (Assinger et.al., 2010; Ermak et.al., 2008). The 
intracellular sources contributing to ROS generation in monocytes include 
cyclooxygenases, lipoxygenases, mitochondrial respiration and predominantly NADPH 
oxidase. Oxidative stress and inflammation represent central and causally linked 
features of the atherosclerotic process. Integral to the oxidative modification hypothesis 
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is that ROS can oxidise lipid or protein (apolipoprotein B-100) components of LDL, 
hence transforming LDL to a high uptake form that is internalised by macrophages and 
resulting in foam cell formation. (Patel et.al., 2000). 
There are a number of sources of ROS that contribute to the progression of 
atherosclerosis. Myeloperoxidase enzyme (MPO) is responsible for HOCl production 
(Glass and Witztum, 2001), and both MPO enzyme and HOCl (detected as 3-
chlorotyrosine) have been found co-localising in atherosclerotic plaques (Daugherty et 
al., 1994; Malle et al., 2000; Sugiyama et al., 2001). ROS can contribute to lesion 
formation in many ways. Depending on the types and availability, oxLDL taken up by 
macrophages may eventually impose an oxidative stress on these cells causing death, 
which is thought to contribute to necrotic core formation. The presence of oxidation 
products of lipids and (lipo)proteins in atherosclerotic plaques further support the roles 
ROS play in the lesion development (Stocker & Keaney, 2004; Leeuwenburgh et al., 
1997). 
 
1.5   Low density lipoprotein 
1.5.1    Native LDL   
LDL is the main carrier of cholesterol within the body and is crucial to the controlled 
transport and metabolism of lipids in the bloodstream. LDL is a spherical molecule 
consisting of approximately 20% protein made up entirely of a single protein, 
apolipoprotein B-100. This  is embedded in a monolayer surface of polar phospholipids 
and cholesterol, surrounding a core of neutral cholesterol esters and triglycerides 
(Esterbauer et al., 1992). LDL is clearly abundant in lipids, of which almost half are 
fatty acids. Of the fatty acids, approximately half are polyunsaturated fatty acids 
(PUFAs), depending on the donor, which makes LDL highly susceptible to free radical-
mediated oxidation. The PUFAs in LDL are normally protected against free radical 
attack and oxidation in the plasma by a range of antioxidants, including α-tocopherol, 
ascorbate, and urate.  
Introduction 
 
 
8 
 
LDL uptake by cells occurs either via a receptor-mediated pathway of the LDL-receptor 
or by non-specific endocytosis. LDL interacts with the LDL-receptor via ionic 
interactions between clusters of amino acids and the acidic amino acids of the receptor 
(Brown & Goldstein, 1979). Modifications to the LDL molecule can cause 
conformational changes to the apolipoprotein B-100 (apoB-100), which affects the 
binding of modified LDL to the LDL receptor (Esterbauer et al., 1992). This results in 
high, unregulated uptake of modified LDL via scavenger receptor-meditated 
endocytosis, in which the cell rapidly internalizes cholesterol leading to foam cell 
formation (Esterbauer et al., 1992). 
The macrophage recognizes these oxidized lipids through a family of pattern 
recognition receptors known as the scavenger receptors. Lesional macrophages express 
at least six classes (A-G) of structurally unrelated scavenger receptors that allow the 
unregulated uptake of oxidized or acetylated LDL (oxLDL, AcLDL) (Moore & 
Freeman, 2006) with the majority of oxidised LDL taken up through a class B receptor, 
CD36 (Pluddemann et.al., 2007).  In addition to recognition and internalization of 
modified lipoproteins, scavenger receptors perform additional functions that can 
modulate atherosclerotic lesion progression, including (1) induction of macrophage 
apoptosis, (2) clearance of apoptotic cells and debris, and (3) activation of cellular 
signalling pathways regulating lipid metabolism and inflammation (Moore & Freeman, 
2006).
 
Thus, these multi-functional receptors regulate numerous pathways that affect 
both the initiation and progression of atherosclerosis. 
In contrast to the single long chain polypeptides of apoB-100 in native LDL, oxLDL has 
many proteolytic fragments derived from apoB-100. The fragmented protein is thought 
to have been covalently modified by lipid peroxidation products such as aldehydes. 
Compared to native LDL, oxLDL contains depleted levels of PUFAs and antioxidants, 
massively increased levels of lipid peroxides and their degradation products, increased 
amounts of oxidised cholesterol products and enzyme break-down products and various 
protein oxidation species (Parthasarathy et al., 1999).  
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1.5.2   LDL oxidative modifications 
It appears from the literature that the most plausible and biologically relevant 
modification of LDL is oxidation. LDL can be oxidatively modified by all major cells 
of the arterial wall. Different types of oxLDL can be produced depending on the 
oxidation conditions. Of influence are the type and concentration of oxidant, level of 
antioxidants and modification of apoB-100. There is potentially a continuous spectrum 
of degrees of oxidation and a great deal of molecular heterogeneity in what we call 
“oxidized LDL”. 
In the early phase, mild oxidation of LDL results in the formation of minimally 
modified LDL (mLDL) in the sub-endothelial space. MLDL is very different in 
composition from heavily oxidised LDL (see figure 1.2). Cholesterol is still the 
prominent sterol, apoB-100 still binds to the LDL receptor, and incubation of mLDL 
with macrophages does not form foam cells (Itabe et al. 2011). However, a significant 
proportion of unsaturated cholesterol esters and phospholipids have been oxidised to 
hydroperoxides and short-chain aldehydes. It is not cytotoxic, which is most likely due 
to the retention of significant levels of α-tocopherol (Gieseg et.al, 2009).  
It is known that LDL must be modified sufficiently to promote its uptake by 
macrophages. The oxidation necessary for this is quite significant with up to 50% of the 
cholesterol converted into 7-ketocholesterol and other oxysterols (Itabe et.al., 2011). 
Furthermore, most of the unsaturated fatty acids are oxidised to a complex mixture of 
products and apoB-100 is extensively fragmented, derivatised and cross-linked. Due to 
the extensive modification of the molecule and apoB-100 protein, oxLDL is no longer 
recognised by the LDL receptor but is taken up avidly by the scavenger receptor 
pathway in macrophages, leading to excessive cholesterol ester accumulation and foam 
cell formation. 
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Figure 1.2: Hypothetical progression of LDL to oxLDL. LDL is thought to be modified in a 
stepwise manner during the generation of oxLDL. In the initial phase of modification, the lipid 
components react with oxidants, resulting in radical chain reactions that produce many types of 
lipid oxidation products. Subsequently lipid oxidation products react with the apoB protein to 
generate adducts and cross-links. Radicals can attack the apoB protein directly, resulting in 
oxidative changes of amino acid side chains and the cleavage of peptide bonds. M-LDL may 
contain lipid oxidation products without extensive protein modification, because it binds to LDL 
receptor rather than scavenger receptors. As modification on the apoB protein proceeds, its 
relative electrophoretic mobility changes greatly, as it loses the affinity to LDL receptor, and, in 
turn, becomes a ligand of scavenger receptors. Adapted from Itabe el.al.,2011) 
 
OxLDL contains a number of oxidised protein products that may be of importance to its 
mechanism of cytotoxicity. The destruction of tryptophan residues on apoB-100 is an 
early and potentially important event in the copper-mediated oxidation of LDL 
(Esterbauer et al., 1995) and it has been shown that LDL oxidation mediated by the 
macrophage myeloperoxidase product, hypochlorous acid, preferentially modifies the 
protein component of lipoproteins (Gerry et al., 2008). In addition, it has been shown 
that protein hydroperoxides are generated at relatively high concentrations on apoB-100 
during  copper-, AAPH-generated peroxyl radical- and cell-mediated LDL oxidation 
(Gieseg et al., 2003). The oxidation of the LDL protein moiety causes the loss of 
structural integrity of the apoB-100 protein, but also results in the loss of select amino 
acids, carbonyl formation, protein fragmentation, and aggregation via protein cross-
linking (Esterbauer et.al., 1990; Fong et.al.,1987). 
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A number of different types of LDL modifications are known to be recognised by these 
scavenger receptors, including aggregation, oxidation, chemical alteration (e.g., 
acetylation) and glycation (Pluddemann et.al., 2007). Each of these changes is likely to 
induce multiple effects and that there is likely to be considerable cross-over between the 
different modifications. Although it is unclear which particular species are responsible 
for oxidative modification of LDL in vivo, many studies have shown that a range of 
oxidation mechanisms which exhibit some of the same biophysical properties 
characteristic of atherosclerosis. 
Metal ions   
Most of the cells present in the arterial intima can promote LDL oxidation, but it 
arguably requires the presence of transition metals, micro-concentrations of iron or 
copper  in the culture medium; and it has been shown that and metal chelators can block 
cell-mediated LDL oxidation (Yoshida et.al., 2010). Even in the absence of cells, high 
concentrations of free metal ions can oxidise LDL (Heinecke, 1998).  
The most widely used procedure for preparing oxLDL for use in model systems 
involves incubation for 12 or more hours in either cell culture media or phosphate 
buffered saline supplemented with Cu
2+
 ions in the range of 5 to 100 µM. The copper 
ion induces lipid peroxidation, and subsequently, the chemical modification of the 
apoB-100 protein side chains with reactive lipid peroxidation products, such as 4-
hydroxynonenal (4-HNE), and malondialdehyde (MDA). The presence of adducts of 
these oxidized products on apoB-100 protein has also been immunologically confirmed 
in atherosclerotic lesions (Esterbauer et al., 1993).     
The oxidation of LDL occurs via a lipid peroxidation chain reaction that is driven by the 
formation of lipid peroxyl radicals. The oxidation is typically described in terms of its 
three consecutive time phases; the lag phase, propagation phase and decomposition 
phase. LDL oxidation with free metal ions begins when a C-H bond in a 
polyunsaturated fatty acyl group (LH) is attacked by a free radical (R
•
), forming a lipid 
alkyl radical (reaction i) (Esterbauer et al., 1990). Once formed, the carbon-centered 
PUFA radical reacts quickly with molecular oxygen to create a lipid peroxyl radical 
(reaction ii). The newly formed lipid peroxyl radical then reacts with a hydrogen atom 
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of an adjacent PUFA, forming a lipid hydroperoxide and a new PUFA radical (reaction 
iii) (Esterbauer et al., 1993), which again yields a lipid peroxyl radical that will react 
with another PUFA molecule creating a chain reaction.  
 
 LH  +  R
•
      L
•
  +  RH      (i) 
 L
•
  +  O2        LOO
•      
(ii) 
 LOO
•
  +  LH    LOOH  +  L
•
     (iii) 
 LOO
•  
+  AH    LOOH  +  A
•
  A   (iv) 
 
During the lag phase, antioxidants within LDL initially compete with these chain 
propagating reactions by scavenging lipid peroxyl radicals (reaction iv) so that minimal 
lipid peroxidation occurs (Esterbauer et al., 1993). Once the LDL has become depleted 
of endogenous antioxidants, the propagation phase commences and the PUFAs within 
LDL are thought to be rapidly oxidised to lipid hydroperoxides at a rate that increases 
exponentially. Decomposition of lipid hydroperoxides follows in the next phase, to 
yield a wide range of products including aldehydes, hydrocarbon gases, epoxides and 
alcohols. The lipid alkoxyl radicals and peroxyl radicals cause secondary oxidative 
damage to cholesterol, generating a range of oxysterols. The breakdown of lipid 
hydroperoxides to peroxyl and alkoxyl radicals generates isoprostanes and short chain 
aldehydes, such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA). These 
lipid-derived aldehydes bind lysine residues of amino acid side chains of apoB-100 
(Gerry et al., 2008).  
Enzyme systems 
Substantial evidence supports the notion that oxidative processes contribute to the 
pathogenesis of atherosclerosis and coronary heart disease.  Studies in cell culture have 
identified a number of enzyme systems that could in principle play a role in the 
oxidation of LDL. These include NADPH oxidase, 15-lipoxygenase, myeloperoxidase, 
the mitochondrial electron transport system, and others (Malle et.al., 2006). Which of 
these contribute to LDL oxidation in vivo and to what extent is still uncertain, but over 
the last ten years, considerable data has been obtained in support of the hypothesis that 
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oxidants generated by the heme enzyme myeloperoxidase play a key role in oxidation 
reactions in the artery wall.  
Macrophages secrete myeloperoxidase, which amplifies the oxidative potential of 
hydrogen peroxide by generating cytotoxic oxidants (Sugiyama et.al., 2001). 
Myeloperoxidase is the only known human enzyme to generate hypochlorous acid, a 
highly reactive species (Heinecke, 1998). Specific oxidation products of hypochlorous 
acid such as 3-chlorotyrosine, α-chloro fatty aldehydes, and hypochlorite-modified 
proteins have been found in human atherosclerotic lesions (Westendorf et.al., 2005). 
Moreover, an increasing number of studies demonstrated that LDL oxidized by 
hypochlorite (HOCl-oxLDL) in vitro is able to mimic fundamental atherogenic 
processes including, formation of foam cells (Hazell et.al., 1993), activation of 
phagocytes with increased intra- and extracellular formation of reactive oxygen species 
(Kopprasch et.al., 1998), and adhesion to endothelial cells (Kopprasch et.al., 2004).  
Oxidation markers confirm that HOCl attacks preferentially the LDL-protein moiety, 
inducing oxidative damage of apoB-100. Moreover, HOCl oxidation increases 
electrophoretic mobility of LDL. This increase in REM is thought to be due to 
modification of the apoB-100 lysine residues, with a concomitant increase in the net 
negative charge of the LDL particle (Ermak et.al, 2008). 
Myeloperoxidase, which is present and catalytically active in human atherosclerotic 
lesions, promotes LDL oxidation in vitro by a variety of mechanisms that do not require 
metal ions; however, the exact mechanism by which it oxidises LDL is uncertain. One 
pathway for damage may be the tyrosyl radical, which promotes dityrosine formation 
and peroxidation of lipids. The detection of elevated levels of dityrosine in LDL 
isolated from lesions implicates the tyrosyl radical in oxidative damage. Elevated levels 
of 3-chlorotyrosine in lesion LDL provides even stronger evidence for the operation of 
the myeloperoxidase pathway in vivo because 3-cholorotyrosine is a specific marker for 
oxidative damage by MPO (Heinecke, 1998). In striking contrast, there appears to be 
little evidence that free metal ions, the most widely studied in vitro LDL oxidation 
system, plays an important role in the early disease process. However, the detection of 
elevated levels of o- tyrosine and other markers for metal-catalysed LDL oxidation in 
advanced atherosclerotic lesions supports the hypothesis that metal ions, perhaps 
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released by cellular breakdown, might contribute to the development of advanced 
lesions (Malle et.al., 2006). 
 
1.6    Hypochlorous acid  
Hypochlorous acid (HOCl) is a powerful 2-electron oxidizing agent and a weak acid 
with pKa approximately 7.5, hence it is present in approximately equal mixture with its 
conjugate base hypochlorite (-OCl) at pH 7.4. For the purpose of simplicity, HOCl/-OCl 
will be referred to as HOCl in this thesis. It has important antibacterial properties, but 
excessive or mis-directed production of HOCl has been implicated in several diseases, 
including atherosclerosis, arthritis and some cancers associated with inflammation 
(Klebanoff, 2005). 
1.6.1    Sources of HOCl  
Stimulated neutrophils and monocytes, cells present under inflammatory conditions, 
produce HOCl via the MPO-catalyzed reaction of H2O2 with Cl
– 
(reaction v). HOCl is a 
highly reactive oxidant and is thought to play an important role in both microbial killing 
and inflammatory tissue injury by neutrophils. HOCl reacts with a wide range of 
biological target molecules, including antioxidants, lipids and proteins to form 
chloramines, which are in turn, also powerful oxidizing agents (Zabe et.al 1999).  
 
H2O2  +  Cl
-
  +  H
+  
             HOCl  +  H2O   (v) 
 
 
Myeloperoxidase (MPO) 
Myeloperoxidase (MPO) is a hemeprotein that is abundantly expressed in 
polymorphonuclear leukocytes (neutrophils) and secreted during their activation. The 
presence of a peroxidase in the cytoplasmic granules of leukocytes was suggested at the 
beginning of 20th century but it was the early 1940s that it was purified for the first 
time. Native MPO is a covalently bound tetrameric complex of two glycosylated alpha 
MPO 
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chains (MW 59 – 64 kDa) and two unglycosylated beta chains (MW 14 kDa) (Podrez et 
al., 2000). MPO is sequestered in granules of neutrophils, where it comprises 2 to 5% of 
total neutrophil proteins (Halliwell and Gutteridge, 2007). It is also present in 
monocytes and in certain subtypes of macrophages and has been found up regulated in 
various disease states (Green et al., 2004; Nagra et al., 1997). Active MPO can lead to 
the formation of a range of oxidation products by catalysing the oxidation of a range of 
substrates and by the reaction of the oxidation products with other substrates. MPO uses 
H2O2 to oxidise halide ions such as chloride, bromide and iodide to form hypochlorous, 
hypobromous and hypoiodous acid, respectively (Harrison & Schultz, 1976; Halliwell 
& Gutteridge, 2007). MPO can also oxidise thiocyanate anions into hypothiocyanite 
(Hampton et al., 1998). However, the high chloride ion concentrations in phagocyte 
cytoplasm and extracellular fluids suggest that HOCl is the major physiological product 
of MPO activity (Thomas & Fishman, 1986). Indeed, 28 to 70% of the H2O2 produced 
by neutrophils has been detected as HOCl (Foote et al., 1983; Weiss et al., 1982).  
MPO appears critical for oxidative killing of microorganisms in experimental systems. 
Neutrophils isolated from the blood of MPO-deficient individuals were inefficient in 
killing a variety of microorganisms (Lehrer & Cline, 1969; Kitahara et al., 1981). In 
addition, inhibitors of MPO such as azide, cyanide and salicylhydroxamic acid impair 
killing by normal cells (Klebanoff, 1970; Humphreys et al., 1989). 
Following phagocytosis, neutrophils undergo degranulation and MPO is rapidly 
released into the phagosome. However, leakage or secretion of MPO to the outside of 
the cell through incomplete closure of the phagosome or “frustrated phagocytosis” also 
occurs (Vissers et al., 1985). This leakage of MPO can induce damage to surrounding 
tissue, and is thought to contribute to the pathogenesis of several diseases (Malle et al., 
2000; Daugherty et al., 1994; Baldus et al., 2002). 
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1.6.1    Biological targets of HOCl   
HOCl is a powerful oxidising agent that can react with many biological molecules such 
as DNA, lipids, proteins and free thiols. How vulnerable a particular target is towards 
oxidation by HOCl depends on: what else is present to compete with HOCl, relative 
concentrations of HOCl and other biomolecules, and on the molecules accessibility to 
HOCl (Folkes et al., 1995; Pullar et al., 1999). HOCl can react with O2
•-
 , amines and 
H2O2 to generate OH
•
, chloramines and singlet oxygen, respectively (Klebanoff, 2005). 
MPO also uses H2O2 to oxidize a variety of aromatic compounds, tyrosine residues 
(Klebanoff, 2005) and nitrite (Eiserich et al., 2002) to generate their respective radicals.   
Reactions of HOCl with membrane constituents resulting in loss of cellular integrity 
could be involved in bacterial killing as well as cytotoxicity/tissue injury caused by 
these inflammatory cells. They could also promote atherosclerosis by contributing to 
oxidative modification of LDL particles either through direct interaction or indirectly 
after transfer of HOC1-modified lipids from other sites (inflamed tissue, erythrocytes) 
to LDL (van den Berg et.al., 1993). Chlorination of unsaturated fatty acids and 
cholesterol to chlorohydrin derivatives has been demonstrated (Pullar et.al., 1999), 
which suggests that the lipid component of cell membranes could be susceptible to 
attack by HOCl. However, this reaction is relatively slow with chlorohydrins only being 
detected in cells after exposure to cytotoxic HOCl concentrations (Carr et al., 1996; 
Vissers et al., 1998).  HOC1-modified lipids can exert cytotoxic and biophysical effects. 
HOCl-modified cholesterol oxidation products have diverse cytotoxic effects. Epoxy-, 
keto-, and hydroxy-derivatives of cholesterol affect de novo sterol biosynthesis, DNA 
synthesis, cellular functions, and cellular growth and proliferation (van den Berg et.al., 
1993). 
Thiol groups and thioethers such as methionine are most readily oxidised at a rate 
approximately 100 times that of amine groups (Pullar et.al., 1999). HOCl can also 
halogenate cell constituents; the most favoured chlorinating reaction is with amines to 
form chloramines (Halliwell & Gutteridge, 2007). Chloramines while longer-lived and 
less reactive than HOCl retain two oxidising equivalents, in which they utilize to 
oxidise thiols and heme proteins thus extending the reactivity of HOCl. Chloramines are 
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also known to be toxic to cells and bacteria, dependent on structure and their ability to 
cross the plasma membrane (Tatsumi & Fliss, 1994; Thomas, 1979) Additionally, 
chloramines can break down to reactive aldehydes which themselves are cytotoxic 
(Hazen et.al., 1996).  
HOCl also reacts with a range of low molecular weight biomolecules and antioxidants. 
HOCl reacts with GSH and ascorbate (Folkes et al., 1995).  In addition to high 
reactivity with free thiols such as GSH, HOCl can also oxidise protein thiols, though 
their reactivity may vary based on their accessibility and pKa (Pullar et al., 1999).  
HOCl has also been shown to cause rapid necrotic cell death, characterized by a rapid 
loss of cellular ATP and cell lysis without caspase-3 activation in HMDM cells (Yang 
et.al., 2011). The mechanism by which HOCl is toxic to cells is proposed though 
destabilization of cytosolic calcium control resulting in the failure of both the 
mitochondria and lysosomes (Yang et.al., 2011).  
 
1.6.2    Effects of HOCl-oxLDL  
Although the existence of HOCl-oxLDL has been known as a probable oxidative 
modification of LDL for many decades, it has not been utilized as much as some of the 
other experimental models. Our knowledge of how HOCl-oxLDL reacts in vivo and the 
role it plays in atherosclerosis is limited and not without holes.   
Internalization of modified LDL into macrophages is a key component to the oxidative 
modification hypothesis. Not only is HOCl-oxLDL known to be internalized via classB 
scavenger receptors CD36 and SR-BI on the macrophages (Assinger et.al., 2010; Ermak 
et.al., 2008; Westendorf  et.al., 2005), but it has been shown that it up regulates CD36 
and PPARγ levels in a dose- and time-dependent manner (Westendorf  et.al., 2005). 
Blood platelets play a central role in advanced atherosclerotic blood vessels, where an 
ulcer or fissure in the fibrous cap of the atheroma serves as an agonist that transforms 
the platelet into a major pro-thrombotic offender. HOCl-oxLDL stimulates the platelet 
Ca
2+
-ATPase and leads to a decreased intracellular Ca
2+
. Others have also noted 
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differences in the properties of Cu
2+
-oxidised versus HOCl-modified lipoproteins (Zabe 
et.al., 1999). The addition of HOCl-oxLDL to human platelets has not only shown its 
ability to stimulate their aggregation (Volf et.al., 2000) but also strongly induces 
formation of ROS, and the impairment of this process by apocynin (Assinger et.al., 
2010) implies an important role of NADPH oxidase. 
HOCl-oxLDL is known to contribute to a specific and directed migration of 
inflammatory cells, by induction of chemokine synthesis in human monocytes 
(Woenckhaus et.al., 1998) and neutrophils (Terkeltaub et.al.1994). HOCl-oxLDL also 
exerts stimulatory effects on various human polymorphonuclear leukocytes (PMNLs); 
including respiratory burst, degranulation, enhanced production of reactive oxygen 
metabolites, enzyme secretion (Kopprasch et.al., 1998), and adhesion to endothelial 
cells (Lehr et.al., 1995b; Kume et.al., 1992).  HOCl-oxLDL induced PMNLs adhesion 
to endothelium involves the generation and action of ROS and can be completely 
prevented in vivo by the antioxidant vitamin C (Lehr et.al., 1995a). This, together with 
the observation that only HOCl-oxLDL stimulated PMNLs showed a significant 
respiratory burst with an extracellular release of both superoxide anions and hydrogen 
peroxide (Kopprasch, et.al, 1998), suggest that formation of ROS may indeed constitute 
a key event in leukocyte-endothelial cell interaction. Alternatively, HOCl-oxLDL can 
increase the adhesive properties of both leukocytes (Lehr et.al., 1995b), and endothelial 
cells (Kume et.al., 1992) by enhancing the expression of adhesion molecules on these 
cells (Kopprasch et.al., 1998). 
Cell death stimulates atherogenesis through induction of inflammation and enlargement 
of the necrotic core as well as contributing to plaque instability (see section 1.4). It is 
important to note that HOCl-oxLDL displays cytotoxic properties and should be 
acknowledged for the role it plays in atherosclerosis. HOCl-oxLDL induces apoptosis in 
all arterial cells, including monocytes, U937 cells (Ermak et.al., 2010) and THP-1 cells 
(Vicca et.al., 2000; Vicca et.al., 2003).  The nature of the apoptotic program varies 
depending on the oxidation type of LDL. The mechanism by which HOCl-oxLDL 
induces apoptosis was recently elucidated by Ermak et.al., (2010) who showed 
apoptosis was induced by HOCl-oxLDL in U937 cells via the caspase-dependent 
pathway leading to activation of the caspase-3. The latter is activated to a minor extent 
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by direct cleavage by caspase-8, and to a major extent indirectly by mitochondrial 
involvement and subsequent activation of caspase-9 (Ermak et.al, 2010). 
 
1.7   Protein oxidation  
The formation of reactive oxygen groups upon protein is considered to be a significant 
contributor to cellular damage and as an indicator of the interruption to normal 
biological systems. For a long time, membrane lipids were thought to be the main 
cellular targets for oxidative damage due to their proximity and tendency to undergo 
self-perpetuating chain reactions. With 75% of the combined mass of potential 
molecular targets, protein has become a front runner in its hypothesised role it plays in 
oxidative stress within the cell.  
Many proteins can stabilize redox metal solubilites so they become capable to redox 
cycle, allowing site-specific formation of very reactive products from hydrogen 
peroxide and superoxide (Halliwell & Gutteridge, 1999). These ROS can then mediate 
Fenton reactions generating protein peroxides and carbonyls along with peptide 
cleavage and cross-linking (Dean et.al., 1993). This oxidation modification of proteins 
in vivo may affect a variety of cellular functions involving proteins, receptors, signal 
transduction mechanisms, transport systems and enzymes. The accumulation of 
oxidised proteins has been associated with many diseases such as Alzheimer‟s, 
atherosclerosis, Parkinson‟s, cystic fibrosis, and arthritis (Berlett & Stadtman, 1997). 
An important  element of this hypothesis is that oxidized proteins may themselves 
contain reactive species which can go on further to damage more proteins and other 
biomolecules.  
Protein hydroperoxides 
Protein hydroperoxides are another product of oxidative attack on proteins, formed 
through a stepwise series of reactions. Oxidation of the polypeptide backbone is 
initiated by the subtraction of an H
•
 of a protein by a radical species (R
•
) to form a 
carbon-centred radical (Pr
•
) (reaction vii). This carbon-centred radical can react with O2 
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to form a protein peroxyl radical intermediate (PrOO
•
) (reaction viii), giving rise to the 
protein hydroperoxides (PrOOH) (reaction ix). 
 
  PrH  +  R
•  
  Pr
•
  + RH    (vii) 
  Pr
•
  +  O2  PrOO
•     
(viii) 
  PrOO
•
 +  e
-
  + H
+  
PrOOH   (ix)   
 
The potential biological importance of protein hydroperoxides (PrOOHs) lies in their 
formation, stability and reactivity. PrOOHs have a relatively long lifetime, enabling 
them to diffuse a considerable distance, intracellularly and into extracellular spaces 
(Gebicki, 1997). This ability to transfer damage to other biomolecules has given 
strength to the argument that protein radicals are a relevant form of oxidative stress, and 
that PrOOHs themselves should be considered as ROS, capable of propagating further 
damage (Gebicki, 1997). 
 
1.7.1    Protein targets of HOCl 
There are many potential targets for HOCl within an amino acid, peptide or protein, 
including thiols, amine groups, aromatic groups and amides. The reaction of HOCl  
with individual amino acids has been thoroughly investigated, and the following order 
of reactivity with various amino acid side chains determined : Met > Cys >> 
cystine~His~α amino acid > Trp > Lys >> Tyr~Arg > backbone amides > Gln~Asn 
(Winterbourn, 1985; Pattison and Davies; 2001).  
Such reaction results in side-chain modification, backbone fragmentation and cross-
linking. For instance, irreversible protein crosslinks have been observed in cell 
membranes of red cells exposed to low doses of HOCl (Vissers et al., 1998). HOCl can 
react with free tyrosine or tyrosine residues of proteins, resulting in the formation of 3-
chlorotyrosine and 3,5-dichlorotyrosine (Domigan et al., 1995; Hazen et al., 1996; 
Kettle, 1996; Hazen et al., 1997; Fu et al., 2000). 
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HOCl reacts rapidly with amines present on the N-terminal of α-amino acids, peptides 
and proteins, as well as amine functional groups on the side chains of the amino acid 
residues Lys, His, and Trp to produce chloramines (Pattison & Davies, 2001). Amides 
react more slowly, so are relatively unimportant protein targets (Hawkins et.al., 2003). 
However, if a large excess of HOCl is generated, reaction with backbone amides may 
occur. This usually results in side chain damage, protein fragmentation (Hawkins & 
Davies, 1998), formation of protein aggregates (Vissers & Winterbourn, 1991; 
Chapman, 2003) and an increased susceptibility to proteolytic degradation (Hawkins 
et.al., 2002). HOCl can also react with the aromatic ring of Tyr, the indole ring of Trp 
and the guanidinium group on Arg, but these are kinetically unfavourable (Pattison & 
Davies, 2001).  
Chloramines are generated by the reaction of HOCl with free amine group (reaction vi). 
These products can undergo secondary reactions with thiols and thiol containing 
proteins (Pullar et al., 2000), induce radical generation that may result in protein 
fragmentation or lipid peroxidation (Hawkins & Davies, 1998; Hazell et al., 1997) or 
break down to form protein carbonyls in proteins (Handelman et al., 1998; Hazen et al., 
1998). By comparison to HOCl, chloramines have a narrower range of targets. In 
particular they demonstrate high reactivity with thiol groups and thioethers (R-S-R) 
resulting in thiol-specific protein oxidation (Peskin & Winterbourn, 2001; Grisham, 
1984; Thomas, 1979). 
RNH2 + HOCl     RNHCl + H2O   (vi) 
As chloramines are inherently unstable compounds and the products of their 
decomposition may be involved in toxicity to cells. Decomposition of chloramines can 
result in the formation of aldehydes and ketones. These are collectively termed protein 
carbonyls and are formed via a range of reaction mechanisms. 
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1.7.2    AOPPs and disease  
Recently a family of oxidised protein compounds, termed “advanced oxidation protein 
products” (AOPPs) has emerged as a novel class of renal pathogenic mediators. AOPPs 
are a class of dityrosine-containing protein products formed during oxidative stress and 
carried mainly by albumin in vivo (Witko-Sarsat et.al., 1996; Witko-Sarsat et.al., 1998). 
Advanced oxidation protein products (AOPPs) were described by Witko-Sarsat et al. 
(1996) for the first time. They described the of presence of high levels of oxidized 
proteins, that they designated AOPPs, in the plasma of haemodialysed patients. 
Formation of AOPPs could be induced in control plasma by chlorinated oxidants such 
as chloramines or hypochlorous acid.  
Accumulation of plasma AOPPs was first identified in patients that underwent dialysis, 
and was subsequently found in subjects with diabetes (Witko-Sarsat et.al., 1998; 
Martin-Gallan et.al., 2003), metabolic syndrome (Atabek et.al., 2006), and non-diabetic 
cardiovascular disease (Witko-Sarsat et.al., 1998). Recent studies have shown that 
chronic accumulation of plasma AOPPs significantly increases urinary protein excretion 
and accelerates glomerulosclerosis (scaring of the kidney tissue) (Zhou et.al., 2009).  
An increase in AOPPs have also been shown to rapidly trigger production of 
intracellular superoxide by activation of  NADPH oxidase leading to the up regulation 
of p53, Bax, caspase -3 activity and apoptosis of podcytes (Zhou et.al., 2009). 
 HOCl-treated human serum albumin and in vivo-generated AOPPs can trigger 
oxidative bursts in neutrophils and monocytes, indicating that they can act as true 
inflammatory mediators (Iwao et.al., 2006).  More interesting is the finding that AOPPs 
are highly correlated to carotid intima media thickness (Drueke et.al., 2002) and may be 
related to atherosclerotic cardiovascular events (Descamps-Latscha et.al., 2005) 
especially with the detection of HOCl-modified proteins (including albumin) in 
atherosclerotic lesions (Hazell et.al., 1996). 
Animal studies on hypercholesterolemic rabbits have enlightened several interesting 
factors about AOPPs. Elevated levels of plasma AOPPs have been shown to be 
associated with increased atherosclerotic plaque areas (Liu et.al., 2006). The 
mechanism by which AOPPs accelerate atherosclerosis remains to be investigated, but 
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it has been proposed that a possible mechanism lies with, spontaneous generation of 
hypercholesterolemia (Liu et.al., 2006) a major risk factor for the propagation of 
atherosclerosis. Animal models have demonstrated that in vivo elevation of plasma 
AOPP levels resulted in excessive inflammatory response, as evidenced by increased 
TNF-α, enhanced macrophage invasion and SMC proliferation in the arterial wall (Liu 
et.al., 2006). Although observational studies in animals suggest a close relationship 
between AOPPs and atherosclerosis, there is little evidence that AOPPs contribute to 
the occurrence or progression of atherosclerosis in vivo with relevance in humans.  
 
1.8    Antioxidant defences  
Normally, cells are able to survive in the presence of a wide range of oxidants because 
they possess antioxidant defences that enable them to combat the oxidant‟s potential to 
cause cellular damage and alter the redox-state of the cell. Typical mechanisms of 
antioxidant action include a) agents that catalytically remove ROS such as superoxide 
dismutase, catalase and peroxidise enzymes, b) agents that decrease ROS formation 
including proteins that decrease the availability of pro-oxidants such as transition metal 
ions, c) proteins that protect biomolecules against oxidative damage by other 
mechanisms and d) the physical scavenging of ROS that neutralises the radical 
(Halliwell & Gutteridge, 2007).  
Glutathione (GSH) is the most significant low molecular weight antioxidant synthesised 
in cells and exists primarily in the thiol-reduced form (Meister, 1988). GSH plays a 
crucial role in a multitude of cellular processes such as cell differentiation, proliferation 
and apoptosis. Disturbances in GSH homeostasis are implicated in the progression of 
many human diseases including atherosclerosis (Ballatori et al., 2009). The most 
important function of GSH appears to be as an antioxidant defence removing oxidative 
stress and maintaining the thiol-redox status of the cell. GSH can act as an antioxidant 
by directly reacting with a range of oxidants such as OH
•
, HOCl, ONOO
-
, RO
•
, NO2
•
 
and less efficiently with O2
•-
 (Halliwell & Gutteridge, 2007). GSH deficiency or a 
decrease in the GSH/glutathione disulfide ratio appears to result in increased 
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susceptibility to oxidative stress or low cellular antioxidant capacity (Ballatori et al., 
2009).  
7,8-dihydroneopterin (78NP) has been shown to exert an antioxidant effect by inhibiting 
oxidative damage to a variety of substrates including U937 cells (Gieseg et al., 2001a). 
The mechanism of inhibition of metal ion- and peroxyl radical-mediated LDL oxidation 
appear to involve scavenging of the lipid peroxyl radical, even though 78NP is a water 
soluble antioxidant. 78NP was further found to inhibit ROS-mediated damage to a range 
of other substrates and cells, including bovine serum albumin (Duggan et al., 2001), 
erythrocytes (Gieseg et al., 2001b) and the U937 monocytic cell line (Gieseg et al., 
2001a; Duggan et al., 2002). These studies noted protection against damage that ranged 
from dityrosine and protein hydroperoxide formation to haemolysis, cell death and thiol 
oxidation.). In addition to the above substrates, 78NP has also been shown to prevent 
oxLDL-induced intracellular GSH loss in U937 cells by scavenging oxLDL-induced 
intracellular oxidants, thus maintaining the intracellular redox environment and 
preventing cell viability loss (Baird et al., 2004; Baird et al., 2005) 
 
1.9    Objectives of research  
HOCl is known to oxidise the protein moiety over the lipid moiety of the LDL particle 
(Ermak, et al., 2010). This research will examine lipid and protein oxidised products 
following oxidation of LDL with HOCl, to access the biological importance of HOCl-
oxLDL in the initiation of cell death. The research will also examine the effect of 
HOCl-oxLDL on cell metabolism, glutahione (GSH) levels, and cell viability. This will 
directly test the hypothesis that HOCl-oxLDL is toxic to cells and show whether it 
could be a source of intracellular stress within the plaque.  
Advanced oxidation protein products (AOPPs) have been shown as a source of 
oxidative stress and a propogating factor in advancing kidney failure (Witko-Sarsat 
et.al., 1998). Close correlations between pathogenesis and inflammatory conditions in 
uremic patients and those presenting with atherosclerosis have been observed, leading 
to the hypothesis that AOPPs play a causal role in the atherosclerosis. This will be 
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tested by creating AOPPs in vitro and examining the effects they exhibit on U937 cells; 
including measurement of cell metabolism, glutahione (GSH) levels, and cell viability. 
As 78NP inhibition mechanism is thought to be through an extracellular mechanism 
(scavenging of oxidants released into the artery walls) it is hypothesized that 78NP will 
be able to inhibt the toxicity of both HOCl-oxLDL and AOPPs. 
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Reagents 
All reagents used in this research were of analytical grade or better.  All solutions were 
prepared using ion-exchanged ultra-filtered water, produced using a NANOpure 
ultrapure water system from Barnstead/Thermolyne (IA/USA). 
 
-mercaptoethanol Sigma Chemical Co., Missouri, USA 
1,1,3,3-Tetramethoxypropane (TMP) Sigma Chemical Co., Missouri, USA 
2-Thiobarituric acid (TBA) Sigma-Aldrich Chemical Co., Steinheim, 
Germany 
2,2‟-azobis(amidinopropane)dihydrochloride 
(AAPH) 
Arcos, N.J  (USA) 
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) 
Sigma Chemical Co., Missouri, USA 
4-Morpholine-propanesulfonic acid (MOPS) Sigma Chemical Co., Missouri, USA 
7,8-Dihydroneopterin (7,8-NP) Schirck Laboratories, Switzerland 
7-Ketocholesterol (7KC) Sigma-Aldrich Chemical Co., Missouri, USA 
Acetic acid (glacial) Merck Ltd, Poole, England 
Acetonitrile (ACN) J.T.Baker (USA) 
Acetone Merck Ltd, Poole, England 
Ammonium ferrous sulfate Hopkin and Williams Ltd, Essex 
Argon gas BOC Gases, Auckland, New Zealand 
Bicinchoninic acid (BCA) protein determination kit Pierce, Illinois, USA 
Bovine serum albumin (BSA) (fraction V- fatty acid 
free) 
Gibco Invitrogen Corporation, Auckland, New 
Zealand 
Bromophenol blue Sigma Chemical Co., Missouri, USA 
Butylated hydroxytoluene (BHT) Sigma Chemical Co., Missouri, USA 
Chelex 100 resin Bio-Rad Laboratories, California, USA 
Cholesterol reagent Roche Diagnostics, USA 
Chloroform Merck and Univar 
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Copper chloride (CuCl2) Sigma Chemical Co., Missouri, USA 
Diethyl ether Merck, Darmstadt, Germany 
Dihydroethidium (DHE) Invitrogen,, Oregon, USA 
Dimethyl sulphoxide (DMSO) AnalaR, Poole, England 
Ethanol Merck, Darmstadt, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma Chemical Co., Missouri, USA 
Glutathione (reduced form) Sigma Chemical Co., Missouri, USA 
Glycerol Sigma Chemical Co., Missouri, USA 
Hexane Mallinckrodt Chemicals, New Jersey, USA 
Hydrochloric acid, fuming 37 % (HCl) Merck, Darmstadt, Germany 
Isopropanol Mallinckrodt Chemicals, New Jersey, USA 
Lipoprotein Electrophoresis Kit Beckman Coulter, USA 
Methanol Merck, Darmstadt, Germany 
Molecular Weight Marker  Fermentas International Inc, Ontario, Canada 
Monobromobimane (MBB) Fluka Analytical, Switzerland 
Nitrogen gas BOC Gases, Auckland, New Zealand 
NuPAGE 4-12% Bis-Tris Gel, 1.0 mm x 10 well Invitrogen, California, USA 
Phenol Sigma Chemical Co, Missouri, USA 
Phosphoric acid (H3PO4) Merck, Darmstadt, Germany 
Potassium bromide (KBr) Merck, Darmstadt, Germany 
Potassium hydroxide (KOH) Merck, Darmstadt, Germany 
Sodium acetate (C2H3NaO2) Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4.H20) 
Scharlau Chemie, Italy 
Sodium dodecyl sulphate (SDS) Sigma Chemical Co., Missouri, USA 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Scharlau Chemie, Italy 
Sodium hypochlorite (NaOCl) Jasol Dynawhite, Christchurch, New Zealand 
Sulfuric acid (H2SO4) BDH lab supplies Ltd, Poole, England 
Trichloroacetic acid (TCA) Merck, Darmstadt, Germany 
Trypan blue solution (0.4%) Sigma Chemical Co., Missouri, USA 
Xylenol orange 
 
 
 
 
Sigma Chemical Co, Missouri, USA 
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2.1.2 Media  
Earle‟s balanced salt solution (EBSS) Invitrogen, California, USA 
Foetal bovine serum (FBS) Invitrogen, California, USA 
Penicillin/Streptomycin (10000 units/ml penicillin G 
and 10000 µg/ml streptomycin) 
Gibco Invitrogen, Auckland, New Zealand 
Roswell Park Memorial Institute (RPMI) -1640 media, 
with phenol red 
Sigma-Aldrich Chemical Co., Missouri, USA 
Roswell Park Memorial Institute (RPMI) -1640 media, 
without phenol red 
Sigma-Aldrich Chemical Co., Missouri, USA 
2.1.3    General solutions, media and buffers 
2.1.3.1    Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS), containing 150 mM sodium chloride and 10 mM 
sodium dihydrogen orthophosphate (pH 7.4) was vacuum filtered through a 0.45 μm 
Phenex filter membrane (Phenomenex). If required for cell culture, the PBS solution 
was sterilized by autoclaving (15 minutes, 121ºC and 15 psi) and stored at 4ºC. PBS 
was warmed in a water bath to 37ºC prior to use with cells. 
2.1.3.2    Roswell Park Memorial Institute (RPMI)-1640 media (with or without 
phenol red) 
The media was prepared as per manufacturer‟s instructions. Powdered RPMI-1640 
(with or without phenol red) was dissolved in nanopure water, followed by addition of 
sodium bicarbonate and pH adjustment to 7.4 with 1 M NaOH. The media was filter-
sterilised using a peristaltic pump (CP-600, Life Technologies) and a 0.20 µm 
Sartolab
®
-P20 filter (Sartorius AG, Goettingen, Germany) into sterile bottles. Media 
was stored at 4ºC and warmed to 37ºC in a water-bath before use.  
2.1.3.3    Bovine serum albumin (BSA) solutions   
Bovine serum albumin – fraction V, fatty acid free (BSA) stock solution (7.5 mg/ml)  
was prepared fresh, and used within one week, by dissolving BSA in filter sterilized 
PBS. Solution was stored under argon at 4 ºC and warmed to 37 ºC in water-bath before 
use.  
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2.1.3.4    7,8-Dihydroneopterin (78NP) solution 
A 2 mM stock of 78NP (MW= 255.2 g/mol) was prepared fresh, immediately before 
each experiment. 78NP was dissolved in degassed ice cold RPMI-1640 medium during 
a 5 -10 minute sonication. 78NP solution was subsequently filter-sterilised using a 0.22 
µm MS
®
 PES syringe filter (Membrane Solutions, USA) and diluted to working 
concentrations in warm RPMI-1640 media.  
 
2.2 Methods 
2.2.1 Cell culture 
All cell experiments were carried out under aseptic conditions in a Class II biological 
safety cabinet (Clyde-Apex BH 200). Sterile plastic wares were supplied by Falcon, 
Terumo, Unomedical and Greiner Bio-one. Media and solutions were sterilised either 
by autoclaving or by filtration through a sterile 0.22 μm membrane filter. All equipment 
and tissue culture items were sprayed thoroughly with 70% (
v
/v) ethanol before being 
transferred to the class II biological safety cabinet. Cells were maintained at 37°C in a 
humidified incubator, with an atmosphere calibrated to 5% carbon dioxide: 95% air 
(Sanyo CO2 Incubator).Viable cells were counted using a haemocytometer and a light 
microscope after staining with trypan blue solution at a ratio of 1:1. 
2.2.1.1    Cell culture media 
RPMI-1640 medium (with phenol red) containing 100 units/ml penicillin G and 100 
µg/ml streptomycin was supplemented with  5% (
v
/v) foetal bovine serum for culturing 
U937 cells. This growth media is referred to in the thesis as U937 culture medium. 
2.2.1.2    Preparation of U937 cell line  
The U937 cell line was originally developed from the pleural fluid of a 37-year old man 
with generalised histiocytic lymphoma (Sundstrom & Nilsson, 1976). Our U937 cells 
were a gift from the Haematology Research Laboratory at the Christchurch School of 
Medicine, University of Otago. A 1 ml vial containing 20 x 10
6
 cells/ml was removed 
from liquid nitrogen storage and defrosted in a 37ºC water-bath until almost completely 
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thawed. The concentrated cell suspension was poured into 30 ml of RPMI-1640 
medium at 37°C in a 50 ml centrifuge tube and centrifuged at 500 g for 5 minutes to 
separate the DMSO freezing medium and cells. The resulting cell pellet was re-
suspended in 10 ml of RPMI-1640 medium in a 25 cm
2 
tissue culture flask. Cell density 
was maintained at 0.4-1.5 x 10
6
 cells/ml by passaging in Cellstar® 75 cm
2
 tissue culture 
flasks (Greiner Bio-one) every 2-3 days.  
2.2.1.3    Cell experiment procedures 
All cell experiments were performed using Cellstar® 12-well suspension culture plates 
(Greiner Bio-one), which were coated with 8 µl of 5% bovine serum albumin (BSA) per 
well, (exception being experiments with treatments involving BSA, oxidised or not), to 
prevent cells adhering to the plastic in the absence of FBS. A 5% BSA solution was 
made up in RPMI-1640 (without phenol red) immediately before each experiment. 
Viable cells were counted using a haemocytometer under a light microscope after 
staining with trypan blue at a ratio of 1:1. The required quantity of cells was pelleted by 
centrifugation at 500 g for 5 minutes at room temperature and re-suspended in RPMI-
1640 (with or without phenol red) at 37 ºC, to a concentration of 1 x 10
6
 cells/ml. The 
cell suspension was then aliquoted into wells containing RPMI-1640 (with or without 
phenol red) and any reagents specific to the experiment, to give a final concentration of 
0.5 x 10
6
 cells/ml.  
2.2.2    Blood collection and plasma preparation 
With ethics approval from Upper South A Ethics Committee, CTY/01/04/036, human 
blood was drawn from healthy volunteers following an overnight fast. Blood was drawn 
by venipuncture using a 21G x 
3
/4 inch or 19 G needle attached to a 30 ml syringe 
(Terumo, USA), subsequently it was transferred into 50 ml polypropylene conical tubes 
containing 0.5 ml of 100 mg/ml EDTA (pH 7.4) 
Whole blood was centrifuged at 4,100 g for 20 minutes at 4ºC with the brake off to 
separate red blood cells and plasma. The resulting top yellow plasma was subsequently 
transferred to SS34 rotor centrifuge tubes and centrifuged at 11,000 g for 30 minutes at 
4ºC, with slow acceleration/deceleration, to remove remaining cellular debris in the 
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plasma. Plasma from all donors was then pooled together into a single measuring 
cylinder, to minimise inter-individual variation. Plasma was stored at -80ºC in 32 ml 
aliquots for up to 6 months until required.  
2.2.3    LDL preparation 
2.2.3.1    Extraction of LDL from plasma  
LDL isolation utilised a Beckman Near Vertical Rotor and employed the method of 
Chung et al. (1980) with modifications described by Gieseg and Esterbauer (1994), 
which was directly adapted from Dr. Wendy Jessup (Heart Research Institute Ltd, 
Sydney) for LDL preparation in a vertical rotor. The protocol requires a single gradient 
that redistributes during ultracentrifugation to form a density gradient, which separates 
lipoproteins.  
A 32 ml tube of frozen human plasma was defrosted under cold running water and 
centrifuged at 4700 rpm for 10 minutes at 4ºC to pellet precipitated fibrinogen. The 
supernatant was decanted into a beaker and placed immediately on ice. Potassium 
bromide (KBr) was gradually dissolved in plasma, to a final concentration of 382 mg 
KBr/ml plasma, altering the plasma density to 1.24 g/ml. The solution was stirred 
gently to prevent foam formation, which is an indication of LDL denaturation. Plasma 
was maintained on ice and under argon gas until ultracentrifugation. 
Eight millilitres of 1 mg/ml EDTA (pH 7.4) was added to each of 8 OptiSeal™ 
polyallomer centrifuge tubes (Beckman Coulter, USA) before under-layering with 4 ml 
of KBr-plasma, using a needle attached to a 5 ml syringe. Ultracentrifuge tubes were 
transferred to the NVTi-65 rotor and centrifuged at 60,000 rpm for 2 hours at 10ºC with 
slow acceleration/deceleration using an Optima™ L-90K Preparative Ultracentrifuge 
(Beckman Coulter, Inc., Fullerton, California). Following centrifugation, a 
yellow/orange coloured band of LDL in the density range of 1.019 – 1.063 g/ml was 
collected using a 20 ml syringe attached to a 90º-bend needle  
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2.2.3.2    Determination of cholesterol content of LDL  
The cholesterol content of LDL was determined by enzymatic cholesterol assay using a 
CHOL kit (Roche Diagnostic). One millilitre of cholesterol reagent was incubated with 
10 µl of LDL at room temperature for 10 minutes. The absorbance was read at 500 nm 
against a blank containing only cholesterol reagent. 
LDL concentration was then calculated from the absorbance, based on the estimate that 
cholesterol accounts for 31.69% of the entire LDL particle, by weight, and that LDL 
has a molecular weight of 2.5 kDa (Gieseg and Esterbauer, 1994).  
Calculation: absorbance x 14.9 = [cholesterol] (nM) 
  [cholesterol] (M) x 386.64 g/mol = [cholesterol] (g/l) 
  [cholesterol] (M) x 100/31.69 = g/1 LDL or [LDL] (mg/ml) 
 
2.2.4    LDL washing and dilution 
2.2.4.1    Dialysis tubing treatment 
Dry dialysis tubing (Medicell International, UK) with 25 mm flat width and molecular 
weight cut off (14,000 Daltons), was cut into 22 cm lengths, and boiled for 20 minutes 
on a heating block in a glass beaker containing a solution of 5% 
w
/v NaHCO3 and 1mM 
EDTA. Following washing with distilled water, the tubes were boiled again in a glass 
beaker containing distilled water. After 20 minutes of boiling, the tubes were washed 
thoroughly with distilled water and stored in 50% ethanol at 4ºC. 
2.2.4.2    LDL washing  
Ten millilitres of LDL was transferred to a piece of dialysis tubing secured at one end 
by a double knot, and closed at the top with a single knot. An Eppendorf tube was 
clipped to the top of the dialysis tubing to make it buoyant. LDL was dialysed against 
three 1 litre changes of sterilized PBS (section 2.1.3.1) over a 24 hour period at room 
temperature. LDL was diluted to a final concentration of 2.5 mg/ml (total mass) before 
any subsequent manipulations or use in experiments, by the addition of sterile PBS 
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based on the concentration calculated after dialysis (section 2.2.3.2).  If no further 
manipulations were to be made to the LDL, it was filter-sterilised using a 0.22 µm 
syringe filter and stored at 4ºC in the dark, under argon gas.  
2.2.5    Measurement of hypochlorite (HOCl) concentration  
The concentration of sodium hypochlorite (NaOCl), stored at 4°C, was measured using 
the method described by van den Berg and Winterbourn (1994). A pH 12 buffer 
containing 25 ml of 0.2 M KCl and 6 ml of 0.2 M NaOH diluted to 100 ml with 
nanopure water was prepared. The buffer was then used to dilute the stock NaOCl 500-
fold, and the absorbance at 292 nm measured on a Shimadzu UV-1601PC UV-visible 
spectrophotometer (Shimadzu Corporation, Japan). The concentration was determined 
using the extinction coefficient (350 M
-1
cm
-1
) of HOCl at pH 12 (Gazda and Margerum, 
1994).  
2.2.6    LDL oxidation  
2.2.6.1    HOCl oxidation of LDL 
Oxidation was induced by incubating LDL (2.5mg/ml) in the presence of 42 mM HOCl 
at the following molar oxidant/protein ratios; 250/1, 500/1, 1000/1, 1500/1 and 2000/1. 
Solutions were warmed to 37 ºC before mixing, and then placed for 30 minutes in a 
shaking incubator (Bioline, Edwards Instrument Company, Australia) in the dark. 
Temperature was maintained at 37 ºC and had an orbital motion at a speed of 118 rpm 
in which the constant motion ensured oxygenation of the solutions. After oxidation the 
hypochlorite-oxidised LDL (referred to herein as HOCl-oxLDL) was filter-sterilised 
using a 0.22 µm syringe filter and stored at 4ºC in the dark, under argon gas. 
2.2.6.2    Copper oxidation of LDL 
LDL at 10 mg/ml (total mass) was transferred to a section of dialysis tubing in the same 
manner as LDL washing (section 2.2.4.2). Fifty millimolar copper chloride (CuCl2) 
solution was combined with the LDL inside the dialysis tubing to give a final 
concentration of 0.5 mM CuCl2. The LDL-containing dialysis tubing was placed in a 
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bottle containing 1 L PBS/50 mg LDL, plus CuCl2 at a final concentration of 0.5 mM 
CuCl2. LDL was dialysed against 0.5 mM CuCl2 in PBS overnight at 37ºC in a heated 
orbital shaker.  
The dialysis tubing containing copper-oxidised LDL (referred to herein as Cu-oxLDL) 
was then transferred to a fresh bottle containing 1 L of PBS and stirred with 1 g of 
washed Chelex-100 at 4ºC for two hours. This was repeated twice, with the final 
incubation taking place overnight. Cu-OxLDL was filter-sterilised using a 0.22 µm 
syringe filter and stored at 4ºC.  
2.2.7    OxALB oxidation  
Oxidised BSA was prepared from a stock solution of 7.5mg/ml BSA (see section 
2.1.3.3) with the addition of sterile PBS (see section 2.1.3.1) and 42 µM HOCl at the 
following molar oxidant/protein ratios; 250/1, 500/1, 1000/1, and 2000/1, to give a final 
concentration of 5 mg/ml BSA. Solutions were warmed to 37ºC before mixing, and then 
placed for 30 minutes in an orbital incubator (Bioline, Edwards Instrument Company, 
Australia) in the dark. Temperature was maintained at 37ºC and had an orbital motion at 
a speed of 118 rpm in which the constant motion ensured oxygenation of the solutions. 
After oxidation the hypochlorite-oxidised BSA (referred to herein as oxALB) was 
filter-sterilised using a 0.22 µm syringe filter and stored at 4ºC in the dark, under argon 
gas and used within 2 weeks. 
Finalised albumin oxidation method 
Following observations made on initial experiments, the oxidation of BSA was altered 
slightly, to remove chloramines. OxALB was prepared as mentioned above, but 
underwent dialysis treatment before filter sterilization.  
After oxidation in the orbital incubator oxALB solutions were dialysed (section 
2.2.4.2 ), against PBS, at room temperature for 4 hours, to remove any excess HOCl. 
The dialysis tubing was subsequently transferred to a fresh 1 L bottle of fresh PBS 
containing 2-fold excess of methionine and dialysed overnight. Following the overnight 
dialysis, oxALB was further dialysed against a fresh 1 L bottle of PBS for 4 hours, 
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before it was filter-sterilised using a 0.22 µm syringe filter and stored at 4ºC in the dark, 
under argon gas and used within 2 weeks.  All experiments using this finalised method 
of oxidation have been noted in the legends of the figures as met-oxALB. 
2.2.8    Cell viability assays  
2.2.8.1    Trypan Blue Exclusion Staining  
Trypan blue exclusion staining measures cell viability by analysing cell membrane 
integrity (Moldeus et al., 1978). Viable cells have intact membranes that are 
impermeable to the dye and, as a consequence, appear opaque when viewed under a 
microscope. Dead cells have compromised membrane integrity and stain a deep blue 
colour due to trypan blue uptake.   
U937 cells were mixed with the stain at 1:1 ratio, and 20 µl added to a haemocytometer 
(Marienfeld, Germany). Subsequently, a light microscope was used to count the number 
of opaque (alive) cells in defined regions of a haemocytometer. The proportion of 
viable cells in that well was calculated by dividing the number of viable cells by the 
total number of cells (both alive and dead). 
2.2.8.2    The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
reduction assay 
A) MTT assay solutions 
Five mg/ml of 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) 
was prepared in RPMI 1640 without phenol red. This solution was filter-sterilised using 
a 0.22 μm MS® PES syringe and stored at -20 ºC in dark until use.  
10% (
w
/v) sodium dodecyl sulphate (SDS) in 0.01 M hydrochloric acid (HCl) was stored 
at room temperature. 
B) MTT assay  
The MTT reduction assay measures cell viability by quantifying metabolically active 
cells through their ability to reduce the MTT reagent. This laboratory has previously 
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shown that results produced by this method agree with results obtained by the trypan 
blue exclusion assay when used on U937 and THP-1 cells (Baird et.al., 2004). 
Metabolically active cells can endocytose and metabolise the yellow MTT compound, 
via the action of cellular NADPH dehydrogenases, into a insoluble purple MTT-
formazan product that can be solubilized and quantified spectrophotometrically 
(Mosmann, 1983). The colour intensity provides an indication of the concentration of 
cells and their metabolic activity. 
Following experimental treatment, U937 cells from each well were washed with warm 
PBS and incubated in 1ml of RPMI-1640 medium (without phenol red) containing 0.5 
mg/ml MTT for 2 hour. The insoluble purple crystals were then dissolved by mixing 
with 1 ml of 10% (
w
/v) SDS. The absorbance was read at 570 nm, against a blank 
lacking cells but containing all other reagents.  
 
2.2.9    PrOOH determination by acetic acid-FOX assay 
2.2.9.1    Solutions for FOX assay 
A) Xylenol orange solution 
5mM xylenol orange was prepared by dissolving xylenol orange (MW 760.6g/mol) in 
25mM sulfuric acid for the acetic acid-FOX assay. The solution was to be used within 
one month. 
B) Ammonium ferrous sulphate solution 
5mM ammonium ferrous sulfate was made by dissolving ammonium ferrous sulphate 
(MW 392.16 g/mol) in 25mM sulfuric acid for the acetic acid-FOX assay. The solution 
was to be used within one week. 
C) 2,2’-azobis(amidinopropane)dihydrochloride (AAPH) solutions 
A stock solution of 250mM was prepared the day of experiment by dissolving AAPH 
(MW 271.19 g/mol) in chilled PBS and stored on ice until required. 
Materials and Methods 
 
 
37 
 
2.2.9.2    PrOOH formation in BSA and LDL 
PrOOHs were measured directly after HOCl insult on LDL and BSA described above 
(section 2.2.6.1 and 2.2.7 respectively) using the ferric-xylenol orange (FOX) assay 
described (section 2.2.9.3). 
PrOOHs were also measured after oxidation of BSA with 10 mM 2,2‟-
azobis(amidinopropane)dihydrochloride (AAPH).  A 5 mg/ml BSA solution was 
incubated with or without AAPH in an incubator (Bioline, Edwards Instrument 
Company, Australia) with a temperature and the orbital motion set to 37 ºC and 118 
rpm respectively. At set time points 1 ml samples were removed and PrOOH formation 
was measured using the FOX assay described below (section 2.2.9.3). 
2.2.9.3    Acetic acid-FOX assay  
The acetic acid-FOX assay is a modified version of the sulphuric acid-FOX assay, as 
developed by Joseph Pearson (2002). This assay was used to detect PrOOHs produced 
in oxidised (lipo)proteins.  
One millilitre samples (1 mg/ml) were extracted in triplicate, into 1.7 ml microtubes 
where 140 μl of 72% TCA was added and then samples were chilled on ice in the dark 
for 5 minutes. This was followed by centrifugation at 10000 rpm at 4ºC for 5 minutes. 
Supernatent was discarded and pellets washed in 1 ml of 1:1 methanol/chloroform (or 
5% TCA for oxALB samples) prior to centrifugation at 10000 rpm at 4ºC for 5 minutes. 
Supernatent was again discarded and resulting protein pellets were dried by inverting 
microtubes for 5 minutes. The pellets were then dissolved in 900 μl of 50% acetic acid, 
if needed pellets were also broken up using a flame-sealed Pasteur pipettes and 
vortexed.  
Once completely dissolved, 50 μl of 5 mM xylenol orange and 50 μl of 5 mM 
ammonium ferrous sulphate were added and samples incubated in the dark, on ice, for 
30 minutes. Following incubation the samples were centrifuged at 10,000 rpm at 4ºC 
for 5 minutes. Afterwards the samples were transferred to couvettes and their 
absorbance read against a water blank at 560 nm. Concentration of PrOOHs in samples 
were quantified as a rise in PrOOHs formation compared to controls, consisting of 900 
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μl of 50% acetic acid, 50 μl of xylenol orange and 50 μl of ammonium ferrous sulphate, 
using the extinction co-efficient for calculating PrOOH concentrations in LDL and BSA 
is 35,500 M
-1
cm
-1
. 
2.2.10    HPLC analyses 
High Performance Liquid Chromatography (HPLC) is a widely used system for 
separating, identifying and quantifying compounds. The HPLC system (Shimadzu 
Corporation, Japan) was used for a number of analyses and comprised of a controller 
(LC-20AD), a fluorescence detector (RF-10AXL), a UV-Vis detector (SPD-M20A), an 
auto sampler (SIL-20AC HT), a column oven (CTO-20A), inline vacuum degasser 
(DGU-20A5), and a communication bus module (CBM-20A). Peak areas were 
quantified using the LCSolution software package (version 1.22 SP1, 2002-2006) .  
All the mobile phases used were sonicated (Alphatech Systems Ltd & Co., Auckland) 
for 15 minutes prior to pumping through the HPLC system. Analytes in samples were 
standardised against pure standards with known concentrations to determine their 
concentrations. 
2.2.10.1    Protein tyrosine residue oxidation  
A) Acid hydrolysis 
Tyrosine residue oxidation serves as an indicator of protein damage by free radical 
exposure (Gieseg et al., 1993; Gieseg et al., 2003). In this research, tyrosine residue 
loss upon HOCl reaction with to LDL and BSA, was examined by measuring tyrosine 
residue levels after acid hydrolysis of proteins and HPLC analysis.  
For the acid hydrolysis of proteins, 200 µl of sample, HOCl-oxLDL or oxALB (diluted 
to 1 mg/ml in nanopure H2O), was placed in triplicate, in glass Durham tubes (7.5 mm x 
50 mm Biolab), and dried down under vacuum for approximately 2 hours. The Durham 
tubes were then placed into a Pico-Tag vial (Millipore, USA) containing 1 ml of 6M 
HCl with 1% (w/v) phenol and 50 μl of β-mercaptoethanol. Argon gas was flushed 
through the Pico-Tag vial for 5 minutes to remove oxygen. The vial was then evacuated 
by connecting to a high vacuum line for 2 seconds (the Vac. gauge pressure was 
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maintained below 200 mm Torr). Subsequently, the vial was incubated in a 110ºC oven 
for 16 hours, and allowed to cool to room temperature before opening. The tubes were 
removed from the vials and dried by centrifugation under vacuum in a Speed Vac for 2 
hours before re-solubilising the pellet with 200 μl of 0.1% trifluoroacetic acid (TFA) 
(pH 2.5). The sample was then centrifuged at 20,800 g for 5 minutes at 4ºC before 
transferring 100 μl of the resulting supernatant to an auto sampling vial.  
Ten μl was injected onto a reverse phase Aqua C18, 250 x 4.6 mm, 5μm column 
(Phenomenex). The column was developed with mobile phase A (0.1% (v/v) TFA at pH 
2.5) and mobile phase B (100% acetonitrile), pumped at a flow rate of 1 ml/minute. 
TFA with a concentration of 0.1% (v/v) at pH 2.5 was prepared by adding 1 ml of TFA 
to 800 ml of nanopure water, adjusting the pH to 2.5 with 10 M NaOH, and making up 
to a final volume of 1 L. Tyrosine and DOPA, were detected by a fluorescence detector 
using excitation and emission wavelengths set at 280 nm and 320 nm, respectively. 
Dityrosine was measured by changing the emission wave length to 410 nm after the 
elution of tyrosine. A comparison of the peaks and elution time produced by a tyrosine 
(MW 181.2) standard of 1 μM concentration, DOPA (MW 197.19) and dityrosine (MW 
360.361) standards of 5 µM concentration, made up in 0.1% (v/v) TFA (pH 2.5), were 
used to quantify the elution time and concentration of tyrosine, DOPA and dityrosine 
within the samples. 
2.2.10.2    Intracellular GSH analysis  
Monobromobimane (MBB) is a cell-permeable fluorescent dye that binds thiol groups, 
that can be used for the detection of GSH. MBB alkylates thiol groups to form GSH-
MBB adducts which can then be detected by the HPLC system after protein 
precipitation (Cotgreave and Moldeus, 1986). All procedures involving MBB were 
performed under minimum exposure of light since MBB is light sensitive.  
A 40 mM stock of MBB was prepared by dissolving MBB (MW 271.1 g/mol) in 
acetonitrile, which was stored at 4ºC in the dark for up to 2 weeks. Reduced GSH (MW 
307.3 g/mol) was dissolved in cold PBS, to 5 and 10 µM concentrations, immediately 
prior to HPLC analysis for use as standards. Mobile phase A was 0.25% acetic acid and 
mobile phase B was 100% acetonitrile.  
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After removal of the incubation medium by centrifugation, cells were washed twice in 
warm sterile PBS and resuspended in 1.5 ml Eppendorf tubes in, 400 μl of PBS, 9 μl of 
0.1 M NaOH (to increase the pH to 8), and 10 μl of 40 mM MBB, in this order. After 
20 minutes of incubation in the dark at room temperature, 20 μl of 100% (w/v) 
trichloroacetic acid (TCA) was added to lyse the cells and precipitate cellular proteins. 
The cell lysate was collected and centrifuged at 10000 rpm for 5 minutes at 4ºC to 
pellet cellular proteins. One hundred microlitres of the resulting supernatant was 
transferred to auto sampling vial inserts and 5 µl injected onto the Phenosphere reverse 
phase C-18, 150×4.6 mm, 5 μm column (Phenomenex, Auckland, NZ), heated to 35°C.  
GSH-MBB adducts were detected by the fluorescence detector with excitation and 
emission wavelengths set at 394 nm and 480 nm, respectively. Mobile phase A 
(consisting of 0.25% acetic acid in nanopure water) and mobile phase B (consisting of 
100% acetonitrile) were pumped through the column at a flow rate of 1.5 ml/minute 
with the following gradient program: 
Time (minutes) Mobile phase A Mobile phase B 
0 90% 10% 
10 90% 10% 
11 0% 100% 
15 95% 5% 
16 95% 5% 
20 95% 5% 
   
2.2.10.3    Simultaneous detection of 7-Ketocholesterol (7KC) and α-Tocopherol  
Detection of free 7KC was performed using a modification of the method described by 
Kritharides et al., (1993). Mobile phase was ACN/isopropanol/H2O in a ratio of 
44:54:2. Lipid extraction of the samples was carried out by the addition of 10 µl of 20 
mg/ml BHT, 20 µl of 100 mg/ml EDTA, 500 µl ethanol and 2 ml of hexane, before 
vortexing for 60 seconds. Samples were then centrifuged at 200 g for 10 minutes at 4ºC 
to obtain complete phase separation. Fourteen hundred microlitres of the top hexane 
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layer was removed, transferred to a tapered glass test tube and dried completely under 
nitrogen gas.  
Esterified 7KC was quantified by measuring both free and total 7KC in a sample and 
calculating the difference. Detection of total 7KC was performed using a lipid 
extraction (as above), followed by alkaline hydrolysis that was used to release esterified 
7KC before detection.  
After evaporation with nitrogen gas, the remaining residue was resolubilised in 2 ml of 
20% (
w
/v) KOH in methanol and 2.5 ml of diethyl ether. The sample was then flushed 
with argon gas and vortexed thoroughly. Samples were incubated on ice for 3 hours, 
vortexing every 30 minutes before the reaction was stopped by the addition of 2 ml of 
20% acetic acid.  Two and a half millilitres of hexane was added and samples were 
vortexed for 60 seconds before transferring 4 ml of the upper layer into a tapered glass 
test tube and evaporating completely under nitrogen gas.  
The residues, free and total, were resolubilised in 100 µl of resolubilising phase 
(ACN/isopropanol in a ratio of 4:5). One hundred microlitres of the resulting 
supernatant was transferred to a glass auto sampling vial insert and 20 µl was injected 
onto the Phenosphere reverse phase C-18, 250 x 4.6 mm, 5 µm column (Phenomenex, 
Auckland, NZ) which was heated to 35 ºC. Analysis of 7KC was performed by 
detecting 234 nm absorbance. Mobile phase was ACN/isopropanol/H2O in a ratio of 
44:54:2.  
Low molecular weight molecule, α-tocopherol, scavengers oxidants such HOCl, and 
can be detected simultaneously in the samples prepared by the 7KC method described 
above. Analysis of α-tocopherol was performed by detection of at an excitation 
wavelength of 295 nm and emission wavelength of 325 nm.  
2.2.10.4    Thiobarbituric acid reactive species (TBARS) analysis  
The TBARS assay provides a means of quantifying general lipid peroxidation. The 
method used is an adaptation of that described by Draper et al., (1993). When 
combined, 2-thiobarbituric acid (TBA) and the maldondialdehyde (MDA) lipid 
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hydroperoxide break-down product readily react, forming the pink coloured TBA-MDA 
adduct which is fluorometrically detected by HPLC.  
The MDA standard was prepared on the day of analysis by the dilution of 6.07 M 
1,1,3,3-tatramethoxypropane (TMP) in ethanol/water (2:3), with subsequent dilution in 
water to the desired concentration. The mobile phase was 50 mM sodium dihydrogen 
phosphate, with the pH adjusted to 6.8 using NaOH, and combined with methanol in a 
ratio of 65:35. A 42 mM 2-thiobarbituric acid (TBA) solution was made fresh on the 
day of analysis by dissolving in nanopure water on a hot plate, ensuring that the 
temperature did not exceed 55ºC.  
Samples were diluted with PBS to 1 mg/ml, before 200 µl of this solution was 
transferred to a 1.7 ml microtube. To this, 100 µl of 50 mM phosphoric acid and 20 µl 
of 20 mg/ml BHT in methanol, were added and vortexed to mix. Then 100 µl of the 
above TBA reagent was added before incubating on a shaking heater block (Eppendorf 
Thermomixer 5436) at 95ºC for 30 minutes. Samples were then placed directly onto ice 
and allowed to cool before centrifugation at 10,000 rpm for 10 minutes at 4ºC.  
One hundred microlitres of the remaining supernatant was transferred to an 
autosampling vial insert and 20 µl was injected onto the Phenosphere reverse phase C-
18, 50 x 4.6 mm, 5 µm column (Phenomenex, Auckland, NZ) which was heated to 
30ºC. TBARS were detected using excitation and emission wavelengths of 525 nm and 
550 nm, respectively. The mobile phase was methanol and 50 mM sodium dihydrogen 
phosphate (pH 6.8) in a ratio of 45:55. The concentration of TBARS was quantified by 
comparison with the peak areas of 0 and 1 µM MDA standards.  
2.2.11    Flow cytometry 
Flow cytometry is a powerful technique that simultaneously measures and analyses 
multiple characteristics of single cells, such as cell size, granularity and relative 
fluorescence intensity, as they flow in a fluid stream through a beam of light. It gives 
high-throughput (for a large number of cells) automated quantification of fluorescence 
instead of producing fluorescent images.  
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Cells were probed with DHE or annexinV/PI for intracellular superoxide or apoptosis 
detection as (see section 2.2.11.1 and 2.2.11.2). Cell samples were then re-suspended in 
500 μl of PBS in Eppendorf tubes, and analyzed using the Accuri@ C6 flow cytometer 
(BD Biosciences, USA). DHE-probed and annexinV/PI probed cells were detected 
using the 585/40 band-pass (BP) filter in FL-2 and 530/30 BP filter in FL-1, 
respectively. Ten thousand cells were analyzed in a sample gated to remove subcellular 
debris.  All data were collected and analyzed using the cFlow Plus software.  
2.2.11.1    Dihydroethidium (DHE)  
Dihydroethidium (DHE) has been widely used for detecting intracellular superoxide 
anions. This cell permeable dye reacts with superoxide resulting in the formation of a 
two-electron oxidised product, ethidium (E
+
), which binds to DNA and leads to 
enhancement of red fluorescence (λex/λem = 510/605 nm) (Budd et al., 1997; Zhao et 
al., 2003). DHE (MW 315.4) stock was prepared in DMSO and stored at -20ºC.  
Following experimental treatment and subsequent removal of incubation medium, cells 
were washed in warm PBS and resuspended in, with 150 μl of 10 μM DHE, dissolved 
in sterile PBS, for 20 minutes. Cells were then again washed in PBS twice to remove 
excess DHE. Cell pellets were resuspended in 500 µl PBS and examined by flow 
cytometry (see section 2.2.11). 
2.2.11.2    Apoptosis analysis by Annexin V/PI  
Apoptosis is a distinct event that triggers characteristic morphological and biological 
changes in the cellular life cycle. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular environment. AnnexinV 
labelled with a fluorescent tag, is a 35-36 kDa Ca
2+
 dependent phospholipid-binding 
protein that has a high affinity for PS. Since AnnexinV staining precedes the loss of 
membrane integrity which accompanies the later stages of cell death resulting from 
either apoptotic or necrotic processes, staining with AnnexinV was used in conjunction 
with a live/dead dye propidium iodide (PI) to allow identification of early apoptotic 
cells (PI negative, AnnexinV positive) from dead cells (PI positive, AnnexinV positive). 
Materials and Methods 
 
 
44 
 
Viable cells with intact membranes exclude PI, whereas the membranes of dead and 
damaged cells are permeable to PI. 
Following experimental treatment and subsequent removal of incubation medium, cells 
were washed in binding buffer and resuspended in 100 μl of binding buffer containing 2 
μl annexinV, 5 μl PI and incubated in the dark  for 15 minutes. After incubation 
samples were topped up to 500 μl with binding buffer and examined by flow cytometry 
(see section 2.2.11).  
2.2.12    SDS-PAGE analysis 
2.2.12.1    Solutions for SDS-PAGE analysis 
Cracker buffer was prepared by dissolving SDS (MW = 288.38 g/mol), glycerol (MW =  
92.10 g/mol), bromophenol blue (MW = 670.02 g/mol) in 0.5 M Tris-HCl in nanopure 
water (pH 6.8) and made up to a final volume of 50 ml. Prior to use, 1 ml of the above 
solution was mixed with 20 μl of β-mercaptoethanol and 2 ul of 100 mg/ml 
ethylenediaminetetraacetic acid (EDTA). The final cracker buffer hence consisted of 
0.125 M Tris-HCl (pH 6.8), 1% (
w
/v) SDS, 20% (
w
/v) glycerol, 0.1% (
w
/v) bromophenol 
blue, 2% (
v
/v) β-mercaptoethanol, and 0.5 mM EDTA.  
Lysis buffer consisted of 40 mM of HEPES (MW = 238.31 g/mol), 50 mM of NaCl 
(MW = 58.44 g/mol), 1 mM EDTA (MW = 372.24 g/mol), and 1 mM EGTA (MW = 
380.4 g/mol) in nanopure water, with pH adjusted to 7.4 using 10 M NaOH and stored 
at 4°C. Prior to use, Complete, Mini protease inhibitor stock (7×) was added to lysis 
buffer. The 7× stock protease inhibitor solution was prepared as per manufacturer‟s 
instructions. One Complete, Mini protease inhibitor cocktail tablet (Roche, Germany) 
was dissolved in 1.5 ml of nanopure water to give a 7× stock solution. The completed 
lysis buffer was stored on ice until use. 
MOPS (4-morpholine-propanesulfonic acid) buffer consisted of 50 mM MOPS, 50 mM 
Tris base, 0.1% (
w
/v)  SDS, and 1 mM EDTA in nanopure water, with the pH adjusted 
to 7.7 by adding concentrated HCl. 
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2.2.12.2    Cell processing of U937 cells for SDS-PAGE analysis 
After experimental treatment, cell samples were collected and washed twice with PBS 
by centrifugation at 500 g for 5 minutes at room temperature. One hundred and fifty μl 
of ice cold complete lysis buffer was used to lyse U937 cell pellet. The samples were 
then vortexed and placed on ice to ensure thorough lysing of the cells for at least 15 
minutes. 
After protein analysis, the volume of cell lysate containing 75 μg of protein was 
transferred to a new 1.7ml Eppendorf tube. Ice cold acetone was then added to 
precipitate the proteins (ratio of cell lysate:acetone 1:10). After incubation on ice for 5 
minutes, the sample was centrifuged at 20,800 g for 5 minutes at 4°C. The resulting 
protein pellet was dissolved in “cracker” buffer for SDS-PAGE analysis (see section 
2.2.12.1). 
2.2.12.3    Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 
Cracker buffer (30 μl) was used to dissolve the acetone-precipitated protein pellet 
described above to give a final protein concentration of 2.5 μg/μl. The sample was then 
heated to 95 ºC in a heating block for 3 minutes and centrifuged for 5 minutes at 20,800 
g at room temperature to remove any cell debris. 
A gradient polyacrylamide gel, 4-12% (Bis-Tris Gel, Invitrogen, Carslband, CA, USA), 
was placed in the XCell SureLock™ Mini-Cell system (Invitrogen, US) and the MOPS 
running buffer added to the buffer reservoir. Five microliters of Fermentas pre-stained 
molecular weight marker mix (Fermentas International Inc, Canada) and 20 μL of 
samples (containing 50 μg proteins) were loaded into the wells of the gel. The gel was 
run at 100V for 15mins to stack the gel before electrophoresis at 200 V for 
approximately 1 hour until the loading buffer dye reached the bottom of the gel.  
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Statistical analysis 
Data were graphed and analysed statistically using GraphPad Prism version 5.0 for 
Windows (GraphPad Software, San Diego, California, USA). Significance was 
confirmed via a one-way analysis of variance (ANOVA) followed by Tukey‟s multiple 
comparison test. Significant levels are indicated in the following manner: (*) p ≤ 0.05, 
(**) p ≤ 0.01 and (***) p ≤ 0.001.  
Results displayed in this thesis are taken from a representative of three separate 
experiments, unless otherwise stated in the legend. The mean and standard error of the 
mean (SEM) shown within each experiment were calculated from triplicate samples in 
every case. Some results, flow cytometry, are the combined result of several separate 
experiments, with the mean and SEM shown and calculated across those experiments. 
This will be stated in the legend.          
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3. RESULTS 
 
3.1 Characterisation of the modification of low-density 
lipoprotein (LDL) by hypochlorous acid (HOCl) 
The majority of previous studies exploring cellular effects of oxLDL have been carried 
out using human oxLDL oxidised in vitro in the presence of metal ions such as Cu
2+
. 
Previous studies in our laboratory have shown that in U937 cells, copper oxidised LDL 
(Cu-oxLDL) kills cells through excessive oxidant production resulting in the loss of 
intracellular anti-oxidant, inactivation of key metabolic enzymes and necrosis. Recently, 
interest has arisen in other forms of oxLDL, with potential relevance to atherosclerosis.   
Only in the past ten years has research begun into the mechansism of HOCl induced 
oxidation of LDL (HOCl-oxLDL), and its toxicity to cells.  Ermak et.al, 2010 and Vicca 
et.al, 2003 have shown certain apoptotic pathways are activated in response to HOCl-
oxLDL.  
Characterisation of the biochemical properties of  HOCl-oxLDL was the first step taken 
in understanding how HOCl oxidises the LDL molecule and how it may play a role in 
the toxicity of cells within an atherosclerotic inflamation site. 
3.1.1 Tyrosine loss on oxidised LDL 
It has been observed that the majority of the oxidant, HOCl, is consumed by reaction 
with proteins, with lipid peroxidation being a secondary reaction (Hawkins et.al., 2002). 
Kinetic evidence shows that the reaction occurs in amino acid side-chains with the order 
of reactivity being Met > Cys >> Cystine ~ His ~ α amino > Trp > Lys >> Tyr ~ Arg > 
Gln ~ Asn (Malle et al., 2006). To investigate whether the protein component of the 
LDL molecule was oxidised, determination of the quantity of protein-bound tyrosine 
remaining on LDL after oxidation was assessed. Tyrosine was chosen as a 
representative amino acid because it is low on the reactivity series. Thus one could 
assume that if tyrosine had become oxidised, then the majority of other amino acids 
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were also being oxidised. After oxidation of the LDL molecule with HOCl at varying 
oxidant/protein molar ratios, the amount of protein-bound tyrosine remaining was 
quantified though acid hydrolysis and subsequent analysis with HPLC (figure 3.1). 
Significant reductions in the levels of tyrosine were observed with increasing molar 
excesses; at the lowest molar ratio (500/1) 64.4 % of native levels were lost, reaching a 
maximum loss of 89.98% induced by the highest molar ratio of 2000/1. 
 
Native 500/1 1000/1 1500/1 2000/1
0
50
100
150
200
250
300
HOCl treatment
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
b
o
u
n
d
 t
y
r
o
s
in
e
(m
o
l/
m
o
l 
L
D
L
)
***
*** *** ***
 
Figure 3.1    Concentration of bound tyrosine to LDL protein. Native LDL (2.5 mg/ml) was 
oxidised following incubation with HOCl at 37  C for 30 minutes at concentrations 
corresponding to oxidant/protein molar ratios of 500/1, 1000/1, 1500/1 and 2000/1. The 
concentration of bound tyrosine was determined by HPLC analysis. Significance is indicated 
from the respective native LDL control. 
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3.1.2     α-Tocopherol loses its protective ability in excess HOCl 
α-Tocopherol is a well characterised antioxidant within LDL with high affinity for 
HOCl. It readily reacts with HOCl preventing it from doing so with other molecules. 
However in excess- HOCl all the α-tocopherol become oxidised and therefore are 
unable to prevent oxidation of the LDL molecule. Of interest was the relationship 
between the loss of tyrosine residues and α-tocopherol levels, which mimicked a near 
identical rate of loss with increasing molar ratios of HOCl. Significant reductions in the 
levels of α-tocopherol were observed with increasing molar excesses. The anti-oxidant 
lost its protective ability as it became oxidised. Even at the lowest molar ratio (500/1), 
69.5 % of native levels were lost, reaching a maximum loss of 92.7% induced by the 
highest molar ratio of 2000/1. These results were graphed together with the tyrosine 
oxidation data (figure 3.1) to show the comparative rate of loss between protein-bound 
tyrosine and α-tocopherol (figure 3.2). 
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Figure 3.2  Concentration of tyrosine and α-Tocopherol after LDL oxidation. Native LDL 
(2.5 mg/ml) was oxidised following incubation with HOCl at 37  C for 30 minutes at 
concentrations corresponding to oxidant/protein molar ratios of 500/1, 1000/1, 1500/1 and 
2000/1. The concentration of tyrosine and with α-tocopherol was determined through HPLC 
analysis of 200 µl samples of native and oxidised LDL. Significance is indicated from the 
respective native LDL control (^^^ for tyrosine, *** for α-tocopherol). 
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3.1.3 Protein oxidation of LDL  
Protein hydroperoxides are another product of oxidative attack on proteins, which have 
the ability to transfer oxidative damage to other biomolecules (Gebicki et.al.,1997). The 
kinetics of protein hydroperoxide (PrOOH) formation on LDL were investigated by 
incubating 1 µM LDL with 10 mM AAPH at 37ºC for 4 hours (figure 3.3) using the 
acetic-acid FOX assay. After an initial lag phase of 2 hours PrOOHs increased rapidly 
at an approximate rate of 15 moles PrOOH/moles LDL per hour, before tapering off at 
40 moles PrOOH/moles LDL. Aside from confirming previous findings regarding the 
kinetics of PrOOH formation, the following experiment aimed to establish the relative 
levels of PrOOH formed when using a radical generator such as AAPH, in order to 
compare to a parallel experiment using HOCl. 
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Figure 3.3    PrOOH formation on apoB when LDL was oxidised by 10 mM AAPH. LDL 
was incubated with 10 mM AAPH at 37ºC on an orbital shaker. Samples were removed at set 
time points and analysed for protein hydroperoxides using the acetic acid-FOX assay. PrOOHs 
were adjusted against a blank control containing FOX reagents and 50 % acetic acid. 
Significance is indicated from the 0 hour time point control. 
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HOCl is highly reactive (within 30 - 40 minutes); therefore measurement of PrOOH 
kinetics is very difficult. Instead, PrOOH formation on LDL with HOCl was 
investigated by measuring final concentrations of PrOOH immediately after oxidation, 
or on two week old oxidation solutions that had been stored under argon at 4 ºC.  
PrOOH formation  increased on samples analysed immediately after oxidation (figure 
3.4a), in an almost linear manner with increasing oxidant/protein molar ratios. There 
was a significant (P < 0.05) 7-fold increase from native levels at the 500/1treatment, 
with the biggest increase of 2 moles/moles LDL at 2000/1 treatment. Over time in an 
oxygen-deprived environment PrOOH formation was still occurring at a very slow rate 
(figure 3.4b). PrOOHs increased by approximately 1 mole/mol LDL compared to their 
respective measurements two weeks prior, except for the 500/1 treatment which 
received a 2.2 mol/mol LDL increase. 
However, even with the increase in PrOOHs after two weeks, the rise from native levels 
was insignificant when compared to the amount formed using the radical generator 
AAPH (figure 3.3). 
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Figure 3.4    PrOOH formation on apoB when LDL was oxidised by varying HOCl 
treatments. LDL was incubated at 37  C with HOCl for 30 minutes. Samples were removed 
immediately after oxidation (A), or removed after storage under argon for two weeks (B); and 
analysed for protein hydroperoxides using the acetic acid-FOX assay. PrOOHs were adjusted 
against blank controls containing FOX reagents and 50 % acetic acid. Significance is indicated 
from the respective native LDL control.  
A) 
B) 
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3.1.4    Thiobarbaturic Acid Reactive Species (TBARS) produced 
during the oxidation of LDL  
LDL contains 22% protein (apoB-100), 22% phospholipids, 8% cholesterol, 42% 
cholesteryl esters, and 6% triglycerides (wt/wt) (Orlova et.al., 1999). Since it was 
determined that HOCl interacted with the protein component of LDL through the 
oxidation of amino acids and the formation of PrOOHs, the next obvious question was; 
is HOCl affecting not only the protein moiety but the lipid moiety as well? Lipid 
peroxidation is studied extensively in relation to not only disease, but also modulation 
of antioxidants and other contexts. A large number of by-products are formed during 
this process which can be measured by various assays. The most common method used 
is the estimation of aldehydic products by their ability to react with thiobarbaturic acid 
(TBA) to form a pink coloured TBA-MDA adduct which is fluorometrically detected by 
HPLC. 
Across the various HOCl-oxLDL treatments, there was no significant increase in 
TBARS compared to native levels in unmodified LDL. However there was a significant 
increase in levels found in native LDL 0.15 ± 0.004 compared to Cu-oxLDL with to 
9.35 ± 0.100 mol of TBARS/mol LDL (figure 3.5). 
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Figure 3.5    Concentration of Thiobarbaturic Acid Reactive Species (TBARS) produced 
by the oxidation of LDL with HOCl. Native LDL was oxidised following incubation at 37  C 
with either; HOCl for 30 minutes at concentrations corresponding to oxidant/protein molar 
ratios of 500/1, 1000/1, 1500/1 and 2000/1 or for 24 hours with 0.5 mM CuCl2. TBARS 
analysis was carried out on samples taken from the oxidised LDL solutions (2.5 mg/ml) and 
diluted 1:5 in nanopure water. Significance is indicated from the native LDL control. 
 
To investigate whether LDL would oxidise further in the presence of contaminating free 
metal ions in RPMI medium and absence of α-tocopherol (see figure 3.2), HOCl-
oxLDL was incubated in 12 well culture plates.  Two hundred microlitres of HOCl-
oxLDL was incubated with 800 µl of RPMI (no phenol red), at 37  C in a CO2 incubator 
(5.0%). TBARS analysis was carried out on samples taken before and after incubation 
for 24 hours (figure 3.6). There was surprisingly significant reductions (P <0.001) in 
TBARS in samples analysed after the 24 hour incubation period across at all treatments, 
this suggests that the initial trace amounts of TBARS found after oxidation were being 
lost or degraded.  
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Figure 3.6    Concentration of Thiobarbaturic Acid Reactive Species (TBARS) in oxLDL 
before and after incubation with RPMI-1640. Native LDL (2.5 mg/ml) was oxidised 
following incubation at 37  C with HOCl for 30 minutes at concentrations corresponding to 
oxidant/protein molar ratios of 500/1, 1000/1, 1500/1 and 2000/1. Using 12 well culture plates, 
200 µl of oxLDL was incubated in 800 µl RPMI-1640, at 37  C in a CO2 incubator (5.0%) for 24 
hours. TBARS analysis was carried out on 200 µl samples taken from wells before and after 
24hr incubation. Significance is indicated between the respective before and after samples at 
each treatment. 
 
It has been shown that HOCl has the ability to break down malondialdehyde (MDA) 
(Winterbourn et.al., 1993). This may explain why the TBARS were degraded after 
prolonged exposure, and even as to why only trace amounts were detected in the initial 
experiment (see figure 3.3). If this is the case then this does not suggest that lipid 
peroxidation is not occurring, simply that the validity of the assay in these 
circumstances should be questioned, and another means of lipid peroxidation measured.  
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3.1.5    7-Ketocholesterol levels in oxLDL compared to Cu-oxLDL 
7-ketocholesterol (7KC) is the major product of cholesterol oxidation and used as a 
biomarker for lipid peroxidation and cytotoxicity. In accordance with previous work in 
this lab, these results (figure 3.7) demonstrate that up to 88% of the total intracellular 
7KC detected was esterified. Note that total 7KC represents combined esterified and 
non-esterified 7KC. These levels significantly increased with higher HOCl/LDL molar 
ratios. This effect was most pronounced at the 2000/1 treatment, where there was an 
84% increase in total 7KC relative to the respective native control. 
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Figure 3.7    Concentration of free and total 7-Ketochoelsterol (mol/mol LDL) after LDL 
oxidation. Native LDL (2.5 mg/ml) was oxidised following incubation with HOCl at 37  C for 
30 minutes at concentrations corresponding to oxidant/protein molar ratios of 500/1, 1000/1, 
1500/1 and 2000/1. The concentration of 7KC was determined via HPLC analysis. Significance 
is indicated from the respective native LDL control (^^^ for free 7KC, *** for total 7KC) 
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A parallel experiment was conducted to compare 7KC formation in HOCl-oxLDL and 
Cu-oxLDL (figure 3.8). Unlike the preceding experiment there was no significant 
increase in 7KC levels as HOCl/LDL molar ratios were increased. However, there was a 
180-fold increase from native levels to those produced with Cu-oxLDL. Overall levels 
of 7KC were minute in the HOCl-oxLDL treatments compared to Cu-oxLDL, with a 29 
fold increase from the highest amount produced in the 2000/1 HOCl-oxLDL treatment.  
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Figure 3.8    Concentration of free and total 7-Ketochoelsterol after LDL oxidation. Native 
LDL was oxidised following incubation at 37  C with either  HOCl for 30 minutes at 
concentrations corresponding to oxidant/protein molar ratios of 500/1, 1000/1, 1500/1 and 
2000/1 or for 24 hours with 0.5 mM CuCl2. The concentration of 7KC was determined with 
HPLC analysis. Significance is indicated from the respective native LDL control (^^^ for free 
7KC, *** for total 7KC). 
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3.1.6    Simultaneous detection of 7-Ketocholesterol and α-Tocopherol 
in oxLDL 
Both 7KC and α-Tocopherol were measured simultaneously following oxidation of 
LDL with HOCl at varying oxidant/protein molar ratios. 7KC increased in an 
approximately linear manner with a rise in 7KC detected as HOCl concentration 
increased. α-Tocopherol levels were lost almost immediately with a significant ten-fold 
reduction at 500/1 treatment compared to control, with none detected at any of the 
higher protein/oxidant molar ratios. This pattern was reflected in both the free (figure 
3.9a) and total (figure3.9b) samples. 
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Figure 3.9    Concentration of 7-Ketochoelsterol (7KC) and α-Tocopherol on LDL 
molecule upon oxidation with HOCl. LDL was oxidised following incubation with HOCl at 
37  C for 30 minutes at varying oxidant/protein molar ratios. The concentration of free 7KC and 
α-tocopherol (A) and total 7KC with α-tocopherol (B) was determined with HPLC analysis. 
Significance is indicated from the respective native LDL control on both graphs (^^^ for free 
7KC, *** for α-tocopherol). 
  
B) 
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3.1.7    Measurement of 7-ketocholesterol before and after incubation 
in RPMI 
To further assess whether HOCl-oxLDL would oxidise in the presence of contaminating 
free metal ions in the RPMI medium and after the loss of α-tocopherol, HOCl-oxLDL 
was incubated with RPMI (no phenol red) for 24 hours at 37  C (figure 3.10). 
Subsequently 7KC was measured, and found that there were significant increases, 
across all treatments, between samples taken before and after incubation. The most 
significant increase (1.5 fold) occurred at the 500/1 treatment. 
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Figure 3.10    Total 7KC before and after incubation in RPMI medium (no serum) for 24 
hours. Native LDL was oxidised following incubation at 37  C with HOCl for 30 minutes at 
concentrations corresponding to oxidant/protein molar ratios of 500/1, 1000/1, 1500/1 and 
2000/1. Using 12 well culture plates, 200 µl of the samples were incubated in 800 µl RPMI-
1640 at 37  C in a CO2 incubator (5.0%). Total 7KC analysis was carried out on 200 µl samples 
taken from wells before and after the 24 hour incubation. Significance is indicated between the 
respective before and after samples of each treatment. 
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7-ketocholesterol correlates strongly with toxicity. Elevated levels of 7KC are thought 
to contribute to the increasing toxicity of oxidised LDL. With such low levels found in 
HOCl-oxLDL compared to Cu-oxLDL, the question arises; is HOCl-oxLDL even toxic 
to cells like its metal ion oxidised counterpart? 
 
3.2    Toxicity of HOCl-oxLDL  
To investigate the potential role of HOCl-oxLDL-induced cytotoxicity, the following 
set of experiments began with examination of the effects of HOCl-oxLDL on the U937 
human monocyte-like cell line before characterising the nature of the cytotoxic 
mechanism triggered by the HOCl-oxLDL. Based on previous studies we expected this 
to involve the generation of oxidative stress leading to cell death. This should be clearly 
demonstrated by the loss of glutathione and the inhibition of cell death by the 
antioxidant 7,8-dihydroneopterin. Aside from confirming previous findings regarding 
its toxicity, these experiments aimed to establish appropriate concentrations of HOCl-
oxLDL at the best oxidant/protein molar ratio for use in later experiments.  
 
3.2.1   Concentration dependant toxicity with HOCl-oxLDL on U937 
cells    
The toxicity of HOCl-oxLDL to U937 cells was examined by exposing cells to 
increasing concentrations of HOCl-oxLDL in RPMI-1640 cell medium for 24 hours. 
Cell viability was subsequently measured using the MTT reduction assay (figure 3.11). 
U937 cells displayed a concentration-dependent decrease in cell viability following 
incubation with HOCl-oxLDL. There was no significant difference in cell viability 
between increasing oxidant/protein ratios, rather there was a concentration dependent 
loss of viability with increasing levels of HOCl-oxLDL given to cells.  Final HOCl-
oxLDL concentrations of 0.25, 0.5, and 1.0 mg/ml, at any given HOCl/LDL ratio, 
reduced cell viability by approximately 29, 39, and 52% of the control, respectively.  
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The precise toxicity of HOCl-oxLDL to U937 cells was found to vary slightly between 
different batches prepared, with the median lethal dose (LD50) between 0.75 -1.0 mg/ml 
HOCl-oxLDL. The LD50  of Cu-oxLDL is known to vary from one batch to another 
although the exact cause has not been  identified (Gieseg et al., 2009). The least 
variation occurred at 1000/1 molar ratio, and so it was decided that subsequent 
experiments would be conducted at 1.0 mg/ml with the 1000/1 treatment, unless 
otherwise stated. 
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Figure 3.11    Viability loss of U937 cells following exposure to different concentrations of 
HOCl-oxLDL with varying HOCl treatments for 24 hours. LDL (2.5 mg/ml) was incubated 
at 37  C with HOCl for 30 minutes at concentrations corresponding to oxidant/protein molar 
ratios of 250/1, 500/1, 1000/1, and 2000/1. U937 cells (0.5 x 10
6
 cells/ml) in RPMI-1640 were 
incubated with varying concentrations of HOCl-oxLDL for 24 hours, and the results analysed 
by MTT assay. Viability was measured as a percentage of a control containing the same cell 
treatment but with PBS in place of native or oxLDL. Significance is indicated between the 
respective concentrations of oxLDL given to cells (*** depicts for all treaments 500/1, 1000/1, 
2000/1).  
Results 
 
 
63 
 
The following experiment (figure 3.12) further illustrates that there is no effect of 
increasing protein/oxidant molar ratios on the toxicity of HOCl-oxLDL. LDL was 
oxidised with increasing concentrations of HOCl to give the following oxidant/protein 
ratios 250/1, 500/1, 1000/1 and 2000/1. HOCl-oxLDL (1.0 mg/ml) was incubated with 
U937 cells in RPMI for 24 hours at 37  C and subsequently measured for viability using 
the MTT reduction assay. Cell viability decreased by approximately 55% compared 
with the cell only control (containing 0.5 x 10
6
 cells/ml, PBS and RPMI) at all oxidising 
treatments. 
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Figure 3.12     Effect of HOCl-oxLDL with varying HOCl treatments on U937s after 24 
hours. LDL (2.5 mg/ml) was incubated at 37  C with HOCl for 30 minutes at concentrations 
corresponding to oxidant/protein molar ratios of 250/1, 500/1, 1000/1, and 2000/1.  U937 cells 
(0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated with 1.0 mg/ml HOCl-oxLDL for 24 hours, 
and the results analysed by MTT assay. Viability was measured as a percentage of a control 
containing the same cell treatment but with PBS in place of native or oxLDL. Significance is 
indicated from the native LDL control. 
 
  
Results 
 
 
64 
 
3.2.2 Effect of chloramines on the toxicity of oxLDL 
HOCl reacts readily with amines to form chloramines which are known to be toxic to 
cells (Thomas et.al., 1985). To investigate whether chloramines were responsible for the 
toxicity of HOCl-oxLDL they were removed during the dialysis step using excess 
methionine (figure 3.13).   Cells were incubated with or without HOCl-oxLDL (0.5 and 
1.0 mg/ml) that had either been treated or not treated, for the removal of chloramines, 
for 24 hours at 37  C. After incubation cell viability was measured using the MTT 
reduction assay, it was found that there was no significant effect of the removal of 
chloramines on the toxicity of oxLDL at both 0.5 and 1.0 mg/ml concentrations. 
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Figure 3.13    Addition of methionine in the oxidation of LDL with HOCl had no effect on 
cell viability loss in U937 cells upon exposure to HOCl-oxLDL. LDL (2.5mg/ml) was 
incubated at 37  C with HOCl for 30 minutes at an oxidant/protein molar ratio of 1000/1.  
During dialysis treatment, methionine was added in two- fold excess to HOCl to remove 
chloramines. U937 cells (0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated with or without 
HOCl-oxLDL (0.5 or 1.0 mg/ml) for 24 hours, and then viability analysed by MTT assay. 
Viability was measured as a percentage of a control containing the same cell treatment with 
PBS in place of native or oxLDL. Significance is indicated from the respective non-met oxLDL 
control (^^^ for 0.5 mg/ml *** 1.0 mg/ml). 
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3.2.3   Intracellular GSH loss on exposure to oxLDL  
To help elucidate the toxic mechanism HOCl-oxLDL exhibits towards U937 cells, 
intracellular oxidative stress production was measured indirectly by quantifying GSH 
concentration in cells after exposure to HOCl-oxLDL. Incubation of U937 cells with 
HOCl-oxLDL caused a marked loss of intracellular GSH (figure 3.14c) closely 
reflecting the pattern of loss that was demonstrated for cell viability (figure 3.14 a&b).  
Cell viability was measured with both trypan blue exclusion assay and MTT reduction 
assay, where they showed similar patterns of viability loss in a concentration dependent 
manner. Although it appeared that either the MTT assay was under estimating, (or 
trypan blue assay was over estimating) viability across lower concentrations 0.25, and 
0.5 mg/ml with differences in viability of approximately -11 and -9% respectively, but 
both assays found similar viability percentages at the higher concentrations. 
GSH loss of approximately 20, 25, 40 and 60% occurred following incubation with 
0.25, 0.5, 0.75 and 1.0 mg/ml HOCl-oxLDL respectively. There was almost complete 
GSH loss (90%) at 1.25 mg/ml HOCl-oxLDL. This suggests that a loss in intracellular 
GSH more than 50% (of the original cellular concentration) is enough to lose most of its 
protective ability against oxidative stress and cause a 50% or greater viability loss upon 
exposure to HOCl-oxLDL. 
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Figure 3.14    Cell viability and intracellular GSH loss  in U937 cells upon exposure to 
varying concentrations of HOCl-oxLDL. Cells (0.5×106 cells/ml) were treated with or 
without varying concentrations of 1000/1 HOCl-oxLDL over 24 hours. After incubation, cells 
were washed and analysed for viability using the trypan blue exclusion assay (A) and the MTT 
viability assay (B), or analysed for intracellular GSH (C) via HPLC analysis. Significance is 
indicated from the respective 0 mg/ml control. 
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3.2.4   7,8-Dihydroneopterin protection of U937 cells upon insult of 
oxLDL 
The water-soluble antioxidant compound 7,8-dihydroneopterin (78NP), has been shown 
by this laboratory, to provide protection to U937 cells against Cu-oxLDL-induced cell 
death. Specifically, 78NP was shown to prevent Cu-oxLDL-induced intracellular GSH 
loss by scavenging Cu-oxLDL-induced intracellular oxidants, independently of other 
antioxidants such as glutathione and α-tocopherol, and therefore maintain the 
intracellular redox environment (Baird et al., 2004). To further investigate the cytotoxic 
mechanism of HOCl-oxLDL, and confirm whether oxidative stress was indeed being 
elevated excessively, as suggested by the previous loss of GSH (figure 3.14), 7,8-
dihydroneopterin was utilised as a probe for oxLDL toxicity mechanism. U937 cells 
were treated with increasing concentrations of 78NP prior to incubation with 1.0 mg/ml 
oxLDL in the cell medium for 24 hours (figure 3.15). The presence of HOCl-oxLDL 
without 78NP treatment caused a 54% decrease in viability. Treatment of cells with 50, 
100, 200, 250 and 300 µM 78NP before incubation with oxLDL resulted in cell viability 
loss of only 31, 20, 11, 7 and 5% relative to the cell-only control. This suggests that like 
Cu-oxLDL, HOCl-oxLDL was generating intracellular oxidants which could be 
scavenged by the 78NP. 
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Figure 3.15    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
cell viability loss in U937 cells upon exposure to HOCl-oxLDL. Cells (0.5×10
6
 cells/ml) were 
pre-incubated in the presence or absence of varying concentrations of 7,8-NP in the dark at 
37°C for 15 minutes, and were subsequently treated with or without 1 mg/ml of 1000/1 HOCl-
oxLDL over 24 hours. After incubation cells were washed and analysed for viability using the 
trypan blue exclusion assay. Viability was measured as ratio of dead versus live cells and 
expressed as a percentage. Significance is indicated from the 0 µM 78-NP control. 
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3.2.5     Kinetics of viability and glutathione loss upon insult with 
oxLDL  
Incubation of U937 cells with HOCl-oxLDL caused a marked loss of intracellular 
glutathione (GSH) (figure 3.16b) closely reflecting the pattern of loss that was 
demonstrated for cell viability (figure 3.16a). These experiments were performed in 
both the presence and absence of 78NP to examine its effect on GSH loss. The pattern 
of HOCl-oxLDL-induced GSH loss was studied over 24 hours using 1.0 mg/ml HOCl-
oxLDL. This lethal concentration of HOCl-oxLDL caused a rapid loss of intracellular 
GSH content to 65% of cellular control within 6 hours of incubation and decreased to 
less than 40% of the initial intracellular GSH level after 9 hours. The pattern of 
intracellular GSH loss illustrated here closely mirrors the pattern of cell viability loss 
(Figure 3.16a).  
As with cell viability, the presence of 78NP appeared to dramatically prevent HOCl-
oxLDL-induced damage by way of GSH loss, and appeared to have the greatest effect at 
9 hours, the presence of 78NP caused a 40% increase in cellular GSH content at this 
time point compared to HOCl-oxLDL alone, preventing around 30% viability loss. 
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Figure 3.16    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
GSH and cell viability losses in U937 cells upon exposure to HOCl-oxLDL. Cells (0.5×10
6
 
cells/ml) were pre-incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C 
for 15 minutes, cells were then treated with or without 1 mg/ml 1000/1 HOCl-oxLDL over 24 
hours. At set time points samples were taken out, cells were washed and analysed for viability 
using the MTT viability assay (A) [control contained 0.5×10
6
 cells/ml in RPMI plus PBS in 
place of native or oxLDL], or analysed for intracellular GSH (B) via HPLC analysis [cell 
control value = 11.2 ± 0.23 Moles GSH/ Moles LDL]. Significance is indicated from the 
respective 0 hour time point control. 
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 3.2.6    7,8-dihydroneopterin prevented oxidative stress upon exposure 
to oxLDL  
Dihydroethidium (DHE), by virtue of its ability to freely permeate cell membranes is 
used extensively to monitor superoxide production. DHE upon reaction with superoxide 
anions forms a red fluorescent product (ethidium) which can be quantified using flow 
cytometry. To fully confirm the presence of oxidative stress and thus the possible 
cytotoxic mechanism of HOCl-oxLDL, cells were incubated with HOCl-oxLDL in the 
presence or absence of 78NP. During incubation cells were washed, probed with DHE 
and oxidative stress was quantified using flow cytometry. Each sample had 10,000 
events recorded within a gate set to exclude cellular debris. Consistent with previous 
results from this laboratory, mean fluorescence intensity rises rapidly and peaks at 3 
hours.  This can be observed (figure 3.17a) with the increasing shift to the right along 
the x-axis as time increases, the widening (and shortening) of the peaks does not suggest 
that less cells were observed at that time point, rather that more cells within the gated 
sample showed some form of fluorescence intensity but at a more varying range. 
As with cell viability and GSH loss, the presence of 78NP appeared to significantly 
reduce HOCl-oxLDL-induced damage by preventing oxidative stress (figure 3.17b). It 
appeared to have the greatest effect at 3 hours, preventing the largest rise in mean 
fluorescence seen with HOCl-oxLDL alone. It caused near complete retention of normal 
cell fluorescence as compared to a cell only control across the entire 24 hour incubation. 
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Figure 3.17    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
oxidative stress in  U937 cells upon exposure to HOCl-oxLDL. Cells (0.5×10
6
 cells/ml) were 
pre-incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C for 15 
minutes, then treated with or without 1 mg/ml 1000/1 HOCl-oxLDL over 24 hours. At set time 
points samples were taken out, and cells analysed for oxidative stress using DHE probe and 
flow cytometry. Controls consisted of 0.5×10
6
 cells/ml, RPMI and PBS in place of HOCl-
oxLDL. Significance is indicated between oxLDL and oxLDL + 78NP, at respective time 
points. 
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3.3 Characterisation of the modification of Bovine 
Serum Albumin (BSA) by hypochlorous acid (HOCl) 
DNA and lipids are historically considered to be the primary target molecules of free 
radicals. More recently, proteins have come to light  for their role as targets for radical 
oxidation due to their abundance in biological systems and their ability to bind 
transition metals (Gebicki et al., 2000). 
In contrast to oxidised lipids, the impact of oxidised proteins in atherogenesis has not 
been extensively studied. Advanced oxidation protein products (AOPPs) are thought to 
be formed in vivo by exposure of serum albumin to HOCl. Significantly increased levels 
of AOPPs have been found in atherosclerotic lesions, with biochemical characterization 
revealing that AOPPs are carried by plasma proteins, especially albumin. (Liu et al., 
2006).  
With the aim of creating a physiologically relevant model for testing the toxicity of 
AOPPs, pure bovine serum albumin was incubated at 37°C with HOCl at varying 
oxidant/protein molar ratios to form oxALB. Characterisation of the biochemical 
properties of oxALB was the first step taken in understanding how HOCl oxidises 
proteins and how it may play a role in the toxicity of cells within an atherosclerotic 
inflamation site. 
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3.3.1   Relative electrophoretic mobility of oxALB 
BSA was incubated with varying oxidant/protein molar ratios of HOCl for 30 minutes at 
37  C. Relative electrophoretic mobility (REM) of (un)modified BSA was examined to 
confirm that oxidation had occurred, and to observe how fragmented the oxALB had 
become. The size of native BSA, and varying oxALB treatments was compared using 
reducing SDS-PAGE gel electrophoresis (figure 3.18). The albumin band at 66.4kD is 
significantly modified in the presence of HOCl. As the HOCl concentrations increased 
the more smeared and fragmented the albumin band becomes. At 2000/1 the oxALB is 
so fragmented that it becomes difficult to discern individual peptide fragments. 
 
 
 
 
Figure 3.18 SDS-PAGE gel of native and modified BSA. Samples of native and modified 
BSA (50 µg protein), having undergone lysis buffer treatment, were loaded onto a gradient 
polyacrylamide gel, along with 5 µl of pre-stained molecular weight marker and run for a 
15minutes at 100 V then for a further hour at 200 V. 
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3.3.2   Tyrosine loss on oxidised BSA 
To determine if BSA was indeed oxidised as the SDS-PAGE gel suggested (figure 3.18) 
tyrosine levels and two of its oxidative products (DOPA and dityrosine) were measured 
after modification of BSA with HOCl. Protein bound tyrosine, DOPA and dityrosine 
were quantified though acid hydrolysis and subsequent analysis with HPLC (figure 
3.19). Significant reductions in the levels of tyrosine were observed with increasing 
molar excesses. At the lowest molar ratio (250/1) 90% of native levels were lost, with 
complete loss of tyrosine detected at 1000/1 and 2000/1. There was a significant (P 
<0.05) rise in DOPA from native levels to 250/1 and 500/1 treatments, then it dropped 
off again in 1000/1 and was almost undetectable at 2000/1. There was a rise in the level 
of dityrosine detected at 250/1 and 500/1, however, these were statistically insignificant. 
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3.19    Concentration of tyrosine and resulting increases to tyrosine oxidation products 
(DOPA and dityrosine) after oxidation of BSA with HOCl. BSA (7.5 mg/ml) was oxidised 
following incubation with HOCl at 37  C for 30 minutes at concentrations corresponding to 
oxidant/protein molar ratios of 250/1, 500/1, 1000/1 and 2000/1. Oxidised BSA was diluted 1:5 
with nanopure water to give a final concentration of 1 mg/ml before acid hydrolysis. The 
concentration of tyrosine and its oxidative products were determined through HPLC analysis of 
the acid hydrolysate. Significance is indicated from the respective native BSA control. 
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3.3.3     PrOOH formation in BSA after exposure to HOCl 
Proteins damaged by free-radical-generating systems in the presence of oxygen yield 
relatively long-lived protein hydroperoxides (PrOOHs). PrOOHs are also formed on 
amino acids and proteins during oxidative stress, and have the potential to cause further 
biological damage. PrOOH formation on the samples analysed immediately after 
oxidation (figure 3.20) increased in an almost linear manner up to the 1000/1 treatment 
where the concentration peaked at 0.27 moles PrOOH/moles BSA, before levels 
declined in subsequent higher molar ratio treatments.   
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Figure 3.20    PrOOH formation on albumin when oxidised by varying HOCl treatments. 
BSA (7.5 mg/ml)  was incubated at 37  C with HOCl for 30 minutes. Samples were removed 
immediately after oxidation and analysed for protein hydroperoxides using the acetic acid-FOX 
assay. PrOOHs were adjusted against blank controls containing FOX reagents and 50% acetic 
acid. Significance is indicated from the native BSA control. 
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3.4    Toxicity of oxALB  
Despite finding elevated levels of oxidised proteins in a wide range of diseases, 
including atherosclerosis, their possible role in the progression of these diseases has not 
been elucidated. It has been postulated that these AOPPS are in fact toxic to cells but no 
conclusive evidence has been brought to light showing evidence of this in vivo. Aside 
from assessing whether oxALB displays cytotoxic properties, the next set of 
experiments aimed to establish appropriate concentrations of oxALB at the best 
oxidant/protein molar ratio, for use in later experiments.  
3.4.1   Cytotoxicity of oxALB on U937 cells    
After oxidation it was noted that oxALB had a strong pungent smell to it, reminiscent of 
a commercial swimming pool, it was suggested that this smell could be coming from a 
cache of unreacted HOCl within the oxALB sample. To eliminate the fact that HOCl 
could be a contributing factor in the toxicity of oxALB, residual HOCl was removed 
after oxidation though a 3 step dialysis against PBS.  
The toxicity of oxALB to U937 cells was examined by exposing U937 cells to 
increasing oxidant/protein molar ratios of oxALB in RPMI-1640 cell medium for 24 
hours. Cell viability was subsequently measured using the MTT reduction assay (figure 
3.21). In contrast to the cytotoxic effects of oxLDL (figure 3.11), oxALB displayed 
statistically significant differences between increasing oxidant/protein ratios and their 
effect on cell viability. This was especially emphasised on oxALB that had undergone 
dialysis treatment (figure 3.21b).    
Cells exposed to oxALB that had not been dialysed (figure 3.21a) had their viability 
reduced dramatically down to 15% at the lowest oxidant/protein molar ratio through to 
7% of the cell only control at 2000/1. Compared to oxALB that had been dialysed 
(figure 3.21b) there was a marked increase in viability with rises of 73, 69, and 39% at 
250/1, 500/1 and 1000/1 respectively. 
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 Figure 3.21   Dialysis treatment of oxALB decreased cell viability loss in U937 cells upon 
exposure to oxALB. BSA (7.5 mg/ml) was incubated at 37  C with HOCl for 30 minutes at an 
oxidant/protein molar ratio of 1000/1.  OxALB then either did (B) or did not (A) undergo 
dialysis to remove any excess HOCl. Cells (0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated 
with or without oxLDL (1.0 mg/ml) for 24 hours, and then viability analysed by MTT assay. 
Viability was measured as a percentage of a control containing the same cell treatment with 
PBS in place of native or oxALB. Significance is indicated from the respective native BSA 
control. 
 
The difference between the two treatments (dialysed versus non-dialysed) was most 
likely due to residual HOCl in the oxALB solution. After establishing that increasing 
oxidant/protein ratios cause an increase in toxicity, the question arises does cytotoxicity 
of oxALB have a concentration-dependent effect on viability? This was examined by 
exposing U937 cells to varying concentrations of 1000/1 oxALB in RPMI-1640 cell 
medium for 24 hours (figure 3.22). Cell viability was subsequently measured using the 
MTT reduction assay (figure 3.21). U937 cells displayed a concentration-dependent 
decrease in cell viability following incubation with oxALB. Comparatively, there was 
no statistically significant difference between dialysed and non-dialysed samples, the 
exception being 1.0 mg/ml in which there was a 32% increase in viability. 
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Figure 3.22   Concentration dependent toxicity through exposure of dialysed and non-
dialysed oxALB to U937 cells. BSA (7.5 mg/ml) was incubated at 37  C with HOCl for 30 
minutes at an oxidant/protein molar ratio of 1000/1.  OxALB then either did (or did not) 
undergo dialysis to remove any excess HOCl. U937 cells (0.5 x 10
6
 cells/ml) in RPMI-1640 
were incubated with varying concentrations of oxALB for 24 hours, and then viability analysed 
by MTT assay. Viability was measured as a percentage of a control containing the same cell 
treatment with PBS in place of native or oxALB. Significance is indicated between the 
respective before and after samples. 
 
The precise toxicity of oxALB to U937 cells was found to vary slightly between 
different batches prepared, with the median lethal dose (LD50) between 0.6 -1.0 mg/ml 
oxALB. The most consistent LD50 occurred at 1000/1 molar ratio with oxALB that had 
been dialysed, and so it was decided that subsequent experiments would be conducted at 
1.0mg/ml with the 1000/1 treatment, unless otherwise stated. 
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3.4.2   Comparison of cytotoxicity between HOCl-oxLDL and oxALB on U937 cells    
The toxicity of oxALB and HOCl-oxLDL to U937 cells was examined by incubating 
cells with both oxidants at equivalent total mass (1.0 mg/ml) for 24 hours. Cell viability 
was subsequently measured using the MTT reduction assay (figure 3.23). 
Comparatively, HOCl-oxLDL was more toxic than oxALB at the two lowest 
oxidant/protein molar ratios (250/1 and 500/1), at the 1000/1 ratio there was no 
significant difference between the level of toxicity, and at the highest ratio oxALB was 
markedly more toxic with only 3% cell viability after treatment compared to 37% with 
HOCl-oxLDL. Contrasting to the cytotoxic effects of HOCl-oxLDL, oxALB displayed 
statistically significant differences between increasing oxidant/protein ratios and their 
effect on cell viability. 
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Figure 3.23    Comparison of HOCl-oxLDL and oxidised albumin with varying HOCl 
treatments given to U937 cells at equivalent total mass (1 mg/ml). LDL and Albumin were 
incubated at 37  C with HOCl for 30 minutes at concentrations corresponding to oxidant/protein 
molar ratios of 250/1, 500/1, 1000/1, and 2000/1 to form HOCl-oxLDL and oxALB. U937 cells 
(0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated with 1.0 mg/ml oxLDL or 1.0 mg/ml oxALB 
for 24 hours, and analysed by MTT assay. Viability was measured as a percentage of a control 
containing the same cell treatment with PBS in place of oxidative solution. Significance is 
indicated between the respective oxLDL and oxALB treatments. 
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To assess whether the toxicity both HOCl-oxLDL and oxALB was due to some toxic 
component produced from the protein moiety or a derivative of protein oxidation, we 
measured comparative toxicity at equivalent protein mass. The toxicity was examined 
by incubating cells with either HOCl-oxLDL at 1.0 mg/ml or oxALB at 0.2 mg/ml, for 
24 hours. Thus the cells were exposed to either 0.2 mg/ml apoB-100 or 0.2 mg/ml 
oxALB. Cell viability was subsequently measured using the MTT reduction assay 
(figure 3.24). OxALB toxicity was dramatically reduced compared to oxLDL across all 
oxidant/protein molar ratios, with increases in viability of 47, 45, 46 and 25% compared 
to the respective oxLDL treatments. 
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Figure 3.24    Comparison of HOCl-oxLDL and oxidised albumin with varying HOCl 
treatments given to U937 cells at equivalent protein mass. LDL and Albumin were incubated 
at 37  C with HOCl for 30 minutes at concentrations corresponding to oxidant/protein molar 
ratios of 250/1, 500/1, 1000/1, and 2000/1 to form HOCl-oxLDL and oxALB. U937 cells (0.5 x 
10
6
cells/ml) in RPMI-1640 were incubated with 1.0 mg/ml HOCl-oxLDL (containing 0.2 
mg/ml ApoB-100) or 0.2 mg/ml oxALB for 24 hours, and analysed by MTT assay. Viability 
was measured as a percentage of a control containing the same cell treatment with PBS in place 
of oxidative solution. Significance is indicated between the respective oxLDL and oxALB 
treatments. 
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3.4.3    Presence of foetal bovine serum shows minimal protection 
against the cytotoxicity of oxALB 
It has been shown previously in this laboratory that the presence of foetal bovine serum 
(FBS) can have a protective effect against oxidative stress due to exposure of Cu-
oxLDL. Could FBS also protect cells against the cytotoxicity of oxALB? This was 
assessed by incubating cells with oxALB at 1.0 mg/ml in the presence and absence of 
5% FBS, after experimental treatment, cell viability was measured using the MTT 
viability assay (figure 3.25). Consequently it was found that presence of FBS had little 
to no effect on the toxicity of oxALB with only slightly significant (P < 0.01) increases 
in viability of 9% and 7% at the 500/1 and 2000/1 ratios respectively. 
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Figure 3.25    Toxicity of oxALB in the presence of FBS on U937 cells after 24 hours. 
Albumin (7.5 mg/ml) was incubated at 37  C with HOCl for 30 minutes at concentrations 
corresponding to oxidant/protein molar ratios of 250/1, 500/1, 1000/1, and 2000/1 to form 
oxALB.  U937 cells (0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated in the absence (A), or 
presence (B) of foetal bovine serum, with 1.0 mg/ml oxALB for 24 hours, and the results 
analysed by MTT assay. Viability was measured as a percentage of a control containing the 
same cell treatment with PBS in place of oxALB. Significance is indicated between the 
respective absence and presence of FBS treatments. 
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3.4.4     Effect of chloramines on the toxicity of oxALB 
Free amino acids readily form chloramines in reactions with HOCl, however the 
reaction can be postponed by the presence of amino acids whose side groups have 
reducing properties such as methionine (Naskalski & Bartosz 2001). 
The potential chloramines were removed from the oxALB during the dialysis step using 
excess methionine (figure 3.26).   Cells were incubated with or without oxALB (0.5 and 
1.0 mg/ml) that had either been treated (or not treated) for the removal of chloramines, 
for 24 hours at 37  C. After experimental treatment cells were checked for viability using 
the MTT reduction assay, where it was found that there were statistically significant 
effects of the removal of chloramines on the toxicity of oxALB at both 0.5 and 1.0 
mg/ml concentrations. 
There appears to be some biphasic mechanism of toxicity. Although removal of 
chloramines did increase viability by 46% and 22% at 0.5 and 1.0 mg/ml respectively, 
methionine-treated oxALB still caused cell viability loss, especially in the 1.0 mg.ml 
treatment where viability was reduced by 75%. 
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Figure 3.26    Addition of methionine in the oxidation of BSA and its effect on cell viability 
loss in U937 cells upon exposure to oxALB. BSA (7.5 mg/ml) was incubated at 37  C with 
HOCl for 30 minutes at an oxidant/protein molar ratio of 1000/1.  During dialysis treatment, 
methionine was added in two- fold excess to HOCl to remove chloramines. U937 cells (0.5 x 
10
6
 cells/ml) in RPMI-1640 were incubated with or without oxALB (0.5 or 1.0 mg/ml) for 24 
hours. Viability was analysed by MTT assay and measured as a percentage of a control 
containing the same cell treatment with PBS in place of native or oxLDL. Significance is 
indicated from the respective native BSA controls (0.5 or 1.0 mg/ml). 
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To assess whether chloramines played a role in the differing of toxicity between 
oxidant/protein molar ratios, chloramines were removed during the dialysis step using 
excess methionine (figure 3.27).   Cells were incubated with or without oxALB at 
varying ratios that had either been treated (or not treated) for the removal of 
chloramines and subsequently tested for cell viability using the MTT reduction assay. 
There were statistically significant effects from the removal of chloramines on the 
toxicity of oxALB at the 1000/1 and 2000/1 ratios which increased viability by 17 and 
24% respectively.  
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Figure 3.27    Addition of methionine in the oxidation of BSA and its effect on cell viability 
loss in U937 cells upon exposure to oxALB. BSA (7.5 mg/ml) was incubated at 37  C with 
HOCl for 30 minutes at concentrations corresponding to oxidant/protein molar ratios of 250/1, 
500/1, 1000/1, and 2000/1 to form oxALB. During dialysis treatment, methionine was either 
added (or not) in two- fold excess to HOCl to remove chloramines. U937 cells (0.5 x 10
6
 
cells/ml) in RPMI-1640 were incubated with or without oxALB (1.0 mg/ml) for 24 hours, and 
then viability analysed by MTT assay. Viability was measured as a percentage of a control 
containing the same cell treatment with PBS in place of native or oxLDL. Significance is 
indicated between the respective non-methionine and methionine treated samples. 
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Time course studies of oxALB incubated with U937 cells provided additional evidence 
for the role chloramines play in the toxicity of oxALB, by assessing if their removal had 
any effect on the rate of cell death. A time course study of oxALB cytotoxicity over 24 
hours with 1.0 mg/ml oxALB was performed. At set time points samples were analysed 
for viability using both the MTT and trypan blue assays (figure 3.28a). In a parallel 
experiment chloramines were removed during dialysis and subsequently viability was 
measured (figure 3.28b). These experiments answered several points of interest; one, 
that there was no significant difference between the two viability assays (confirming the 
validity of the MTT assay which has been questioned in the past for over estimating 
viability loss) and two,  further confirming the presence of chloramines and their role in 
the cytotoxicity of oxALB.  
The results illustrated a rapid decrease in viability that occurred primarily within the 
first 6 hours for non-methionine treated oxALB (figure 3.28a). Although marked 
viability loss in methionine treated oxLDL treatment did occur, it had an initial lag 
phase before dropping off suddenly to have most loss occurring between 6 and 9 hours 
(figure 3.28b).The removal of chloramines did show a significant increase in viability 
with maximum loss reaching around 84% compared to non-methionine treatment which 
achieved a 97% loss in cell viability compared to cell only control. 
The use of trypan blue assay illuminated the morphology changes that the cells went 
through upon exposure to oxALB and subsequent cell death, the corresponding 
microscopy showed that a large degree of cell lysis occurred between 3 and 9 hours in 
both experiments. 
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Figure 3.28   Addition of methionine in the oxidation of BSA and its effect on cell viability 
loss in U937 cells upon exposure to oxALB during a 24 hour time course. BSA (7.5mg/ml) 
was incubated at 37  C with HOCl for 30 minutes at an oxidant/protein molar ratio of 1000/1. 
During dialysis treatment, methionine was either added (B) (or not (A)) in two-fold excess to 
HOCl to remove chloramines. U937 cells (0.5 x 10
6
 cells/ml) in RPMI-1640 were incubated 
with or without oxALB (1.0 mg/ml) for 24 hours. At set time points during incubation, samples 
were taken out, and analysed for viability by the MTT assay and trypan blue exclusion assay. 
Viability was measured as a percentage of a control containing the same cell treatment with 
PBS in place of native or oxLDL. Significance is indicated from the respective 0 hour time 
point control. 
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3.4.5    Intracellular GSH loss on exposure to oxALB 
Although chloramines were found to contribute to the toxicity of oxALB, their removal 
did not prevent cell death in U937 cells. Cu-oxLDL and HOCl-oxLDL appear to kill 
U937 cells by inducing an intracellular oxidative stress. It was investigated whether 
oxALB also caused an oxidative stress in U937 cells. This was assessed by measuring 
intracellular GSH loss. Incubation of U937 cells with increasing concentrations of 
oxALB caused a marked loss of intracellular GSH (figure 3.29a). U937 cells displayed 
a concentration-dependent decrease in GSH loss following incubation with oxALB.  
Comparatively greater GSH loss occurred in oxALB that had not had chloramines 
removed, with significant increases in GSH levels found in methionine treated oxALB 
of 4.1, 4.4, 3.7 and 3.1 nmol GSH/10
6
 cells at 0.5, 0.75, 1.0 and 1.25 mg/ml treatments 
respectively. 
There were differences between increasing oxidant/protein molar ratios and their effect 
on intracellular GSH loss (figure 3.29b). Cells were incubated with 1.0 mg/ml oxALB 
(methionine treated) at varying ratios for 24 hours, following which intracellular GSH 
levels were measured using HPLC. Significant GSH losses of 2.9 and 10.6 nmol 
GSH/10
6
cells were seen at 500/1 and 1000/1 ratios compared to cell only control.  
However at 250/1 there was actually a small but statistically insignificant increase in 
GSH levels possibly suggesting the cells in the lower HOCl/BSA molar ratio treatment 
triggered some sort of survival mechanism increasing cellular GSH content.  
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Figure 3.29    Addition of methionine in the oxidation of BSA and its effect on intracellular 
GSH loss in U937 cells upon exposure to oxALB. Cells (0.5 x 10
6
 cells/ml) in RPMI-1640 
were incubated with or without 1000/1 oxALB (treated with or without methionine), at varying 
concentrations (A), or with varying oxidant/protein ratios of met-oxALB at 1.0 mg/ml (B), for 
24 hours and then analysed for intracellular GSH via HPLC analysis. Significance is indicated 
from the respective 0 mg/ml control (A), or from the native BSA control (B). 
 
  
A) 
B) 
Results 
 
 
91 
 
3.4.6   7,8-Dihydroneopterin protection of U937 cells upon insult of 
oxALB 
It has been shown previously that 7,8-dihydroneopterin (78NP) inhibits cytotoxicity 
caused by Cu-oxLDL and now HOCl-oxLDL (see section 3.2); so it was investigated 
whether it could it also protect against cell death caused by oxALB. As with previous 
studies suggesting a role for reactive oxygen species (ROS) in cell death, this 
experiment aimed to determine whether ROS represent a contributing factor in oxALB-
induced cell death. U937 cells were treated with increasing concentrations of 78NP 
prior to incubation with 1.0 mg/ml oxALB (figure 3.30a) or methionine-treated oxALB 
(figure 3.30b) in the cell medium for 24 hours.  
The presence of oxALB without 78NP treatment caused a near complete loss in cellular 
viability (figure 3.30a). Treatment of cells with 50, 100, 200, 250 and 300 µM 78NP 
before incubation with oxALB resulted in cell viability loss of only 98, 86, 68, 57, and 
45% relative to the cell-only control.  
There was much greater protection with 78NP in cells that were exposed to met-oxALB 
(treated for the removal of chloramines) (figure 3.30b). Although methionine treated 
oxALB was not as toxic (causing around 82% viability loss compared to untreated 
oxALB which caused 99.5% loss) the levels in which 78NP raised viability was much 
greater. Treatment of cells with 50 and 100 µM 78NP before incubation with oxALB 
resulted in cell viability loss of only 51, 35% relative to the cell-only control. Treatment 
with 200, 250 and 350 µM 78NP actually raised viability past the control, not 
necessarily suggesting that these treatments had more alive cells but rather these cells 
were more metabolically active. 
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Figure 3.30    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
cell viability loss in U937 cells upon exposure to oxALB. Cells (0.5×10
6
 cells/ml) were pre-
incubated in the presence or absence of varying concentrations of 7,8-NP in the dark, at 37°C 
for 15 minutes. Cells were incubated with or without 1 mg/ml of 1000/1 oxALB, that had been 
treated with (B) or without (A) methionine, over 24 hours. After incubation cells were washed 
and analysed using the MTT reduction assay. Viability was measured as a percentage of control 
containing the same cell treatment but with PBS in place of native or oxALB. Significance is 
indicated from the respective 0 µM 78-NP control on both graphs. 
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Having shown that 78NP does protect cells from cell death caused by oxALB, the next 
step was to assess whether this was due to a reduction in the intracellular oxidative 
stress. The primary function of GSH lies in reducing oxidative stress and maintaining 
the thiol-redox status of the cell (Forman et al., 2009). GSH deficiency or a decrease in 
the GSH/glutathione disulfide ratio appears to result in increased susceptibility to 
oxidative stress or low cellular antioxidant capacity (Ballatori et al., 2009), and is 
therefore a good measure of the presence of oxidative stress. 
Incubation of U937 cells with oxALB caused a marked loss of intracellular glutathione 
(GSH) (figure 3.31b) closely reflecting the pattern of loss that was demonstrated for cell 
viability (figure 3.31a). In the absence of 78NP, GSH loss of more than 50% occurred 
following incubation with 1.0 mg/ml oxALB and almost complete GSH loss occurred at 
a concentration of 2.0 mg/ml oxALB. This experiment was performed in both the 
presence and absence of 78NP to examine its effect on GSH loss. As with cell viability, 
the presence of 78NP appeared to dramatically prevent oxALB-induced damage by way 
of GSH loss, and appeared to have the greatest effect at the lower end of oxALB 
concentrations used. At 0.5 mg/ml oxALB, the presence of 78NP caused slightly 
increased cellular GSH content compared to the native control, preventing GSH loss 
that occurred in its absence, at these concentrations of oxALB. 
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Figure 3.31    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
GSH and cell viability losses in U937 cells upon exposure to oxALB. Cells (0.5×10
6
 cells/ml) 
were pre-incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C for 15 
minutes. Cells were treated with or without 1000/1 met-oxALB at 0.5 or 1.0 mg/ml over 24 
hours. Cells were washed and analysed for viability using the trypan blue exclusion (A), or 
intracellular GSH (B) via HPLC analysis. Significance is indicated from the respective 0 µM 
78-NP controls. 
A) 
B) 
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3.4.7     Kinetics of viability and glutathione loss upon insult with 
oxALB  
Incubation of U937 cells with oxALB caused a marked loss of intracellular glutathione 
(GSH) (figure 3.33) closely reflecting the pattern of loss that was demonstrated for cell 
viability (figure 3.32).  These experiments were performed in both the presence and 
absence of 78NP to examine its effect on the rate of viability and GSH loss.  
The presence of 200 µM 78NP appeared to dramatically prevent almost all oxALB-
induced viability loss, and appeared to have the greatest effect at 9 hours. 78NP caused 
a 65% increase in cellular GSH content at this time point compared to oxALB alone, 
preventing around 60% viability loss. In the absence of 78NP cell death occurred slowly 
over the first 6 hours before rapidly plummeting to 40% of the control viability between 
6 and 9 hours (figure3.32).  
The pattern of oxALB-induced GSH loss was studied over 24 hours using 1.0 mg/ml 
oxALB. This lethal concentration of oxALB caused a rapid loss of intracellular GSH 
content to 35% of cellular control within 6 hours of incubation and decreased to less 
than 18% of the initial intracellular GSH level during the next 18 hours (figure 3.33). 
Interestingly, the rapid loss in GSH, between 3 and 6 hours, preceded the dramatic loss 
of cell viability between 6 and 9 hours.   
Results 
 
 
96 
 
Time (hours)
C
e
ll
 v
ia
b
il
ty
 (
%
 o
f 
c
o
n
tr
o
l)
0 3 6 9 12 15 18 21 24
0
20
40
60
80
100
120 oxALB
oxALB + 200uM 78NP*
*** ***
***
 
Figure 3.32    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
cell viability loss in U937 cells upon exposure to oxALB. Cells (0.5×10
6
 cells/ml) were pre-
incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C for 15 minutes. 
Then cells were treated with or without 1 mg/ml 1000/1 met-oxALB over 24 hours. At set time 
points samples were taken out, cells were washed and analysed for viability using the MTT 
viability assay. Significance is indicated between treatments at each respective time point. 
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Figure 3.33    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
intracellular GSH loss in U937 cells upon exposure to oxALB. Cells (0.5×10
6
 cells/ml) were 
pre-incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C for 15 
minutes. Then cells were treated with or without 1 mg/ml 1000/1 met-oxALB over 24 hours. At 
set time points, samples were taken out and analysed for intracellular GSH via HPLC analysis, 
[cell control value = 10.28 ± 1.13 Moles GSH/ Moles LDL]. Significance is indicated between 
treatments at each respective time point.  
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3.4.8    7,8-dihydroneopterin prevented oxidative stress upon exposure 
to oxALB  
Previous data (intracellular GSH loss, figure 3.29; and protection by antioxidant 78NP, 
figure 3.30) suggests that oxALB-induced cell death is caused in part by an excessive 
rise in intracellular oxidative stress. DHE was utilised as a probe to examine superoxide 
production. It specifically reacts with superoxide anions to form a red fluorescent 
product to give a direct measure of oxidative stress within the cell. Cells were incubated 
with oxALB in the presence or absence of 78NP. During incubation cells were washed, 
probed with DHE and oxidative stress was quantified using flow cytometry. Each 
sample had 10,000 events recorded within a gate set to exclude cellular debris.  
Comparatively, mean fluorescence intensity rises rapidly and peaks at 3 hours as with 
HOCl-oxLDL (figure 3.17).  This can be observed (figure 3.34a) with the increasing 
size of the second peak to the right along the x-axis. As with cell viability and GSH 
loss, the presence of 78NP appeared to significantly reduce oxALB-induced damage by 
preventing oxidative stress (figure 3.34b). It appeared to have the greatest effect at 3 
hours, preventing the largest rise in mean fluorescence seen with oxALB alone. It 
caused near complete retention of normal cell fluorescence as compared to a cell only 
control across the entire 24 hour incubation. 
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Figure 3.34    7,8-dihydroneopterin (7,8-NP) added to the incubation medium prevented 
oxidative stress in U937 cells upon exposure to oxALB. Cells (0.5×10
6
 cells/ml) were pre-
incubated in the presence or absence of 7,8-NP (200 µM)  in the dark at 37°C for 15 minutes, 
then treated with or without 1 mg/ml 1000/1 met-oxALB over 24 hours. At set time points, 
samples were taken out and analysed for oxidative stress using DHE probe and flow cytometry 
through the FL-2 filter. Controls consisted of (0.5×10
6
 cells/ml), RPMI and PBS in place of 
oxALB. The change in mean fluorescence over the first 3 hours can be seen through; an 
overlaid histogram (A), which can be deciphered using the legend (B). Alternatively all data 
points are shown in (C).  Significance is indicated between treatments at each respective time 
point.  
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3.4.9    Detection of both apoptosis and necrosis in U937 cells following 
exposure to oxALB 
The previous data clearly shows oxALB triggers cell death through oxidative stress and 
subsequent GSH loss. The nature of the cell death, whether it occurred by apoptosis or 
necrosis was investigated by flow cytometry. Cells (0.5×10
6
 cells/ml) treated with 1.0 
mg/ml 1000/1 oxALB over 24 hours. At set time points samples were taken out and 
analysed for cell death using AnnexinV-FITC (apoptosis) and PI (necrosis) probes using 
flow cytometry through FL3 and FL1 filters. Each sample had 10,000 events recorded 
within a gate set to exclude cellular debris. Mean fluorescence in the FL3 filter, 
measuring PI, only increased at 3 hours and each following measurement (figure 3.35a). 
Comparatively mean fluorescence in the FL1 filter, measuring AnnexinV-FITC, 
increased from 1 hour until peaking at 3 hours, before decreasing to control levels in 
subsequent time points (figure 3.35b). This suggests that there were separate 
populations of cells undergoing both apoptosis and necrosis at early time points before 
apoptosis is stalled, and cytotoxicity is due to secondary necrosis from around 6 to 24 
hours.  
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Figure 3.35   Apoptosis and necrosis follow after exposure of U937 cells to oxALB. Cells 
(0.5×10
6
 cells/ml) treated with or without 1 mg/ml 1000/1 met-oxALB over 24 hours. At set 
time points samples were taken out and analysed for cell death using AnnexinV-FITC and PI 
probes using flow cytometry through FL3 and FL1 filters. The change in mean fluorescence for 
the necrosis probe (PI) over the first 3 hours can be seen through an overlaid histogram (A). The 
change in mean fluorescence for the apoptosis probe (AnnexinV-FITC) over the first 3 hours 
can be seen through an overlaid histogram (B). 
A) 
B) 
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4. DISCUSSION 
 
4.1    Hypochlorous acid as a relevant oxidant in atherosclerosis 
It is now well accepted that high plasma low-density lipoprotein (LDL) levels are a key 
risk factor in cardiovascular disease, and that oxidised LDL contributes to the pathology 
of atherosclerosis. There has been much interest in determining the precise nature of 
this oxidation, and identifying the agents responsible for it. Recently attention has 
focused on the role of phagocytic cells as a major source of reactive oxygen species, 
including the neutrophil, which produces large amounts of hypochlorous acid (HOCl) in 
a reaction catalysed by the highly abundant, heme enzyme myeloperoxidase (MPO) 
(Arnhold, 2004). There is a wealth of knowledge on myeloperoxidase and its product, 
HOCl and the evidence for their involvement in atherosclerosis is compelling. 
Catalytically active myeloperoxidase has been found in atherosclerotic lesions 
(Daugherty et.al., 1994). Chlorinated tyrosine derivatives, which are thought to be 
specific products of MPO, have been detected during all stages of development of 
atherosclerosis (Heinecke, 1997), with elevated levels of 3-chlorotyrosine found in 
patients presenting with atherosclerotic complications (Hazen & Heinecke, 1997). 
Immunohistochemical studies have shown HOCl-generated protein oxidation products 
co-localized with macrophages and LDL in various lesion types (Hazell et.al., 1996; 
Malle et.al., 2000). However, many details regarding the mechanism, site of damage, 
and molecular events in the pathology remain to be answered. 
A clear understanding of the products of HOCl-induced oxidation, together with 
analysis of oxidation products in vivo will allow evaluation of the role in atherosclerosis 
of myeloperoxidase, and the phagocytic cells that produce it. LDL contains both a 
protein and a lipid component, either of which may be involved in the oxidative damage 
during atherosclerosis, and consequently this study started by examining the effects 
HOCl had on this macromolecule.   
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4.2    Modification of LDL by HOCl 
One important question arising from this study is whether HOCl concentrations utilised 
within this research were such that they favour HOCl-modification of lipoproteins in 
vivo, thus allowing appropriate pathophysiological conclusions to be drawn on the 
results. At sites of acute inflammation, HOCl concentrations are reported to be in the 
range of 340 M or above (Katrantzis et.al., 1991) which would result in a minimum 
molar oxidant/protein ratio of 250/1. Thus LDL was modified by incubating with 
varying oxidant/protein ratios ranging from 250/1 to 2000/1. 
This laboratory has shown previously that protein hydroperoxide formation is tightly 
coupled to lipid oxidation during both copper- and AAPH-mediated LDL oxidation. 
Also, that THP-1 monocyte cell-mediated LDL oxidation induces the generation of 
significant levels of protein hydroperoxides (Gieseg et al., 2003). Considering that 
protein hydroperoxides are found in atherosclerotic plaque  (Fu et al., 1998), are known 
to consume protective cellular thiols and ascorbate (Gebicki, 1997) and give rise to 
further radicals that damage other target molecules (Fu et al., 1998, Gebicki, 1997), 
then evidence for a role of such protein oxidation products in oxLDL toxicity seems 
likely. Quantification of protein hydroperoxides (PrOOHs) formed from the oxidation 
of LDL with HOCl was carried out using the acetic acid FOX assay. PrOOH formation 
whilst increasing in a concentration dependent manner across varying HOCl/LDL molar 
ratios (figure 3.4a), did not exhibit anywhere near the yield found from the oxidation of 
LDL with AAPH (Gieseg et.al, 2003). This may be due to the fact that reactions with 
HOCl are very rapid and measurements of PrOOH were conducted after the 
hydroperoxides had already stated to decay, although this is not likely as Simpson et.al., 
(1992) found their half-lives to be 5 days, and a subsequent experiment showed that the 
levels of PrOOH actually increased with time (figure 3.4b). A more probable scenario is 
that the radicals generated from HOCl oxidation with LDL failed to produce peroxyl 
radical (indicating no interaction with poly unsaturated fatty acids), hence no carbon 
centred radical was formed, which is integral in the series of reactions that occurs in 
PrOOH formation.  
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To determine whether the protein moiety of LDL was being oxidised by HOCl an 
alternative measure of protein oxidation was utilised. Tyrosine loss is an indicator of 
general protein damage. HOCl caused tyrosine loss in a concentration-dependent 
manner (figure 3.1). Tyrosine is relatively low on the reactivity series of HOCl, 
therefore if tyrosine is oxidised one can assume that other amino acids are also being 
oxidised, and thus the protein moiety effected in the oxidation of LDL with HOCl. 
With the majority (80%) of the LDL molecule made up of cholesterol and lipids, the 
protein moiety is by far not the only available target for HOCl. A common marker of 
lipid peroxidation is the formation of thiobarbaturic acid reactive species (TBARS), and 
high levels have been found in Cu-oxidised LDL. Although TBARS did increase with 
HOCl oxidation, comparatively the levels were negligible to those produced with Cu-
oxLDL (figure 3.5). It has been shown that HOCl has the ability to break down 
malondialdehyde (MDA) (Winterbourn et.al., 1993) a key component to the TBARS 
assay and may explain why there were such low levels of TBARS produced. If this is 
the case then this does not necessarily suggest that lipid peroxidation is not occurring, 
simply the validity of the assay is questionable under these parameters, and an 
alternative method of lipid peroxidation should be assessed. 
An exploration of the lipid composition of Cu-oxLDL and of a macrophage foam-cell 
model generated by the uptake of oxLDL demonstrated that when LDL undergoes 
oxidation in vitro a number of changes in lipid composition occur, including the 
substantial loss of free and esterified cholesterol and the generation of oxysterols 
(Brown et al., 1996). Oxysterols are the 27-carbon products of cholesterol oxidation and 
have been widely implicated in the development of atherosclerosis. During the copper-
mediated oxidation of LDL in vitro, it has been shown that up to 50% of the cholesterol 
is converted to oxysterols, with the major oxysterol present as 7-ketocholesterol (Brown 
et al., 1996). Unlike the previous studies with Cu-oxLDL, only trace amounts of 7-
ketocholesterol (7KC) were detected when LDL was oxidised with HOCl (figure 3.8). 
This result, along with the lack of interaction with polyunsaturated fatty acids, 
demonstrates clearly that the lipid component of the LDL molecule is not the main 
target of attack for HOCl.  
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Given that lipid peroxidation products have been found in atherosclerotic lesions 
(Brown & Jessup et.al., 1999) and elevated levels of 7-ketocholesterol have been linked 
to cell death within the plaque (Lizard et.al.,1999), it was of interest to determine if 
HOCl-oxLDL underwent secondary reactions with free metal ions present in the 
incubation medium, RPMI-1640; especially after the removal of HOCl and the 
complete loss of the antioxidant α-tocopherol (figures 3.2 & 3.9). Surprisingly, the 
minute levels of TBARS went down after the 24 hour incubation in RPMI-1640 
medium. Whilst this is probably due to the prolonged exposure to HOCl and breakdown 
of MDA, no definite conclusions could be made due to the limitations of this assay. 
Were TBARS actually decreasing overtime due to its half-life and/or forming further 
by-products, or were TBARS not detected because the MDA had reacted with HOCl 
giving a false negative result? 7-ketocholesterol levels did increase; however, levels 
were still significantly lower than those found with copper-mediated LDL oxidation. It 
would be interesting to see whether 7KC levels did continue to increase over time 
during a longer incubation period, and whether removal of metal ions still allowed for 
further lipid peroxidation. It would also be of interest to use a more oxidative 
permissive media such as Ham‟s F-10 in further studies. This would substantiate the 
hypothesis for a role protein oxidation products play in the propagation of lipid 
peroxidation 
OxLDL plays a crucial role in atherosclerosis as a cause of foam cell formation, cell 
proliferation and migration, adhesion of endothelial cells and extracellular matrix 
propagation at atherosclerotic lesions. It has long since been established that it is also 
involved in the advancement of atherogenesis as a cause of cell death within the 
necrotic core. Cu-oxLDL has been shown to be toxic to several cell types including: 
smooth muscle cells (Ding et.al., 2011), endothelial cells (Kuzuya et.al., 1990), U937s 
(Baird et.al., 2004), THP-1s (Namgaladze et.al.,2008) and macrophages (Baird et.al., 
2005). The cause of this toxicity is subject to vigorous debate. Many propose that the 
toxic agent within the oxLDL is the lipid-peroxidation product 7-ketocholesterol. 
However, a recent study from this laboratory has found that to be unlikely (Rutherford 
& Gieseg, 2012), and brought the involvement of 7-Ketocholesterol in the toxicity of 
oxLDL into question. This raises the question of whether the toxic agent is a protein 
oxidation product.  
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4.3    Toxicity of HOCl-oxLDL 
The U937 human monocytic cell line was selected for use in this model system since 
monocytes are involved in the primary and on-going interactions with modified 
lipoproteins within the artery wall (Lusis, 2000). Importantly, this laboratory has 
previously shown that the Cu-oxLDL-induced cell death mechanism in U937 cells is the 
same as that seen in human monocyte-derived macrophages prepared from human blood 
(Baird et al., 2004). In both cell types, Cu-oxLDL causes large reactive oxygen species-
induced oxidative stress, loss of cellular glutathione and oxidative loss of regulatory 
metabolic enzymes, triggering caspase-independent necrosis (Gieseg et al., 2009b). 
U937 cells are a commonly used atherosclerotic model since they allow for the 
investigation of relatively homogeneous groups of cells, compared to the more 
heterogeneous nature of comparatively small quantities of human monocyte-derived 
macrophages isolated from human blood samples. U937 cells have a doubling time of 
between 3-4 days depending on the presence of serum in the cell culture medium. The 
use of a rapidly growing cell line over relatively long incubation periods means that cell 
growth must be taken into consideration during experimental design, for instance 
conducting toxicity experiments on cells in the same cell cycle. For this reason, 
experiments were designed such that the effects of cell proliferation were minimised, 
for example, data were expressed as a percentage of, or relative to cell-only control 
treatments.  
This investigation began by examining the effect of HOCl-oxLDL on U937 cells, in 
terms of cell viability and glutathione content. HOCl-oxLDL showed a high degree of 
toxicity to U937 cells, with the median lethal dose found to be between 0.5-1.0 and up 
to 1.25 mg/ml oxLDL, depending upon the individual oxLDL preparation. The 
concentrations of HOCl-oxLDL used in the experiments are within the range of LDL 
concentrations in vivo, as serum concentrations of LDL in normolipidemic persons are 
maintained at approximately 3.0 mg/ml (Esterbauer et al., 1992). 
There was no significant difference in cell viability loss between varying 
oxidant/protein molar ratios, rather there was increased loss with increased 
concentrations of HOCl-oxLDL given to cells (figure 3.11). This suggests that the cause 
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of the toxicity from HOCl-oxLDL is bound to the molecule and has become saturated 
by the HOCl even at the lowest HOCl/LDL molar ratio. It is the presence of more of the 
HOCl-oxLDL molecules (carrying the toxic component) that is the cause for increased 
toxicity. 
Time course studies indicated that the loss of cell viability caused by HOCl-oxLDL 
occurred rapidly, between 6 and 9 hours (figure 3.16a). This progression of viability 
loss was very closely correlated with loss of cellular glutathione content (figure 3.16b), 
although glutathione loss appeared to occur slightly ahead, and more rapidly than 
viability loss. Glutathione loss provides a direct measure of the cellular antioxidant 
status and it has been established previously that cellular glutathione loss results in a 
further increased susceptibility to oxidative stress (Ballatori et al., 2009). HOCl-oxLDL 
clearly induces an oxidative stress in U937 cells, causing reduced glutathione content in 
parallel with reduced cell viability, which is consistent with previous findings by this 
laboratory (Baird et.al., 2004). 
In the case that 7-ketocholesterol was the toxic agent within oxLDL, one would expect 
HOCl-oxLDL with low-levels of 7-ketocholesterol not to be cytotoxic. This study found 
otherwise, which suggests that we need to look elsewhere to determine the cytotoxic 
mechanism of HOCl-oxLDL. 
 
4.4    Mechanism of oxLDL toxicity 
In exploring the mechanism of action of HOCl-oxLDL to U937 cells, it is necessary to 
consider firstly whether HOCl-oxLDL is actually internalised by cells. Although there 
has been debate as to whether U937 cells express scavenger receptors necessary for the 
unregulated uptake of HOCl-oxLDL, it is now widely accepted that they do. The CD36 
receptor (belonging to scavenger receptor class B) has been shown to internalise HOCl-
oxLDL in U937 cells (Pietsch et al., 1996). Expression of class A scavenger receptors 
has been shown to occur during PMA-induced differentiation of U937 monocytes to 
macrophages (Banka et al., 1991, Shimaoka et al., 2000) and differentiation of U937 
cells by 0.1 mg/ml oxLDL was shown to induce scavenger receptor expression (Lei et 
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al., 2002) which indicates that HOCl-oxLDL is actively absorbed by U937 cells. The 
current hypothesis for Cu-oxLDL cytotoxicity is that it causes high levels of 
intracellular oxidative stress, including the formation of highly reactive oxidised lipid 
and protein species that overwhelm the cells' antioxidant capacity, inducing imbalances 
in the intracellular redox environment, changes in various signalling pathways and gene 
expression, leading to cell death via caspase-independent necrosis (Baird et.al, 2004).  
Chloramines are a significant by-product of HOCl interaction with proteins, and are 
known to be toxic towards many cell types (Tatsumi & Fliss, 1994; Thomas, 1979). 
Given that the previous results in this study show that the protein component of LDL is 
the main target of HOCl attack, removal of chloramines after oxidation of LDL, 
surprisingly did not affect the toxicity of HOCl-oxLDL (figure 3.13). This suggests that 
chloramines were not present in the HOCl-oxLDL solution and not the cause of HOCl-
oxLDL toxicity. This could be due to a number of reasons: either no chloramines were 
formed because there was little to no accessibility of amine targets on the LDL 
molecule during HOCl attack; or chloramines have broken down either back to amines 
or onto reactive aldehydes. The latter is more plausible as previous studies have found 
chloramine formation upon HOCl-oxLDL (Hazell & Stocker, 1993).  Chloramines 
although relatively stable at 4 ˚C, are rapidly lost with a half-life of 100 minutes in PBS 
at 37 ˚C (Hazell & Stocker, 1993). Since the oxidation method and subsequent dialysis 
of LDL occurs for 24 hours before chloramines removal, it is more than likely there 
were no chloramines to remove, but broken down to reactive aldehydes, which 
themselves are cytotoxic (Hazen et.al., 1996), and  could contribute to the toxicity of 
the HOCl-oxLDL.  
For cells to function properly at inflammation sites, including in atherosclerotic lesions, 
they need to possess antioxidative mechanisms defending themselves against oxLDL 
induced stress. The physiological role of glutathione is multi-faceted and has been 
implicated in a multitude of cellular functions, such as the transport of amino acids, 
synthesis of proteins and nucleic acids, and maintenance of enzymes in active forms 
(Pastore et al., 2003).  Glutathione (GSH) is the major intracellular antioxidant and its 
deficiency has been implicated in a number of diseases, possibly due to the increased 
susceptibility of cells/tissues to oxidative stress (Ballatori et al., 2009). The antioxidant 
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function of GSH depends primarily on its role as a component of the enzymatic 
pathway that cells developed against ROS. GSH provides a first line of defence against 
ROS, as it can scavenge free radicals and reduce H2O2 (Pastore et al., 2003). Moreover, 
GSH is significantly lost in red cells (Vissers & Winterbourn, 1995) and neutrophils 
(Carr & Winterbourn, 1997) before cell lysis occurs, indicative of its role in defending 
cells against oxLDL. 
It was found that U937 cells treated with HOCl-oxLDL showed significant cell viability 
loss (between 6 and 9 hours) after the intracellular GSH level was significantly 
decreased (between 3 and 6 hours) (figures 3.14 & 3.16). This implies that HOCl-
oxLDL did not react with cell membranes first causing membrane integrity loss, but 
penetrated the plasma membrane to react with intracellular GSH first. Morphological 
examination of the cells at each time point showed that the cells began to swell and 
underwent necrotic cell death rather than apoptosis. The above results also imply that 
once GSH was no longer abundant enough in cells to effectively scavenge HOCl-
oxLDL, the remaining HOCl-oxLDL then reacted with other biomolecules, causing 
membrane integrity loss and cell death. This hypothesis is consistent with previous 
studies, which showed significant Cu-oxLDL-induced intracellular GSH loss before cell 
lysis or cell swelling were observed (Baird et.al., 2004).  
Oxidative modification of lipids alters their physical properties to such an extent that 
they may undermine the structural integrity of the membrane. Most cells have an 
impressive arsenal of antioxidant compounds and enzymes at their disposal that protects 
against the generation and accumulation of lipid oxidation products in their membranes. 
Along with GSH mentioned above, 7,8-dihydroneopeterin is a relevant antioxidant to 
study for its role it plays in inflammation and potentially atherosclerotic lesions. Human 
macrophages can synthesize and release neopterin and its reduced form, 7,8- 
dihydroneopterin (78NP), upon induction by interferon-γ (IFN-γ) (Wachter et al., 1989; 
Wachter et al., 1992). 78NP may be produced and play a role within the lesions, and has 
been detected in atherosclerotic lesions of humans (Hansson et al., 1989; Libby, 1995; 
Zhou et al., 1998). In addition, neopterin levels are found to be significantly elevated in 
patients with vascular disease (Schumacher et al., 1992; Tatzber et al., 1991; Rudzite et 
al., 2003). It has been hypothesized that 78NP is synthesised by γ-IFN-stimulated 
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macrophages to protect the cells against the oxidants encountered within an 
inflammatory site; including oxLDL (Gieseg et al. 2007). U937 cells were fully 
protected from 1000/1 HOCl-oxLDL induced cell viability and glutathione loss by 
addition of 250 µM 78NP (figures 3.15 & 3.16). This indicates that 78NP scavenged 
HOCl-oxLDL efficiently to prevent it from oxidizing intracellular GSH and causing cell 
death. This is in agreement with previous studies, which showed that 78NP is a potent 
antioxidant scavenger and protects U937 cells and HMDM cells from Cu-oxLDL 
cellular damage (Baird et al., 2004, Baird et al., 2005). The effective concentrations of 
78NP added to cells in the above experiments appeared to be higher than the in vivo 
neopterin concentrations reported. Up to 2 μM neopterin has been reported in 
atherosclerotic plaques from carotid artery (Gieseg et al., 2007). However, the 78NP 
concentrations in the local environment of cells are likely to be higher than the above 
reported value.  
With the previous findings that suggest a role for reactive oxygen species in Cu-oxLDL 
cell death, DHE was measured to determine whether reactive oxygen species represent a 
cause or product of HOCl-oxLDL-induced cell death. DHE fluorescence rose steadily 
from initial contact with HOCl-oxLDL and peaked at 3 hours. This is preceded GSH 
loss and subsequent viability loss. 78NP did protect U937 cells from the oxidative stress 
induced by HOCl-oxLDL (figure 3.17) which suggests that intracellular oxidative stress 
is a key factor in driving cell death.  
 
4.5    Protein oxidation in atherosclerosis 
In a review of oxidative modifications (Stocker & Keaney, 2004), it was highlighted 
that the correlation between levels of oxidised lipids and lesion development, as 
predicted by the widely accepted oxidative modification hypothesis, is not observed in 
either ex vivo or in vitro studies. Together with the results of this study, it seems 
appropriate that alternative mechanisms of oxLDL cytotoxicity be considered. Although 
there is solid evidence to suggest that lipid oxidation and toxicity are linked (Clare et 
al., 1995), indications that protein oxidation may play an important role in cytotoxicity 
are numerous (Hazell et al., 1996, Stocker & Keaney, 2004, Upston et al., 2002). This 
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provides an opening for the suggestion that the products of protein oxidation may be at 
the heart of oxLDL-induced cell death and the development of the necrotic core. 
Of direct relevance is an investigation that aimed to distinguish and examine processes 
resulting from the direct oxidation of protein (as compared to the derivatisation of lysine 
residues on apoB-100). The study examined which oxidative species might contribute to 
protein-bound oxidation products such as chlorotyrosine, dityrosine, 3,4-
dihydroxyphenylalanine (DOPA), o-tyrosine and m-tyrosine, which are detected in 
advanced atherosclerotic plaques. Their findings indicated that hydroxyl radical-induced 
damage to protein is a plausible influence in atherosclerotic plaque (Fu et al., 1998). 
Their findings also raised the issue of the source of hugely increased dityrosine levels 
that are measured in atherosclerotic plaques. Levels of dityrosine (a well-established 
hallmark for oxidised protein levels) have been shown to increase significantly from the 
early to late stages of plaque development. It has also been established by Heinecke 
et.al. (1993) that tyrosine can act as a substrate for MPO-derived HOCl, resulting in the 
formation of a tyrosyl radical which is then able to cause oxidation of cholesterol or the 
cross-linking of proteins via dityrosine formation (Savenkova et.al., 1994). 
Further to this, hypochlorite (HOCl)-modified proteins that have been identified in 
human atherosclerotic plaque have been shown to transform LDL to a high-uptake form 
without significant lipid oxidation (Hazell et al., 1996). The accumulation of oxidised 
modifications may decrease the proteolytic susceptibility of some portions of oxidised 
protein (Grant et al., 1993). This is particularly significant in the case of long-lived 
resident macrophage cells, where the accumulation of reactive protein oxidation 
products such as advanced oxidation protein products (AOPPs) may cause further 
damage to other cellular macromolecules in the vicinity.  
 
4.6    Modification of Albumin by HOCl 
Advanced oxidation protein products (AOPPs) are dityrosine-containing, cross-linked 
protein products formed during the oxidative burst of monocytes via myeloperoxidase 
reaction, and are carried mainly on albumin in the plasma (Witko-Sarsat et.al., 1996; 
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Witko-Sarsat et.al., 1998). AOPPs are not innocent end products of the activation of 
macrophages, they are biologically active molecules capable of mediating oxidative 
stress and respiratory burst in monocytes (Witko-Sarsat et.al., 1996). AOPPs are 
capable of inducing/accelerating renal injury in the tubular cells, via the CD36 pathway 
(Iwao et.al., 2006), and in vascular endothelial cells, via a receptor for advanced 
glycation end-products (RAGE)-mediated signalling pathway (Sebekova et.al., 2012). 
With the aim of creating a physiologically relevant model for testing the toxicity of 
AOPPs, bovine serum albumin was incubated with HOCl at varying oxidant/protein 
molar ratios ranging from 250/1 – 2000/1. Increasing HOCl/BSA molar ratios bands on 
SDS-PAGE gels became increasingly blurred and fragmented (figure 3.18). There was 
also significant loss of tyrosine residues coinciding with an increase in oxidative 
tyrosine products, including dityrosine (figure 3.19). Although these results suggest that 
AOPPs have formed (and validate the oxidation of BSA as a relevant model in studying 
AOPPs), it cannot be determined for certain, so the oxidative product was termed 
oxALB.   
 
4.7    Toxicity of oxALB 
OxALB caused a concentration-dependent loss of cell viability (figure 3.22). This is in 
agreement with a number of studies using  different cell types including U937 cells 
(Vicca et al., 2003; Ermak et al., 2010) and THP-1 cells (Vicca et.al., 2000). In contrast 
to the cytotoxic effects of HOCl-oxLDL, oxALB displayed significant differences 
between increasing HOCl/BSA molar ratios, which was especially emphasised on 
oxALB that had undergone dialysis treatment (figure 3.21). The precise toxicity of 
oxALB towards U937 cells was found to vary between oxALB preparations, however 
this difference was minimized after dialysing residual HOCl that had not reacted from 
the oxALB solution. 
Comparisons of toxicity between HOCl-oxLDL and oxALB were determined by 
incubating cells with equivalent total mass (1.0 mg/ml) or equivalent protein mass (1.0 
mg/ml HOCl-oxLDL and 0.2 mg/ml oxALB).  OxALB (1.0 mg/ml) displays a high 
level of toxicity to U937 cells, comparable to that of Cu-oxLDL, and HOCl-oxLDL 
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(figure 3.23). OxALB was significantly less toxic than HOCl-oxLDL when exposed to 
U937 cells at equivalent protein mass (figure 3.24). HOCl-oxLDL and oxALB more 
than likely share a similar toxic protein component. However, HOCl-oxLDL also 
possesses a significant amount of lipids, which although not initially a target of HOCl 
attack could undergo peroxidation propagated by oxidative protein products formed 
from the initial HOCl exposure, and may explain the difference in toxicity. 
Cell viability was measured by both MTT reduction assay and trypan blue exclusion 
assay (figure 3.28). The MTT reduction assay measures metabolic activity of cells; 
MTT compound is reduced by mitochondrial NADH dehydrogenases to formazan only 
in living, metabolically active cells (Mosmann, 1983). Yet, stimulated cells can produce 
more formazan than resting cells, suggesting that the observed cell viability loss could 
be attributed to either an increased ratio of dead to viable cells or decreased metabolic 
activity in the viable cells. Cell viability measured by the trypan blue exclusion assay 
(monitors cell membrane integrity) agrees with that obtained by the MTT assay. This 
indicates the observed cell viability loss was indeed due to cell death. Irrespective of 
their different mechanisms for detecting cell death, these two assays provided strong 
corroboration of all viability results obtained. 
The time course of oxALB-induced cell viability loss showed that all viability loss 
occurred rapidly during the first 6 hours (figure 3.28). The rapid metabolic energy loss 
(measured by MTT assay) and perturbation of cellular membranes (seen though 
swelling and lysis of cell in the trypan blue assay) implied that oxALB induced necrotic 
cell death in U937 cells.  
 
4.8    Mechanism of oxALB toxicity 
Removal of chloramines reduced the toxicity of  oxALB (figure 3.26) significantly but 
not completely, this was especially apparent when cells were exposed to higher 
concentrations of oxALB. The reason for this seems to be some biphasic toxic 
mechanism. Chloramines appear to be responsible for this toxicity, but cannot be 
attributed for the entirety of the toxic mechanism of oxALB. This anomaly could be due 
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to the reactivity of chloramines as they retain sufficient oxidizing capacity to directly 
modify biomolecules. In addition, chloramines can break down to form reactive 
aldehydes or nitrogen-centered radicals (Carr et.al., 2000). They themselves are 
cytotoxic and may be responsible for the remaining toxicity of oxALB after the removal 
of chloramines. Because the half-lives of chloramines are relatively short (see section 
4.4) it would be interesting to see if the toxic agent of oxALB is due to the initial 
chloramine production and subsequent aldehyde formation. One way to examine this 
may be to add methionine directly to oxidation solution, but methionine is highly 
reactive with HOCl (Winterbourn, 1985; Pattison & Davies, 2001) and would act as a 
scavenger reducing the HOCl attack on the BSA. By oxidising BSA at 4˚C it will 
mitigate the reactivity of chloramines, which are stable and unreactive (3 day half-lives) 
at this lower temperature (Hazell & Stocker, 1993). Although this would not be 
physiologically relevant as it would not mimic the conditions of HOCl oxidation found 
in vivo. This may be a dilemma which cannot be resolved by the modification of the 
oxidation process but rather experimentation with further analytical techniques. 
U937 cells treated with oxALB showed rapid GSH loss between 3 and 6 hours (figure 
3.33). A point of similarity between the two mechanisms (HOCl-oxLDL and oxALB) of 
toxicity is that the viability loss was preceded by a rapid loss in GSH.  Such a close 
relationship between cellular glutathione loss and viability loss generally indicates the 
involvement of radical oxygen species. DHE was utilised as a probe to determine 
whether oxidative stress increased upon exposure to oxALB. As with HOCl-oxLDL, 
oxALB induced an increase in DHE fluorescence which rose steadily, peaking at 3 
hours (figure 3.34). It appears that oxALB induced cell death of the U937 cells in the 
same manner as HOCl-oxLDL, by inducing oxidative stress, leading to a rapid GSH 
loss and subsequent viability loss. In addition 200 µM 78NP could prevent all of these 
effects from occurring and completely prevented cell death (figures 3.30, 3.31, 3.32, 
3.33 & 3.34). 
Research directed at understanding the functional consequences of cell death in 
atherosclerosis has revealed opposing roles for cell death in atherosclerotic plaque 
progression. In early lesions, apoptosis limits lesion cellularity and suppresses plaque 
progression (Liu et.al., 2005; van Vlijmen et.al., 2001). In advanced lesions, cell death 
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promotes the development of the necrotic core, a key factor in rendering plaques 
vulnerable to disruption and acute lumenal thrombosis (Seimon & Tabas, 2009). 
Apoptosis seems to be clearly advantageous, because the elimination of the apoptotic 
cells or resulting apoptotic bodies by phagocytosis prevent the release of intracellular 
content and consequent damage of the surrounding tissue, as it occurs in necrosis. 
Therefore discovering the type of cell death that occurs when cells are exposed to 
oxALB is of great importance in determining the role oxALB may play in the 
advancement of atherogenesis. 
Flow cytometric analysis of phosphatidylserine exposure, detected by AnnexinV-FITC 
binding, showed the cells were becoming apoptotic in the first 3 hours of incubation 
with oxALB (figure 3.34), coinciding with the peak in ROS. After 3 hours little to no 
apoptosis staining was detected. OxALB caused a rapid increase of propidium iodide 
(necrosis marker) in U937 cells after GSH depletion at 6 hours (figure 3.34). This result 
was in agreement with the earlier results where morphological changes were observed, 
which demonstrated that oxALB caused U937 cell swelling and cell membrane rupture. 
The suppression of apoptosis and the induction of necrosis was observed when 
depletion of GSH occurred.   An increase in intracellular oxidation may determine the 
selection between apoptosis and necrosis. Nagai et al., (2002) have reported that GSH 
depletion causes necrosis in mouse hepatocytes. Apoptosis is an energy-dependent 
process and the decrease in ATP below critical levels prevents the execution of 
apoptosis whilst promotes necrosis. The results of this work suggest that changes in 
GSH status play a critical role in the mechanisms that regulate apoptosis and necrosis. 
OxALB clearly has the potential to play a major part to play in cell death. Protein 
oxidation products may be responsible for not only cell death in atherosclerotic lesions, 
but may also propagate lipid peroxidation resulting in further oxidative stress and 
cellular death, enhancing the necrotic core causing destabilization of the plaque.  
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4.9    Summary 
It appears that HOCl reacts preferentially with the protein moiety of LDL, and it is 
hypothesised that lipid damage takes place more slowly via a secondary reaction 
involving the breakdown of protein-based products. The few studies carried out that 
investigate the kinetic progression of such damage show that protein oxidation is an 
early event in ROS-initiated events (Du & Gebicki, 2004). The derivatisation of protein 
is known to occur at the same time that LDL becomes toxic and also correlates with the 
conversion of LDL to the high-uptake form (Du & Gebicki, 2004).  
HOCl-oxLDL generated in such a manner, with a near absence of oxysterols, displays a 
high level of toxicity to U937 cells, comparable to that of Cu-oxLDL. HOCl-oxLDL 
and oxALB caused concentration-dependent losses of cell viability. Rapid metabolic 
energy loss (measured by MTT reduction assay), cell membrane integrity loss, cell 
membrane rupture, and cell swelling were observed (measured by trypan blue exclusion 
assay). This implies that HOCl-oxLDL and oxALB caused U937 cells to undergo 
necrotic cell death. Depletion of intracellular GSH rendered cells more sensitive to 
necrosis. These results indicate that intracellular GSH played an important role in 
protecting U937 cells from HOCl-oxLDL and oxALB induced oxidative stress. 
Exposing U937 cells to HOCl-oxLDL and oxALB in the presence of 78NP significantly 
reduced intracellular GSH and cell viability loss, indicating that 78NP was an efficient 
scavenger of HOCl-oxLDL and oxALB and out-competed intracellular GSH for HOCl 
(see figure 4.1). 
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Protein oxidation products may act as a novel class of pro-inflammatory mediators, 
which accumulate and increase oxidative stress and inflammation at atherosclerotic 
sites. As a result of increased stress, further AOPP formation may occur though the 
stimulation of leukocytes to produce more oxidants. This positive feedback loop could 
amplify or maintain oxidative stress and inflammation, thus contribute to atherogenesis. 
They may also cause cellular death within the necrotic core by inducing intracellular 
oxidative stress, leading to the depletion of antioxidants and destabilisation of the cell 
homeostasis for controlling apoptotic cell death, leading to necrosis and growth of the 
necrotic core. 
Mechanisms by which protein oxidation products accelerate atherosclerosis remain to 
be investigated. Further studies should focus on the toxic agent within the protein 
moiety of the LDL molecule, and that on AOPPs. This may include:  isolation of protein 
fragments from gels after oxidative modification which could then be tested for toxicity 
and identified using mass spectrometry; cleavage of selected amino acids off LDL and 
albumin, with subsequent oxidation to see if toxicity is reduced; and identification of 
chloramines and reactive aldehydes produced using HPLC. In addition the toxic 
mechanism of HOCl-oxLDL and oxALB should be further elucidated. What causes the 
induction of oxidative stress? How is NOX involved, could inhibitors of NOX prevent 
toxicity of these HOCl-oxidised proteins? Identification of the toxic protein 
modifications causing these effects would allow for the development of new diagnostic 
assays, and elucidation of the cytotoxic mechanism may allow for advancement of 
therapeutic applications. 
Acknowledgements 
 
 
119 
 
ACKNOWLEDGEMENTS 
 
This thesis would not have been possible without my supervisors Associate Professor 
Steven Gieseg and Dr Ashley Garrill. Over the years Steven has shared his contagious 
enthusiasm for research and incredible ability to make science research as interesting 
and exciting as it deserves to be. I would also like to express thanks for his incredible 
patience, support and advice which led to the completion of this thesis. I am also 
thankful for the input and advice of my co-supervisor, Dr. Ashley Garrill and very 
grateful to our technician, Maggie Tisch, for looking after the running of the laboratory 
and for her always cheerful nature. I have been incredibly fortunate to be surrounded by 
such an amazing group of researchers. I would like to give special thanks to all of the 
members of the Free Radical Biochemistry Laboratory for their help and sharing of 
ideas, especially to Hanadi and Lucy for being patient teachers during my first couple of 
months; to Raj and Anastasia for helping me with HPLC and to Hannah, Alpha and 
Wafaa, for being lovely people to share an office with. We‟ve been though some pretty 
tough times together, earthquakes, moving, extensions, and I appreciate the time you 
had for me and for keeping sane during the stressful times. I would also like to 
especially acknowledge and thank Hannah, for being a willing proof-reader and supplier 
of smiles.  
Thank you very much to all of the generous people who donated blood that was used for 
the isolation of LDL, as this was a crucial part of my work. Also a big thank you to 
Sally Mckormick and her laboratory for supplying our lab with LDL when we could no 
longer make our own. I would also like to acknowledge the National Heart Foundation 
of New Zealand for supplying the funding for my research.  
Most importantly, I would like to thank my parents Karen and Ian for supporting me 
throughout my entire education and believing that I could do it. Without support earlier 
in my life this thesis would not have been possible. And of course, thank you to Tom, 
my partner and best friend. Although incredibly busy with his own work, Tom‟s 
understanding, passion for learning, and great work ethic motivated me in times of self-
doubt. 
References 
 
 
120 
 
REFERENCES 
 
Arnhold, J. (2004). Free Radicals - Friends or Foe? Properties, functions and secretion 
of human myeloperoxidase. Biochemsistry (Moscow), 69(1); 4-9. 
Assinger, A., Koller, F., Schmid, W., Zellner, M., Koller, E., & Volf, I. (2010). 
Hypochlorite-oxidised LDL induces intraplatelet ROS fomration and surface 
exposure of CD40L - A prominent role of CD36. Atherosclerosis, 213(1): 129-
134. 
Atabek, M. E., Keskin, M., & Yazici, C. (2006). Protein oxidation in obesity and insulin 
resistance. Eur J Pediatr, 165, 753-756. 
Baird, S. K., Hampton, M., & Gieseg, S. P. (2004). Oxidised LDL triggers 
phosphatidylserine exposure in human monocyte cell lines by both caspase-
dependent and independent mechanisms. FEBS Letters, 578, 169-174. 
Baird, S. K., Reid, L., Hampton, M. B., & Gieseg, S. P. (2005). OxLDL induced cell 
death is inhibited by the macrophage synthesised pterin, 7,8-dihydroneopterin, 
in U937 cells but not THP-1 cells. Biochim Biophys Acta, 1745(3); 361-369. 
Baldus, S., Eiserich, J. P., Brennan, M. L., Jackson, R. M., Alexander, C. B., & 
Freeman, B. A. (2002). Spatial mapping of pulmonary and vascular nitrotyrosine 
reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in 
inflammatory diseases. Free Rad Biol Med, 33(7); 1010. 
Ballatori, N., Krance, S. M., Notenboom, S., Shi, S., Tieu, K., & Hammond, C. L. 
(2009). Glutathione dysregulation and the etiology and progression of human 
diseases. Biological Chemistry, 390, 191-214. 
Banka, C. L., Black, A. S., Dyer, C. A., & Curtiss, L. K. (1991). THP-1 cells form foam 
cells in response to coculture with lipoproteins but not platelets. J. Lipid 
Research, 32, 35-43. 
Berliner, J., & Heinecke, J. (1996). The role of oxidised lipoproteins in atherogenesis. 
Free Radical Biology & Medicine, 20(5), 707-727. 
Bjorkerud, B., & Bjorkerud, S. (1996). Contrary effects of light and stongly oxidised 
LDL with promotion of growth versus apoptosis on artery smooth muscle cells, 
macrophages and fibroblasts. Atherosclerosis, Thrombosis and Vascular 
Biology, 16, 416-424. 
Brown, A. J., & Jessup, W. (1999). Oxysterols and Atherosclerosis. Atherosclerosis, 
142,1-28. 
References 
 
 
121 
 
Brown, A. J., Dean, R. T., & Jessup, W. (1996). Free and esterified oxysterol formation 
during copper-oxidation of low-density lipoprotein and uptake by macrophages. 
Journal of Lipid Research, 32, 320-335. 
Brown, A. J., Leong, S., Dean, R. T., & Jessup, W. (1997). 7-Hydroperoxyxholesterol 
and its products in oxidised low density lipoprotein and human atherosclerotic 
plaque. Journal of Lipid Research, 38, 1730-1745. 
Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol 
homeostasis. Science, 232-234. 
Budd, S. L., Castilho, R. F., & Nicholls, D. G. (1997). Mitochondrial membrane 
potential and hydroethidine-monitored superoxide generation in cultured 
cerebellar granule cells. FEBS Letters, 415(1): 21-24. 
Carr, A. C., & Winterbourn, C. C. (1997). Oxidation of neutrophil glutathione and 
protein thiols by myeloperoxidase-derived hypochlorous acid. Biochem J, 327 
(Pt1); 275-271. 
Carr, A. C., McCall, M. R., & Frei, B. (2000). Oxidation of LDL by Myeloperoxidase 
and Reactive Nitrogen Species: Reaction pathways and antioxidant protection . 
Arterioscler. Thromb. Vasc. Biol, 20, 1716-1723. 
Carr, A. C., van den Berg, J. J., & Winterbourn, C. C. (1996). Chlorination of 
cholesterol in cell membranes by hypochlorous acid. Arch Biochem Biophys, 
332(1); 63-69. 
Chapman, A. L. (2003). Characterization of non-covalent oligomers of proteins treated 
with hypochlorous acid. Biochem J, 375, 33-40. 
Chung, B. H., Wilkinson, T., Geer, J. C., & Segrest, J. P. (1980). Preparative and 
quantitative isolation of plasma lipoproteins: rapid, single discontinuous density 
gradient ultracentrifugation in a verticle rotor. Journal of Lipid Research, 21, 
284-291. 
Clare, K., Hardwick, S., Carpenter, K. L., Weeratunge, N., & Mitchinson, M. J. (1995). 
Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis, 118, 
67-75. 
Cotgreave, I. A., & P, M. (1986). Methodologies for the application of 
monobromobimane to the simultaneous analysis of soulable and protein thiol 
componetns of biological systems. J Biochem Biophys Methods, 13(4-5): 231-
249. 
Crisby, M., Kallin, B., Thyberg, J., Zhivotoysky, B., Orrenius, S., Kostulas, V., et al. 
(1997). Cell death in human atherosclerotic plaques invovles both oncosis and 
aopotosis. Atherosclerosis, 130, 17-27. 
References 
 
 
122 
 
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994). Myeloperoxidase, a 
catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. 
Journal of Clinical Investigation, 94, 437-444. 
Dean, R. T., Gieseg, S. P., & Davies, M. J. (1993). Reactive species and their 
accumulation on radical-damaged proteins. Trends in biochem sci, 18(11); 437-
441. 
Ding, Z., Liu, S., Yang, B., Fan, Y., & Deng, X. (2011). Effect of oxidized low-density 
lipoprotein concentration polarization on human smooth muscle cells' 
proliferation, cycle, apoptosis and oxidized low-density lipoprotein uptake. J R 
Soc Interface (Epub ahead of print). 
Domigan, N. M., Charlton, T. S., Duncan, M. W., Winterbourn, C. C., & Kettle, A. J. 
(1995). Chlorination of tyrosyl residues in peptides by myeloperoxidase and 
human neutrophils. J Biol Chem, 270(28); 16542-16548. 
Draper, H. H., Squires, E. J., Mahmoodi, H., Wu, J., Agarwal, S., & Hadley, M. (1993). 
A comparative evaluation of thiobarbituric acid methods for the determination 
of malondialdehyde in biological materials. Free Radical Biology & Medicine, 
15, 353-363. 
Du, J., & Gebicki, J. M. (2004). Proteins are major initial cell targets of hydroxyl free 
radicals. Int. J. Biochem. Cell Bio, 36, 2334-2343. 
Duggan, S., Rait, C., Gebicki, J. M., & Gieseg, S. P. (2001). Inhibition of protein 
oxidation by the macrophage-synthesised antioxidant 7,8-dihydroneopterin. 
Redox Rep, 6(3); 188-190. 
Eiserich, J. P., Baldus, S., Brennan, M. L., Ma, W., Zhang, C., Tousson, A., et al. 
(2002). Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science, 
296(5577); 2391-2394. 
Ermak, N., Lacour, B., Drueke, T. B., & Vicca, S. (2008). Role of reactive oxygen 
species and Bax in oxidized low density lipoprotein-induced apoptosis of human 
monocytes. Atherosclerosis, 200, 247-256. 
Ermak, N., Lacour, B., Goirand, F., Drueke, T. B., & Vicca, S. (2010). Differential 
apoptotic pathways activated in response to Cu-induced of HOCl-induced LDL 
oxidation in U937 monocytic cell line. Biochem.Biophys. Res. Commun., 
doi:10.1016/.jbbrc.2010.02.082. 
Esterbauer, H., Dieber-Rotheneder, M., Waeg, G., Striegl, G., & Jurgens, G. (1990). 
Biochemical, structural, and functional properties of oxidized low-density 
lipoprotein. Chem Res Toxicol, 3, 77-92. 
References 
 
 
123 
 
Esterbauer, H., Gebicki, J., Puhl, H., & Jurgens, G. (1992). The role of lipid 
peroxidation and antioxidants in oxidative modification of LDL. Free Radical 
Biology & Medicine, 13, 341-389. 
Esterbauer, H., Gieseg, S. P., Giessauf, A., Ziouzenkova, O., & Ramos, P. (1995). Free 
Radicals and oxidation modification of LDL: Role of natural antioxidants. In F. 
P. Woodford, Atherosclerosis X. Netherlands: Elsevier. 
Esterbauer, H., Waeg, G., & Puhl, H. (1993). Lipid peroxidation and its role in 
atherosclerosis. British Medical Bulletin, 49, 566-576. 
Fogelman, A. M., Shechter, I., Seager, J., Hokom, M., Child, J. S., & Edwards, P. A. 
(1980). Malondialdehyde alteration of low density lipoprotein leads to 
cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl 
Acad Sci USA, 77, 2214. 
Folkes, L. K., Candeias, L. P., & Wardman, P. (1995). Kinetics and mechanisms of 
hypochlorous acid reactions. Arch Biochem Biophys, 323(1); 120-126. 
Fong, Parthasarathy, L. G., Witztum, J. L., & Steinberg, D. (1987). Nonenzymatic 
oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res, 28, 1466-
1477. 
Foote, C. S., Goyne, T. E., & Lehrer, R. I. (1983). Assessment of chlorination by human 
neutrophils. Nature, 301(5902); 715-726. 
Forman, H. J., Waeg, G., & Puhl, H. (2009). Glutathione: Overview of its protective 
roles, measurement, and biosynthesis. Molecular Aspects of Medicine, 30, 1-12. 
Fu, S., Davies, M., Stocker, R., & Dean, R. T. (1998). Evidence fora role of radicals in 
protein oxidation in advanced human atherosclerotic plaque. Biochemical 
Journal, 333, 519-525. 
Fu, S., Wang, H., Davies, M., & Dean, R. (2000). Reactions of hypochlorous acid with 
tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products 
in addition to 3-chlorotyrosine. J Biol Chem, 275(15); 10851-8. 
Gazda, M., & Margerum, D. W. (1994). Reactions of monochloroamine with Br2, Br3-
,HOBr, and OBr-: formation of bromochloroamines. Inorg. Chem, 33, 118-123. 
Gebicki, J. M. (1997). Protein hydroperoxides as new reactive oxygen species. Redox 
Report, 3, 99-110. 
Gebicki, J., Du, J., Collins, J., & Tweeddale, H. (2000). Peroxidation of proteins and 
lipids in suspensions of liposomes, in blood serum, and in mouse myeloma cells. 
Acta Biochemica Polonica, 47(4), 1-11. 
References 
 
 
124 
 
Gebicki, S., & M, G. J. (1999). Formation of peroxides in amino acids and proteins 
exposed to oxygen free radicals. Biochem J, 338 (Pt3); 629-636. 
Gerry, A. B., Satchell, L., & Leake, D. S. (2008). A novel method for production of 
lipid hydroperoxide- or oxysterol-rich low-density lipoprotein. Atherosclerosis, 
197, 579-587. 
Gieseg, S. P., & Esterbauer, H. (1994). Low density lipoprotein is saturable by po-
oxidant copper. FEBS Letters, 343, 188-194. 
Gieseg, S. P., Crone, E., & Amit, Z. (2009a). Oxidised low density lipoprotein 
cytotoxicity and vasular disease. Endogenous toxins: Diet, Genetics, Disease 
and Treatment. 
Gieseg, S. P., Flavall, E. A., & Amit, Z. (2007). Potential to inhibit growth of 
atherosclerotic plaque development through modulation of macrophage 
neopterin/7,8-dihydroneopterin synthesis. Br J Pharmacol, 1-9. 
Gieseg, S. P., Leake, D. S., Flavall, E. M., Amit, Z., Reid, L., & Yang, Y. (2009b). 
Macrophage antioxidant protection within atherosclerotic plaques. Frontiers in 
Bioscience, 14, 1230-1246. 
Gieseg, S. P., Pearson, J., & Firth, C. A. (2003). Protein hydroperoxides are a major 
product of low density lipoporotein oxidation during copper, peroxyl radical and 
macrophage-mediated oxidation. Free Radical Research, 37(9): 983-991. 
Gieseg, S. P., Simpson, J. A., Charlton, T. S., Duncan, M. W., & T, D. R. (1993). 
Protein-bound 3,4-dihydroxyphenylalanine is a major reductant formed during 
hydroxyl radical damage to proteins. Biochemistry, 32(18): 4780-4786. 
Gieseg, S. P., Whybrow, J., Glubb, D., & Rait, C. (2001). Protection of U937 cells from 
free radical damage by the macrophage synthesized antioxidant 7,8 
dihydroneopterin. Free Radical Research, 35, 311-318. 
Glass, C. K., & Witztum, J. L. (2001). Atherosclerosis: the road ahead. Cell, 104, 503-
516. 
Goldstein, J. L., Ho, Y. K., Basu, S. K., & Brown, M. S. (1979). Binding site on 
macrophages that mediates uptake and degradation of acetylated low density 
lipoporotein, producing massive cholesterol deposition. Proc Natl Acad Sci 
USA, 76, 333. 
Grant, A. J., Jessup, W., & Dean, R. T. (1993). Inefficient degradation of oxidized 
regions of protein molecules. Free Rad. Res. Comms, 18, 259-267. 
References 
 
 
125 
 
Green, P. S., Mendez, A. J., Jacob, J. S., Crowley, J. R., Growon, W., Hyman, B. T., et 
al. (2004). Neuronal expression of myeloperoxidase is increased in Alzheimer's 
disease. J Neurochem, 90(3); 724-733. 
Grisham, M. B., Jefferson, M. M., & L, T. E. (1984). Role of monochloramine in the 
oxidation of erythrocyte hemoglobin by stimulated neutrophils. J Biol Chem, 
259, 6757-6765. 
Halliwell, B., & Gutteridge, J. M. (2007). Free Radicals in Biology and Medicine. 
Oxford: Oxford University Press. 
Hampton, M. B., Kettle, A. J., & C, W. C. (1998). Inside the neutrophil phagosome: 
oxidants, myeloperoxidase, and bacterial killing. Blood, 92(9); 3007-3017. 
Handelman, G. J. (1998). Formation of carbonyls during attack on insulin by submolar 
amounts of hypochlorite. Anal Biochem, 258, 339-348. 
Hansson, M. J., Persson, T., Friberg, H., Keep, M. F., Rees, A., Wieloch, T., et al. 
(2003). Powerful cyclosporin inhibition of calcium-induced permeability 
transition in brain mitochondria. Brain Res, 960(1-2); 99-111. 
Harada-Shiba, M., Kinoshita, M., Kamido, H., & Shimokado, K. (1998). Oxidised low 
density lipoprotein induces apoptosis in cultures human umbilical vein 
endothelial cells by common and unique mechanisms. Journal of Biological 
Chemistry, 273, 9681-9687. 
Harrison, J. E., & Schultz, J. (1976). Studies on the chlorinating activity of 
myeloperoxidase. J Bio Chem, 251(5); 1371-1374. 
Hawkins, C. L., & Davies, M. J. (1998). Hypochlorite-induced oxidation of proteins in 
plasma: formation of chloramines and nitrogen-centred radicals and their role in 
protein fragmentation. Biochem J, 340(Pt 2); 539-548. 
Hawkins, C. L., & Davies, M. J. (2001). Hypochlorite-induced damage to nucleosides: 
formation of chloramines and nitrogen-centered radicals. Chem Res Toxicol , 
14(8); 1071-1081. 
Hawkins, C. L., Morgan, P. E., & Davies, M. J. (2009). Quantification of protein 
modification by oxidants. Free Rad. Biology & Medicine, 46, 965-988. 
Hazell, L. J., & Stocker, R. (1993). Oxidation of low-density lipoprotein with 
hypochlorite causes transformation of the lipoprotein into a high-uptake form for 
macrophages. Biochem J, 290, 165-172. 
Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., & Stocker, R. (1996). 
Presence of hypochlorite-modified proteins in human atherosclerotic lesions. 
Journal of Clinical Investigation, 97, 1535-1544. 
References 
 
 
126 
 
Hazell, L. J., Davies, M. J., & Stocker, R. (1999). Secondary radicals derived from 
chloramines of apolipoprotein B-100 contribute to HOCl-induces lipid 
peroxidation of low denisty lipoproteins. Biochem J, 339,489-495. 
Hazen, S. L., & Heinecke, J. W. (1997). 3-Chlorotyrosine, a specific marker of 
myeloperoxidase-catalyzed oxidation, is markedly elevated in low density 
lipoprotein isolated from human atherosclerotic intima. J. Clin Invest, 99, 2075-
2081. 
Hazen, S. L., d'Avignon, A., Anderson, M. M., Hsu, F. F., & Heinecke, J. W. (1998). 
Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride 
system to oxidize alpha-amino acids to a family of reactive aldehydes. 
Mechanistic studies identifying labile intermediates along the reaction pathway. 
J Biol Chem, 273(9); 4997-5005. 
Hazen, S. L., Hsu, F. F., & Heinecke, J. W. (1996). p-Hydroxyphenylacetaldehyde is 
the major product of L-tyrosine oxidation by activated human phagocytes: A 
chloride-dependent mechanism for the conversion of free amino acids into 
reactive aldehydes by myeloperoxidase. J. Biol. Chem, 271, 1861-1867. 
Heinecke, J. (1998). Oxidants and antioxidants in the pathogenesis of atherosclerosis: 
implications for the oxidised low density lipoprotein hypothesis. 
Atherosclerosis, 141, 1-15. 
Heinecke, J. W. (1997). Mechanism of oxidative damage of low-density lipoprotein in 
human atherosclerosis. Curr Opin Lipidol, 8, 268-274. 
Heinecke, J. W., Li, W., Francis, G. A., & Goldstein, J. A. (1993). Tyrosyl radical 
generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. 
J. Clin. Invest, 91(6); 2866-2872. 
Humphreys, J. M., Davies, B., Hart, C. A., & Edwards, S. W. (1989). Role of 
myeloperoxidase in the killing of Staphylococcus aureus by human neutrophils 
studies with the myeloperoxidase inhibitor salicylhydroxamic acid. J Gen 
Microbiol, 153(5); 1187-1193. 
Itabe, H., Obama, T., & Kato, R. (2011). The dynamics of oxidised LDL during 
atherogenesis. Journal of Lipids, 1-9. 
Iwao, Y., Anraku, M., Hiraike, M., Kawai, K., Nakajou, K., Kai, T., et al. (2006). The 
stuctural and pharmacokinetic properties of oxidised humanserum albumin, 
Advanced Oxidation Protein Products (AOPP). Drug Metab Pharmacokinet, 
21(2); 140-146. 
Katrantzis, M., Baker, M. S., Handley, C. J., & Lowther, D. A. (1991). The oxidiant 
hypochlorite (OCL-), A product of the myeloperoxidase system, degrades 
References 
 
 
127 
 
articular-cartilage proteoglycan aggregate. Free Radical Biology & Medicine, 
10(2); 101-109. 
Kettle, A. J. (1996). Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. 
FEBS Letters, 379(1); 103-106. 
Kitahara, M., Eyre, H. J., Simonian, Y., Atkin, C. L., & Hasstedt, S. J. (1981). 
Hereditary myeloperoxidase deficiencey. Blood, 57(5); 888-893. 
Klebanoff, S. J. (2005). Myeloperoxidase: friend and foe. J Leukoc Biol, 77(5); 598-
625. 
Kopprasch, S., Leonhardt, W., Pietzsch, J., & Kuhne, H. (1998). Hypochlorite-modiifed 
low-density lipoprotein stimulates human polymorphonuclear leukocytes for 
enhanced production of reactive oxygen metabolites, enzyme secretion, and 
adhesion to endothelial cells. Atherosclerosis, 136(2); 315-324. 
Kritharides, L., Jessup, W., Gifford, J., & Dean, R. T. (1993). A method for defining the 
stages of low-density lipoprotein oxidation by the seperation of cholesterol and 
cholesterol ester-oxidation products using HPLC. Analytical Biochemistry, 213, 
79-89. 
Kume, N., Cybulsky, M. I., & Gimbrone, M. A. (1992). Lysophosphatidylcholine, a 
component of atherogenic lipoproteins, induces mononuclear leukocyte 
adhesion molecules in cultures human and rabbit arterial endothelial cells. J Clin 
Invest, 90, 1138-1144. 
Leeuwenburgh, C., Rasmussen, J. E., Hsu, F., Mueller, D. M., Pennathur, S., & 
Heinecke, J. W. (1997). Mass spectrometric quanitification of amrkers for 
protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density 
lipoprotein isolated from human atherosclerotic plaques. The Journal of 
Biological Chemistry, 272, 3520-3526. 
Lehr, H. A., Frei, B., Olofsson, M., Carew, T. E., & Arfors, K. E. (1995a). Protection 
from oxidised LDL-induced leukocyte adhesion to microvascular endothelium 
in vivo by vitamin C but not vitamin E. Circulation, 91, 1525-1532. 
Lehr, H. A., Krombach, F., Münzing, S., Bodlaj, R., Glaubitt, S. I., Seiffge, D., et al. 
(1995b). In vitro effects of oxidised low density lipoprotein on CD11b/CD18 an 
L-selectin presentation on neutrophils and monocytes with relevance for the in 
vivo situation. Am J Pathol, 146, 218-227. 
Lehrer, R. I., & Cline, M. J. (1969). Leukocyte myeloperoxidase deficiency and 
disseminated candidiasis: the role of myeloperoxidase in resistance to Candida 
infection. J Clin Invest, 48(8); 1478-1488. 
References 
 
 
128 
 
Lei, Z. B., Zhang, Z., Jing, Q., Qin, Y. W., Pei, G., Cao, B. Z., et al. (2002). OxLDL 
upregulates CXCR2 expression in monocytes via scavenger receptors and 
activation of p38 mitogen-activated protein kinase. Cardiovascular Research, 
53, 524-532. 
Libby, P. (1995). Molecular bases of the acute coronary syndromes. Circulation, 
91(11); 2844- 2850. 
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420, 868-874. 
Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. 
Circulation, 105, 1135-1143. 
Liu, J., Thewkw, D. P., Su, Y. R., Linton, M. F., Fazio, S., & Sinensky, M. S. (2005). . 
Reduced macrophage apoptosis is associated with accelerated atherosclerosis in 
low-density lipoprotein receptor-null mice. Arterio. Thromb. Vasc. Biol, 25, 
174-179. 
Liu, S. X., Hou, F. F., Guo, Z. J., Nagai, R., Zhang, W. R., Liu, Z. Q., et al. (2006). 
Advanced oxidation protein products accelerate atherosclerosis though 
promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol, 
26, 1156-1162. 
Liu, S. X., Hou, F. F., Guo, Z. J., Nagai, R., Zhang, W. R., Liu, Z. Q., et al. (2006). 
Advanced oxidation protein products accelerate atherosclerosis through 
promoting oxidative stress and inflamation. Arterioscler Thromb Vasc Biol, 26, 
1156-1162. 
Lizard, G., Monier, S., Cordlet, C., Gesquiere, L., Deckett, V., Gueldry, S., et al. 
(1999). Characterization and Comparison of the Mode of Cell Death, Apoptosis 
Versus Necrosis, Induced by 7ß-Hydroxycholesterol and 7-Ketocholesterol in 
the Cells of the Vascular Wall . Arterio Thromb Vasc Bio, 19, 1190-1200. 
Lusis, A. J. (2000). Atherosclerosis. Nature, 407, 233-241. 
Malle, E., Marsche, G., Arnhold, J., & Davies, M. (2006). Modification of low-density 
lipoprotein by myeloperoxidase-derives oxidants and reagent hypochlorous acid. 
Biochemica et Biophysica Acta, 1761, 392-415. 
Malle, E., Waeg, G., Schreiber, R., Grone, E. F., Sattler, W., & Grone, H. (2000). 
Immunohistochemical evidence for the myeloperoxidase/H202/halide system in 
human atherosclerotic lesions. FEBS, 267, 4495-4503. 
Martinet, W., Schrijvers, D. M., & De Meyer, G. R. (2011). Necrotic cell death in 
atherosclerosis. Basic Res Cardiol, 106(5): 749-760. 
References 
 
 
129 
 
Martin-Gallan, P., Carrascosa, A., Gussinye, M., & Dominguez, C. (2003). Biomarkers 
of diabetes-associated oxidative stressand antioxidant status in young diabetic 
patients with or without subclinical complications. Free Radical Biology & 
Medicine, 34, 1563-1574. 
Meister, A. (1988). Glutathione metabolism and its selective modification. Journal of 
Biological Chemistry, 263, 17205-17208. 
Moldeus, P., Hogberg, J., & Orrenius, S. (1978). Isolation and use of liver cells. 
Methods in Enzymology, 52, 60-71. 
Moore, K. J., & Freeman, M. W. (2006). Scavenger receptors in atherosclerosis: 
Beyond lipid uptake. Arterioscler Thromb Vasc Biol, 26, 1702-1711. 
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods, 65(1-
2); 55-63. 
Nagai, H., Matsumaru, K., Feng, G., & Kaplowitz, N. (2002). Reduced glutathione 
depletion causes necrosis and sensitization to tumor necrosis factor-alpha-
induced apoptosis in cultured mouse hepatocytes. Hepatology, 36, 55-64. 
Nagra, R. M., Becher, B., Tourtellotte, W. W., Antel, J. P., Gold, D., Paladino, T., et al. 
(1997). Immunohistochemical and genetic evidence of myeloperoxidase 
involvement in multiplesclerosis. J Neuroimmunol, 78(1-2);97-107. 
Namgaladze, D., Kollas, A., & Brunel, B. (2008). Oxidized LDL attenuates apoptosis in 
monocytic cells by activating ERK signaling. J. Lipid Research, 49,58-65. 
Naskalski, J. W., & Bartosz, G. (2001). Oxidative Modification of Protein Structures. In 
Advances in Clinical Chemistry vol 35 (pp. 161-253). Elsevier Science. 
Newby, A. C., & Zaltsman, A. B. (1999). Fibrous cap formation or destruction - the 
critical importance of vascular smooth muscle cell proliferation, migrationa dn 
matrix formation. Cardiovascular Research, 41, 345-360. 
Orlova, E. V., Sherman, M. B., Chiu, W., Mowri, H., Smith, L. C., & Gotto Jr, A. M. 
(1999). Three-dimensional structure of low density lipoproteins by electron 
cryomicroscopy. PNAS, 96(15), 8420-8425. 
Parthasarathy, S., Santanam, N., Ramachandran, S., & Meilhac, O. (1999). Oxidants 
and antioxidants in atherogenesis: An appraisal. Journal of Lipid Research, 40, 
2143-2157. 
Pastore, A., Federici, G., Bertini, E., & Piemonte, F. (2003). Analysis of glutathione: 
implication in redox and detoxification. Clinica Chimica Acta, 333, 19-39. 
References 
 
 
130 
 
Patel, R. P., Moellering, D., Murphy-Ullrich, J., Jo, H., Beckman, J. S., & Darley-
Usmar, V. M. (2000). Cell signaling by reactive nitrogen and oxygen species in 
atherosclerosis. Free Radical Biology & Medicine, 28(12): 1780-1794. 
Pattison, D. I., & Davies, M. J. (2001). Absolute rate constants for the reaction of 
hypochlorous acid with protein side chains and peptide bonds. Chem Res 
Toxicol, 14(10); 1453-1464. 
Pearson, J. (2002). Oxidative modification of apolipoprotein B-100. Unpublished M.Sc 
Thesis, University of Canterbury, Christchurch, New Zealand. 
Peskin, A. V., & Winterbourn, C. C. (2001). Kinetics of the reactions of hypochlorous 
acid and amino acid chloramines with thiols, methionine, and ascorbate. Free 
Radic Biol Med, 30, 572-579. 
Pietsch, A., Erl, W., & Lorenz, R. L. (1996). Lovastatin reduces expression of the 
combined adhesion and scavenger receptor CD36 in human monocytic cells. 
Biochemical Pharmacology, 52, 433-439. 
Pluddemann, A., Neyen, C., & Gordon, S. (2007). Macrophage scavenger receptors and 
host-derived ligands. Methods, 43, 207-217. 
Podrez, E., Abu-Soud, H., & Hazen, S. (2000). Myeloperoxidase-generated oxidants 
and atherosclerosis. Free Rad. Bio. Med, 28, 1717-1725. 
Pullar, J. M., Vissers, M. C., & Winterbourn, C. C. (2000). Living with a killer: the 
effects of hypochlorous acid on mammalian cells. IUBMB Life, 50, 259-266. 
Pullar, J. M., Winterbourn, C. C., & Vissers, M. C. (1999). Loss of GSH and thiol 
enzymes in endothelial cells exposed to sublethal concentrations of 
hypochlorous acid. Am J Physiol, 277(4 Pt 2); H1505-1512. 
Reid, V. C., & Mitchinson, M. J. (1993). Toxicity of oxidised low density lipoprotein 
towards mouse peritoneal macrophages in vitro. Athersclerosis, 98, 17-24. 
Rudzite, V., Jurika, E., Fuchs, D., Kalnins, U., Erglis, A., & Trusinskis, K. (2003). 
Serum concentration of C-reactive protein, neopterin and phospholipids in 
patients with different grade of coronary heart disease. Pteridines, 14(4); 133-
137. 
Rutherford, L., & Gieseg, S. P. (2012). 7-Ketocholesterol is not cytotoxic to U937 cells 
when incorporated into acetylated low density lipoprotein. Lipids, 41, 239-247. 
Salvayre, R., Auge, N., Benoist, H., & Negre-Salvayre, A. (2002). Oxidised low density 
lipoprotein-induced apoptosis. Biochemica et Biophysica Acta, 1585, 213-221. 
References 
 
 
131 
 
Savenkova, M. I., Mueller, D. M., & Heinecke, J. W. (1994). Tyrosyl radical generated 
by myeloperoxidase is a physiological catalyst for the initiation of lipid 
peroxidation in low density lipoprotein. J. Biol. Chem, 269; 20394-20400. 
Schumacher, M., Eber, B., Tatzber, F., Kaufmann, P., Esterbauer, H., & Klein, W. 
(1992). Neopterin levels in patients with coronary artery disease. 
Atherosclerosis, 94(1); 87-98. 
Sebekova, K., Klenovicsova, K., Ferenczova, J., Hedvig, J., Podracka, L., & Heidland, 
A. (2012). Advanced oxidation protein products and advanced glycation end 
products in children and adolescents with chronic renal insufficiency. Journal of 
Renal Nutrition, 22(1); 143-148. 
Seimon, T., & Tabas, I. (2009). Mechanisms and consequences of macrophage 
apoptosis in atherosclerosis. J. Lipid Research, 50, 382-387. 
Shimaoka, T., Kume, N., Minami, M., Hayashida, K., Kataoka, H., Kita, T., et al. 
(2000). Molecular cloning of a novel scavenger receptor for oxidized low 
density lipoprotein, SR-PSOX, on macrophages. J. Biological Chemistry, 275, 
40663-40666. 
Simpson, J. A., Narita, S., Gieseg, S. P., Gebicki, S., M, G. J., & Dean, R. T. (1992). 
Long-lived reactive species on free-radical-damaged proteins. Biochem. J, 282, 
621-624. 
Steinberg, D. (2009). The LDL modification hypothesis of atherogenesis: an update. 
Journal of Lipid Research, 376-381. 
Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989). 
Beyond Cholesterol: Modifications of low density lipoprotein that increase its 
atherogenicity. The New England Journal of Medicine, 320, 915-924. 
Stocker, R., & Keaney, J. F. (2004). Role of oxidative modification in atherosclerosis. 
Physiol Rev, 84, 1381-1478. 
Sugiyama, S., Okada, Y., Sukhova, G. K., Virmani, R., Heinecke, J. W., & Libby, P. 
(2001). Macrophage myeloperoxidase regulation by granulocyte macrophage 
colony-stimulating factor in human atherosclerosis and implications in acute 
coronary sydromes. American Journal of Pathology, 158(3): 879-891. 
Sundstrom, C., & Nilsson, K. (1976). Establishment and characterization of a human 
histiocytic lymphoma cell line (U937). International Journal of Cancer, 17, 
565-577. 
Tatsumi, T., & Fliss, H. (1994). Hypochlorous acid and chloramines increase 
endothelial permeability: Possible involvement of cellular zinc. American 
Journal of Physiology, 267, 1597-1607. 
References 
 
 
132 
 
Tatzber, F., Rabl, H. K., Erhart, U., Puhl, H., Waeg, G., Krebs, A., et al. (1991). 
Elevated serum neopterin levels in atherosclerosis. Atherosclerosis, 89(2-3); 
203-208. 
Terkeltaub, R., Banka, C. L., Solan, J., Santoro, D., Brand, K., & Curtiss, L. K. (1994). 
Oxidised LDL induces monocytic cell expression of interleukin-8, a chemokine 
with T-lymphocyte chemotactic activity. Arterioscler Thromb, 14, 47-53. 
Thomas, E. L. (1979). Myeloperoxidase hydrogen and peroxide-chloride antimicrobial 
system: Effect of exogenous amines on antibacterial action against Escherichia 
coli. INfect. Immun, 25, 110-116. 
Thomas, E. L., & Fishman, M. (1986). Oxidation of chloride and thiocynate by isolated 
leukocytes. J Biol Chem, 261(21); 9694-9702. 
Thomas, E. L., Grisham, M. B., Melton, D. F., & Jefferson, M. M. (1985). Evidence for 
a role of taurine in the in vitro oxidative toxicity of neutrophils towards 
erythrocytes. J. Biol. Chem, 260, 3321-3329. 
Upston, J. M., Niu, X., Brown, A. J., Mashima, R., Wang, H., Senthilmohan, R., et al. 
(2002). Disease stage-dependent accumulation of lipid and protein oxidation 
products in human atherosclerosis. Am J. Pathology, 160, 710-720. 
van den Berg, J., & Winterbourn, C. .. (1994). Measurement of reaction products from 
hypochlorous acid and unsaturated lipids. Methods in Enzymology, 233, 639-
649. 
van den Berg, J., & Winterbourn, C. C. (1994). Measurement of reaction products from 
hypochlorous acid and unsaturated lipids. Methods in Enzymology, 233, 639-
649. 
van Vlijmen, B. J., Gerritsen, G., Franken, A. L., Boesten, L. S., Kockx, M. M., Gijbels, 
M. J., et al. (2001). Macrophage p53 deficiency leads to enhanced 
atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. , 88, 780-786. 
Vicca, S., Hennequin, C., Nguyen-Khoa, T., Massy, Z. A., Descamps-Latscha, B., 
Drueke, T. B., et al. (2000). Caspase dependent apoptosis in THP-1 cells 
exposed to oxidised low-density lipoproteins. Biochem Biophysi Res Comm, 
273, 948-954. 
Vicca, S., Massy, Z. A., Hennequin, C., Rihane, D., Drueke, T. B., & Lacour, B. (2003). 
Apoptotic pathways involved in U937 cells exposed to LDL oxidised by 
hypochlorous acid. Free Rad. Biology & Medicine, 35(6), 603-615. 
Vissers, C. M., & Winterbourn, C. C. (1995). Oxidation of intracellular glutathione after 
exposure of human red blood cells to hypochlorous acid. Biochem J, 307, 57-62. 
References 
 
 
133 
 
Vissers, M. C., & Winterbourn, C. C. (1991). Oxidative damage to fibronectin. The 
effects of the neutrophil myeloperoxidase system and HOCl. Arch Biochem 
Biophys, 285, 53-59. 
Vissers, M. C., Carr, A. C., & Chapman, A. L. (1998). Comparison of human red cell 
lysis by hypochlorous and hypobromous acids: insights into the mechanism of 
lysis. J Biochem, 330, 131-138. 
Vissers, M. C., Day, W. A., & Winterbourn, C. C. (1985). Neutrophils adherent to a 
nonphagocytosable surface (glomerular basement membrane) produce oxidants 
only at the site of attachment. Blood, 66(1); 161-6. 
Volf, I., Roth, A., Cooper, J., Moeslinger, T., & Koller, E. (2000). Hypochlorite 
modifed LDL are a stronger agonist for platelets than copper oxidized LDL. 
FEBS Letters, 483, 155-159. 
Wachter, H., Fuchs, D., Hausen, A., Reibnegger, G., & Werner, E. R. (1989). Neopterin 
as marker for activation of cellular immunity: immunologic basis and clinical 
application. Adv Clin Chem, 27, 81-141. 
Wachter, H., Fuchs, D., Hausen, A., Reibnegger, G., Weiss, G., Werner, E. R., et al. 
(1992). Neopterin: Biochemistry-Methods-Clinical Application. New York: 
Walter de Gruyter. 
Weiss, S. J., Klein, P., Slivka, A., & Wei, M. (1982). Chlorination of Taurine by Human 
Neutrophils: evidence for hypochlorous acid generation. J. Clin Invest, 70, 
1341-1349. 
Westendorf, T., Graessler, J., & Kopprasch, S. (2005). Hypochlorite-oxidised low-
density lipoprotein upregulates CD36 and PPAR mRNA expression and 
modulates SR-BI gene expression in murine macrophages. Molecular and 
Cellular Biochemistry, 227, 143-152. 
Winterbourn, C. C. (1985). Comparative reactivities of various biological compounds 
with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant 
to hypochlorite. Biochim Biophys Acta, 840(2); 204-210. 
Winterbourn, C. C., & Carr, A. C. (1993). Myeloperoxidase-dependent loss of 
malondialdehyde: a limitation for detecting neutrophil-mediated lipid 
peroxidation. Arch Biochem. Biophys, 30(2), 461-467. 
Witko-Sarsat, V., Friedlander, M., Khoa, T. N., Capeillere-Blandin, C., Nguyen, A. T., 
Canteloup, S., et al. (1998). Advanced oxidation protein products as novel 
mediators of inflammation and monocyte activation in chronic renal failure. J 
Immunol, 161, 2524-2532. 
References 
 
 
134 
 
Witko-Sarsat, V., Gausson, V., & Descamps-Latscha, B. (2003). Are advanced 
oxidation protein products potential uremic toxins? Kidney International, 81, 
511-514. 
Woenckhaus, C., Kaufmann, A., Bussfeld, D., Gemsa, D., Sprenger, H., & Grone, H. 
(1998). Hypochlorite-Modified LDL: Chemotactic Potential and Chemokine 
Induction in Human Monocytes. Clinical Immunology and Immunopathology, 
86(1); 27-33. 
Yang, Y. T., Whiteman, M., & Gieseg, S. P. (2011). HOCl causes necrotic cell death in 
human monocyte derived macrophages through calcium dependent calpain 
activation. Biochimica et Biophysica Acta, 1823, 420-429. 
Ylaherttuala, S., Palinski, W., Rosenfiels, M. E., Parthasarathy, S., Carew, T. E., Butler, 
S., et al. (1989). Evidence for the presence of oxidatively modified low density 
lipoprotein in atherosclerotic lesion of rabbit and man. Journal of Clinical 
Investigation, 84, 1086-1095. 
Yoshida, H., & Kisugi, R. (2010). Mechanisms of LDL oxidation. Clinica Chimica 
Acta, 1875-1882. 
Zabe, M., Feltzer, R. E., Malle, E., Sattler, W., & Dean, W. L. (1999). Effects of 
hypochlorite modified low density and high density lipoproteins on intracellular 
Ca2+ and plasma membrane Ca2+-ATPase activity of human platelets. Cell 
Calcium, 26(6); 281-287. 
Zhao, H., Kalivendi, S., Zhang, H., Joseph, J., Nithipatikom, K., Vasquez-Vivar, J., et 
al. (2003). Superoxide reacts with hydroethidine but forms a fluorescent product 
that is distinctly differnt from ethidium: potential implications in intracellular 
fluorescence detection of superoxide. Free Radical Biology & Medicine, 34(11): 
1359-1368. 
Zhou, L. L., Hou, F. F., Wang, G. B., Yang, F., Xie, D., Wang, Y. P., et al. (2009). 
Accumulation of advanced oxidation protein products induces podocyte 
apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int, 76, 
1148-1160. 
Zhou, X., Paulsson, G., Stemme, S., & Hansson, G. K. (1998). Hypercholesterolemia is 
associated with a T helper (Th) 1/Th2 switch of the autoimmune response in 
atherosclerotic apo E-knockout mice. J Clin Invest, 101(8); 1717-1725. 
 
 
